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Venoms are complex mixtures of biological macromolecules and other com-
pounds that are used for predatory and defensive purposes by hundreds of
thousands of known species worldwide. Throughout human history, venoms
and venom components have been used to treat a vast array of illnesses, causing
them to be of great clinical, economic, and academic interest to the drug dis-
covery and toxinology communities. In spite of major computational advances
that facilitate data-driven drug discovery, most therapeutic venom effects are
still discovered via tedious trial-and-error, or simply by accident. In this dis-
sertation, I describe a body of work that aims to establish a new subdiscipline
of translational bioinformatics, which I name “computational toxinology”.
To accomplish this goal, I present three integrated components that span
a wide range of informatics techniques: (1) VenomKB, (2) VenomSeq, and (3)
VenomKB’s Semantic API. To provide a platform for structuring, representing,
retrieving, and integrating venom data relevant to drug discovery, VenomKB
provides a database-backed web application and knowledge base for compu-
tational toxinology. VenomKB is structured according to a fully-featured on-
tology of venoms, and provides data aggregated from many popular web re-
sources. VenomSeq is a biotechnology workflow that is designed to generate
new high-throughput sequencing data for incorporation into VenomKB. Specif-
ically, we expose human cells to controlled doses of crude venoms, conduct
RNA-Sequencing, and build profiles of differential gene expression, which we
then compare to publicly-available differential expression data for known dis-
eases and drugs with known effects, and use those comparisons to hypothesize
ways that the venoms could act in a therapeutic manner, as well. These data
are then integrated into VenomKB, where they can be effectively retrieved and
evaluated using existing data and known therapeutic associations. VenomKB’s
Semantic API further develops this functionality by providing an intelligent,
powerful, and user-friendly interface for querying the complex underlying data
in VenomKB in a way that reflects the intuitive, human-understandable mean-
ing of those data. The Semantic API is designed to cater to the needs of
advanced users as well as laypersons and bench scientists without previous ex-
pertise in computational biology and semantic data analysis.
In each chapter of the dissertation, I describe how we evaluated these 3
components through various approaches. We demonstrate the utility of Ven-
omKB and the Semantic API by testing a number of practical use-cases for
each, designed to highlight their ability to rediscover existing knowledge as well
as suggesting potential areas for future exploration. We use statistics and data
science techniques to evaluate VenomSeq on 25 diverse species of venomous an-
imals, and propose biologically feasible explanations for significant findings. In
evaluating the Semantic API, I show how observations on VenomSeq data can
be interpreted and placed into the context of past research by members of the
larger toxinology community.
Computational toxinology is a toolbox designed to be used by multiple
stakeholders (toxinologists, computational biologists, and systems pharmacolo-
gists, among others) to improve the return rate of clinically-significant findings
from manual experimentation. It aims to achieve this goal by enabling access to
data, providing means for easy validation of results, and suggesting specific hy-
potheses that are preliminarily supported by rigorous inferential statistics. All
components of the research I describe are open-access and publicly available,
to improve reproducibility and encourage widespread adoption.
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Preface
It is a common convention for dissertations to be written in the first-person, but given the
amount of work performed by my various coauthors, I prefer to use the pronoun “we” rather
than “I” when describing the research herein (unless referring to the dissertation itself). For
ease-of-use, all cross-references (figure and table numbers, chapter/section references, and
citation labels) and URLs are hyperlinks in the PDF version of this document.
Matrices are represented by upper-case bold letters (e.g., X), while vectors are rep-
resented by lower-case bold letters (e.g., x). Unless otherwise specified, matrix indices are
denoted using “C-style” notation (row-major ordering). For example, both Rij and R[i, j]
refer to the cell in the ith row and jth column of matrix R. Occasionally I use “typewriter
text” (monospace) fonts for specific variable names and other stylized proper nouns, such
as VenomSeq. I use capitalized typewriter text to refer to computational subroutines, such
as RANK(Vij). All figures and images are reproduced with permission from the copyright
holders. Any figures or photographs borrowed from external authors are cited appropriately,
unless they are in the public domain. All other conventions follow the guidelines set forth
by the Graduate School of Arts and Sciences of Columbia University.
To readers looking for an abridged (i.e., “tl;dr”) version of this dissertation, I recom-




Venoms are complex mixtures of organic molecules and inorganic cofactors that animals
use for defensive or offensive purposes (or, in some cases, both). The number of extant
venomous species is vast, with current counts of known species exceeding 46,000 venomous
spiders [195], 2,000 venomous fish [229], 600 venomous snakes [214], among many others.
Current estimates suggest that these only comprise a small fraction of the actual number of
venomous species in nature.
Since at least the dawn of recorded history, humans have used animal venoms and
other natural toxins for therapeutic purposes, including the treatment of infectious diseases,
chronic conditions, and trauma [141]. Therapeutic applications of venoms have continued
to be used in modern medicine to great scientific and commercial success, with molecular
characterization of venom effects on the human body being one of the most popular and well-
funded areas of toxinology. Their highly targeted nature and bioavailability both suggest
that venom-derived compounds are ideal for drug discovery.
In spite of these facts, the venom-based drug discovery industry faces many scientific
obstacles compared to other classes of drug candidates. Venoms present unique challenges to
researchers, including difficulty of compound isolation/characterization/synthesis, powerful
toxic effects, and difficulties in working with the large macromolecules that comprise most
active venom components. Furthermore, it is often challenging to work with venomous
1
1.0 CHAPTER 1. BACKGROUND AND INTRODUCTION
species, due both to risks in handling as well as complex issues related to animal conservation
and trade laws. Although the study of venoms has made extensive use of emerging next-
generation sequencing technologies, proteomics, and related computational approaches to
studying venom composition and molecular function [35], other informatics and data science
methods have been substantially underutilized.
Figure 1.1.: Some examples of venoms and venom components with known therapeutic
effects. Ziconotide (marketed as Prialt) is one of the most potent treatments for chronic
pain. Exenatide (marketed as Byetta) is a successful drug for treating type-2 diabetes.
Bombesin has demonstrated the ability to treat various gastrointestinal illnesses.
In this dissertation, I describe the development, integration, and application of two
related resources that use cutting-edge translational bioinformatics to identify drug leads
2
1.1 DISSERTATION OVERVIEW
from venoms. VenomKB is an open-source knowledge repository and standardized data
representation framework for venoms, venom components, and their effects (both molecular
and systemic) on the human body. It provides a number of advanced tools for programmatic
interaction with large quantities of standardized venom data, alongside a responsive, modern
web interface for graphical browsing of the knowledge base contents. VenomSeq is a next-
generation sequencing workflow that characterizes the effects that venoms have on gene
expression in human cells, and uses these data as signals for inferring potential therapeutic
effects of those venoms. VenomKB and VenomSeq—which are tightly integrated—provide
considerable advantages over existing venom data analysis tools, especially for drug discovery.
1.1. Dissertation Overview
1.1.1. Specific aims
The goals of this dissertation can be broadly generalized into 3 specific aims. Aim 1 concerns
the development of VenomKB, Aim 2 focuses on VenomSeq and the process of generating
new data using the VenomSeq approach, and Aim 3 involves the integration of these two
components to perform discovery and validation (including the conceptualization and imple-


















Figure 1.2.: Schematic overview of VenomKB and VenomSeq.
AIM 1: Create a centralized knowledge representation and data repository for
computational toxinology
Aim 1 essentially consists of three components:
1. VenomKB v1.0 [205]
2. Venom Ontology [206]
3. VenomKB v2.0 [204]
These three parts comprise a unified informatics framework hosted at venomkb.org that
provides structure and a formal representation for both new and previously existing venom
data, which are required to answer the major questions I pose in this dissertation.
4
1.1 DISSERTATION OVERVIEW
In VenomKB v1.0, we used literature mining techniques to retrieve MEDLINE arti-
cles describing therapeutic uses of venoms, and extracted specific mentions and biomedical
predications corresponding to those uses, building a public database comprised of those
results. Since the semantic landscape of venoms is poorly characterized, this provides a
starting point for the development of more rigorous representations of venoms and venom
data. We then built an ontology of venoms using data from the ToxProt annotation project
of UniProtKB/Swiss-Prot [113], and populated the ontology to allow for formal structuring
of venom knowledge. In VenomKB v2.0 we used the Venom Ontology to restructure the
data from v1.0, ToxProt, and other public resources pertaining to various aspects of venoms
and therapeutic applications of those venoms, and present them in a modern interface along
with several analysis tools and APIs that make the data more accessible, both for humans
and for computer programs.
AIM 2: Design a biotechnology platform for high-throughput screening of
therapeutic venom effects
To accomplish Aim 2, we developed the biotechnology aspect of this dissertation—namely,
the data generation pipeline I have named VenomSeq (which I stylize in a separate font to
indicate its ability to stand alone and be reused as a contiguous workflow). VenomSeq is a
transcriptomic computational screening approach for drug discovery that consists of exposing
human cells in culture to dilute concentrations of venoms. After exposure, we carried out the
PLATE-Seq protocol to obtain per-sample counts for nearly 20,000 human genes, yielding
gene expression profiles under venom perturbation for differential expression analysis. In
order to assess the efficiency of VenomSeq we compared the protocol to traditional RNA-Seq,
focusing particularly on cost, time expenses, and resolution of the final data.
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To test VenomSeq in a practical setting, we obtained venom samples from 25 diverse ven-
omous species and carried out the VenomSeq protocol as described. We then used differential
expression analysis software to identify which genes are significantly up- and down-regulated
upon exposure to specific venoms. By comparison to public databases of gene expression,
we compared these expression signatures to those for existing drugs and known diseases us-
ing various similarity metrics that allowed us to pose new hypotheses about the potentially
therapeutic effects these venoms exert on human cells.
AIM 3: Integrate VenomSeq and VenomKB using semantic data analysis to improve
detection and validation of therapeutic venom effects
Aim 3 seeks to unify the previous two aims by means of semantic data integration and
harmonization to enable capabilities that are otherwise unattainable. In other words, Aim
3 is a case study in using classical informatics techniques to improve the application of
emerging next-generation sequencing technologies in the domain of natural product drug
discovery.
After analyzing the data generated by VenomSeq, we incorporated both the raw data
and the analysis results into the database schema of VenomKB. Under this expanded struc-
ture, gene expression data are considered instances of the ontology class MolecularEffect,
and the analysis of the expression profiles effectively annotates them to instances of the
ontology class SystemicEffect. We demonstrate that ontological inference can be used to
link venomous species directly to clinically meaningful SystemicEffects. To demonstrate
the usability of this logical model, I also describe browsing and retrieval functionalities built
into the VenomKB web application.
Beyond these routine data integrations, I conceptualized and constructed a new service
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that interfaces with VenomKB, the Venom Ontology, and a server-side graph database to
deliver responses to semantic queries submitted by users of VenomKB. This system—which I
have named the Semantic API—is a novel application of bioontologies and software engineer-
ing to extract relevant and highly domain-specific knowledge from complex data schemas.
A semantic query consists of an intuitive description of the type of data the user is trying
to obtain, which the Semantic API interprets and executes on the graph database. The
Semantic API is a tool for both novices and veterans of manipulating complex data, serv-
ing multiple roles, including standardization, reduction of errors, saving time, reducing the
complexity of querying the database, and even performing novel discovery. We demonstrate
exactly how the Semantic API is beneficial both by validating known therapeutic associa-
tions of venoms as well as by exploring the plausibility of novel associations discovered by
use of VenomSeq. The Semantic API is a general tool for intelligent information retrieval
and knowledge discovery that can be ported to other domains.
The overarching goal of Aim 3 is to demonstrate true translational research in the con-
text of drug discovery from venoms: VenomKB is the application of traditional informatics
and knowledge engineering techniques to a new problem, while VenomSeq provides new ca-
pabilities for generating and analyzing molecular data. However, it is only by using both of
them in conjunction that we can translate observations on molecular data to findings that
can improve human health.
1.1.2. Knowledge gaps
This dissertation is motivated by an overall need to incorporate certain classes of modern
informatics techniques into toxinology and venom-based drug discovery research. Toxinol-
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ogists have enthusiastically embraced next-generation sequencing for understanding venom
composition at the levels of genomes, transcriptomes, and proteomes, and there is no lack
of new research in these areas. However, the number of venomous species is vast, and new
solutions are needed to apply venomics efficiently and economically to a larger fraction of
these species. The technical challenges presented by this goal feed into the second major
knowledge gap facing computational toxinology: namely, the need for standardization and
centralization of venom-related data. Venom data are largely fragmented across a multitude
of general-purpose biomedical databases that cannot adequately leverage the special char-
acteristics of venoms that make them particularly attractive for drug discovery. A limited
number of specialized venom databases do exist [94,115,192], but their scopes are too narrow
to effectively convey information and knowledge about all venoms1. Also, since these exist-
ing databases are manually assembled and annotated, the data they contain are generally of
high quality, but the amounts of data they contain are limited by available manpower and
other human factors.
This dissertation also tackles other knowledge gaps beyond those in toxinology. Al-
though perturbational differential expression analysis has been widely adopted by biomedical
data scientists over the past decade, almost all molecular perturbations are conducted using
small molecule drugs or drug candidates. Many compounds—including natural toxins—
perturb cells in highly complex ways, especially when those compounds contain numerous
types of molecules (e.g., venom peptides) [84,122,202]. The patterns in gene expression that
result from these perturbations are almost completely uncharacterized. With VenomSeq,
1It should be mentioned that they can be very well-suited for representing data related to constrained
groups of venomous species. Two excellent examples are Conoserver and ArachnoServer (described later
in the dissertation, in §2.3.2).
8
1.1 DISSERTATION OVERVIEW
we provide a set of these kind of data for analysis (using 25 crude venoms applied to one
human cell line), and begin to explore the behavior of these perturbations using existing
algorithms and by comparison to publicly accessible databases of small-molecule and disease
perturbation.
Bioontologies are resources that have been touted for their ability to structure and
formally represent virtually all types of biomedical data [28]. However, in recent years,
interest in ontology-enabled biomedical data science has arguably waned, with attention
instead being driven towards probabilistic (i.e., “knowledge-free”) methods [251], meaning
that impactful studies unifying bioontology research with cutting-edge computational meth-
ods have either failed to come to fruition or have simply been eclipsed by the surge in fields
like machine learning and deep learning.
1.1.3. Significance and contributions
Contributions to toxinology
VenomKB and VenomSeq are intended to be major resources for the larger toxinology com-
munity. VenomKB has already been discussed at major conferences on venoms and covered
in the popular media (see, for example, [174]), and we have begun to work in collaboration
with highly established venom researchers to use VenomSeq in new contexts. Perturbational
differential expression data is not a new concept, but we are the first to generate, analyze,
and disseminate these data using crude venoms as perturbagens. Furthermore, we use these
data to pose several novel hypotheses for therapeutic uses of venoms, and then validate those
using real biological knowledge that is already contained in VenomKB. We also hope that
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the Semantic API proves popular and effective for bench and field biologists who do not have
the expertise to construct complex data queries and aggregations.
Contributions to informatics
Together, these studies comprise an example of ‘full-stack informatics’, in that they range
from the fundamentals of information representation to next-generation sequencing and sys-
tems pharmacology. Many fields of biomedicine have utilized the tools provided by the
informatics community to great success, but toxinology has currently only done so in a few
specific areas (see §1.1.2). The set of tools and techniques we develop in these studies seek to
change that, by structuring existing venom knowledge and providing a foundation for data
generation and analysis in the future.
Contributions to computer science
The Semantic API, in spite of its use in a highly biological context, is at its core computer
science and software engineering. By abstracting ontologies as directed graphs, we use com-
mon and fundamental algorithms—such as filtering, sorting, and shortest path finding—and
combine them using the complex domain knowledge asserted in the Venom Ontology to re-
sult in an intelligent software tool for information retrieval and knowledge discovery. Most
modern tools for similar tasks rely on expensive computation (such as training deep learn-
ing models on distributed computing platforms) [55], constantly have to grapple with the
bias–variance tradeoff (mitigated through the use of appropriately built ontologies) [82], and
struggle to cope with relatively narrow domains (e.g., venom components and their effects
on the human body) [161]. Although the individual components of the semantic query al-
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gorithm are mechanistically simple and well-established, they still make use of cutting-edge
paradigms in software engineering, including graph databases and asynchronous execution.
1.1.4. Limitations
Like any body of scientific research, there are limitations to the studies described in this
dissertation.
Limitations in Aim 1
One of the frequent criticisms regarding resources like VenomKB is that defining new stan-
dards, databases, and knowledge representations rather than improving existing ones perpet-
uates the issue of having too many competing resources that are not intrinsically compatiblee.
Unfortunately, there is no easy solution to this problem. General resources used to create
VenomKB (such as ToxProt, MEDLINE/MeSH, and others) cannot adequately address the
characteristics unique to venoms, and other more specific databases (such as Conoserver and
ArachnoServer) are too specific to yield translational discoveries that apply to all venoms—
VenomKB hopes to reconcile these issues, but it is certain to inherit them to some degree,
as well.
Limitations in Aim 2
VenomSeq comes with its own set of limitations, as well. In order to make the study tractable,
it was necessary to place technical limitations on its methods that limit the generalizability
of the study’s results. For example, in order to mitigate between-sample variability and to
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Figure 1.3.: New standards (such as VenomKB, Venom Ontology, and VenomSeq) should
be introduced cautiously. Used with permission from https://xkcd.com/927/.
capitalize on the availability of existing data, I made the decision to develop the protocol
using the IMR-32 human neuroblastoma cell line [200]. Venoms and their components in-
teract with different cell lines in different and unexpected ways, so the entire protocol needs
to be eventually repeated for many human cell lines in order to obtain a more complete
understanding of the effects of venoms on human gene transcription. A number of other
issues are related to factors that are challenging (or even impossible, given present technical
limitations) to control:
• The 25 venoms were selected ad hoc based on availability and cost, and therefore may
inadequately represent certain groups of venomous taxa.
• It is particularly difficult to determine the effects of individual components of the
25 venoms, although we are working with collaborators to address this by applying
VenomSeq to purified venom peptides in the near future.
• PLATE-Seq—although inexpensive and well-validated—still suffers from a lack of res-
olution compared to traditional RNA-seq; it is unclear precisely how this loss of reso-
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lution impacts our findings.
• Determining an adequate dosage for venoms is challenging. To remain systematic, we
opted to set dosages using observed GI20 concentrations to mitigate cytotoxic effects
while ensuring the venom is still effecting the biochemistry of the cell.
Limitations in Aim 3
The Semantic API is arguably the least proven of the tools we have developed for compu-
tational toxinology. One of the major limiting factors in promoting the Semantic API as a
highly effective and general purpose tool is that we have not had the ability to perform exten-
sive user testing. In other words, although we designed the Semantic API to be friendly for
computational novices as well as data science experts, we have not yet established whether
each of these groups can effectively use it to solve real problems that they encounter in
their research. Therefore, user testing will be essential moving forward. We also have yet to
evaluate time complexity of the algorithms and how well they scale with increasing amounts
of data. Since the Semantic API is really meant to be a general tool, we plan to continue
to develop and refine it beyond the boundaries of this dissertation and its applications to
computational toxinology.
1.2. Toxins, toxinology, and natural products
Toxinology—the study of venoms, poisons, and other naturally occurring toxins—is a scien-
tific field that incorporates diverse aspects of venom research, including venom composition,
the phylogeny of venoms and the species that produce them, the ecological functions of
venom, and the interactions between humans and venoms (including the use of venoms to
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treat disease) [257]. Toxinology should not be confused with toxicology, which is the scientific
study of adverse effects that chemicals (natural or otherwise) have on living organisms, espe-
cially humans. Toxinology and toxicology can, of course, overlap, since toxins by definition
cause adverse effects. The different classes of toxins present in nature comprise subgroups of
a larger class of chemical compounds known as natural products (NPs). Since other classes
of NPs also form excellent chemical libraries for mining therapeutic effects, we will next
explore the techniques available for drug discovery from NPs, which will help to provide
perspective on methods available in searching for therapeutic effects of venoms in particular,
as well as additional challenges and opportunities we face that have not yet been covered in
this chapter.
1.3. Informatics methods in natural product drug discovery
Drug discovery is the process by which new pharmaceutical drugs are identified, and along
with drug development (validating, testing, and marketing a new drug), it comprises one
of the most substantial activities in pharmaceutical science. A 2018 analysis showed that
roughly 20% of the US National Institutes of Health (NIH) budget for the years 2010–2016
funded the discovery and development of 210 new molecular entities [44]. Since the advent
of modern medical science, most systematic drug discovery has focused on small molecule
candidates—for example, over 86% of the drugs (both approved and experimental) in the
DrugBank database are comprised of small molecules [261]. This is due to many reasons, in-
cluding relative ease of synthesis, generally high chemical stability, and more straightforward
characterization of reactivity [63]. The pervasiveness of small molecules in drug discovery is
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Figure 1.4.: Informatics methods for natural product drug discovery covered in this review.
Numbers preceding methods correspond to section/subsection numbers in the manuscript
describing the method. Dashed lines indicate inferred links between various data resources.
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Table 1.1.: Summary of popular computational drug discovery methods described in this
review and their applicability to NP drug discovery, stratified by the major branches of
informatics discussed in this review.
Informatics branch Method Use with NPs
Cheminformatics QSAR analysis (§1.3.2) Multiple
Molecular docking (§1.3.2) Multiple
Computational library design (§1.3.2) Multiple
Bioinformatics Gene expression perturbation (§1.3.3) Little to none
Protein modeling (§1.3.3) Multiple
Phylogenetic approaches (§1.3.3) Multiple
Semantic methods Literature mining (§1.3.4) Limited
EHR mining (§1.3.4) None
Linking HTS data to effects (§1.3.4) Little to none
even reflected in Lipinski’s “rule of five,” which defines a set of common best-practice guide-
lines for filtering potential orally-active drug candidates: “Good” compounds should have
a molecular mass less than 500, no more than 5 hydrogen bond donors, and no more than
10 hydrogen bond acceptors, among other principles [144]. In recent decades, the ubiquity
of computers and computational methods in science has extended to drug discovery [227].
Cheminformatics, for example, is the application of computer science to understanding and
characterizing molecular attributes and chemical behavior of specific compounds. These
methods have generated massive libraries of small molecules to screen against specific thera-
peutic processes [27]. Once candidates are identified, other cheminformatics methods can be
used to generate libraries of compounds structurally and chemically similar to the identified
‘hits,’ in order to optimize stability, toxicity, and kinetics. Complementarily, bioinformatics
techniques can be used to discover how candidate drugs cause therapeutic activity within the
human body, which can include predicting interactions between drugs and proteins, analysis
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of impact on biological pathways and functions, and elucidating genomic variants that can
alter drug response [63].
Despite these technological advances in drug discovery, the approval of new therapeutic
drugs has slowed considerably in recent years. For example, between 1996 and 2007, the
number of new molecular entities approved by the US FDA has fallen from 53 to 17 per
year—the same rate as over 50 years ago [73, 175]. This seems to be due to many factors,
including the following:
1. The “lowest hanging fruits” in terms of small molecule drug candidates have been
extensively investigated, and computational challenges hinder extension of traditional
methods to more complex structures. Researchers refer to “rediscovering the sweet
spot” in the discovery process [30], and have devoted a great amount of effort to
producing new, targeted screening libraries that leverage anticipated characteristics of
lead compounds [41,256].
2. Many remaining diseases of top clinical priority have highly complex etiologies, and
are accordingly difficult to associate with potential drug targets [199].
3. Model organisms may not provide adequate templates for testing treatments of more
complex diseases, due to inter-species variations that are crucial to therapeutic ac-
tion [68,106].
A natural way to address the first two challenges is to focus on new classes of potential drugs
outside of small molecules. Natural products (NPs) may serve this need by returning to
the sources of therapeutic compounds that have treated illness for thousands of years [59].
Although rigorous pharmaceutical science is young in comparison to the historical use of
NP drugs, many cutting-edge advances have emerged with the promise of ‘modernizing’ this
field [90]. Along with a renewed interest for NP drugs within the biomedical research commu-
nity, this has already resulted in substantial developments in the pharmaceutical industry—a
comprehensive enumeration by Newman and Cragg shows that 41% (646/1562) of all new
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drug approvals between 1981 and 2014 are NPs or derived from NPs [180]. Several recent
reviews provide excellent summaries of NP drugs and the broad spectrum of techniques that
have been used both for their identification and characterization [119,203], particularly from
the perspective of bench research techniques and state-of-the-art developments in biotech-
nology. Considering the aforementioned trends in new computational methods and advances
in classical informatics for translational applications of these methods, these reviews can
be complemented by a dedicated discussion restricted to in silico approaches for NP drug
discovery.
Another trend in drug discovery enabled by informatics and computational methods
is an increasing shift towards a data driven drug discovery [147, 240]. Traditionally, drug
discovery has been performed as follows: basic scientists first find a target structure in the
human body related to a disease or illness, followed by screening for “lead” compounds that
show affinity for the target. Subsequently, the list of candidates is narrowed down (using
some of the methods described in this review) to find the most promising leads, which then
go through the development process to assess safety and efficacy in model organisms and,
eventually, humans. A detailed description of these steps can be found in other reviews [105].
Failure at any stage in this workflow can—and usually does—necessitate starting over from
the beginning, contributing to the estimated cost of 2.6 billion USD to bring a new drug
to market [10]. Data-driven drug discovery turns ths process on its head, by using data
mining on large data repositories of candidate compounds and disease knowledge to gener-
ate novel therapeutic hypotheses systematically rather than hoping for a single therapeutic
hypothesis to deliver actionable results. Aside from avoiding systematic biases present in
the hypothesis-driven model, this additionally helps to improve the return rate on subse-
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quent manual experimentation and validation of lead compounds, ultimately lowering costs
and increasing productivity [111]. Data-driven drug discovery leverages new data types that
were previously inaccessible, and relies heavily upon computers and informatics techniques
to produce increasingly accurate results [34].
In this review, we first discuss various major classes of natural products based both on
source organism and their biological functions. In addition, we provide examples of specific
members of those classes with demonstrated therapeutic potential. We then explore sev-
eral major disciplines based upon informatics and computational methods—cheminformatics,
bioinformatics, and semantic (or ‘knowledge-based’) informatics—and their associated meth-
ods that can be used specifically for NP drug discovery. These methods are summarized
graphically in Figure 1.4. Finally, we conclude with a recap of the major gaps currently
facing the field of computational NP drug discovery, and suggest actions for the future that
could help to resolve these problems.
1.3.1. Classes of therapeutic natural products
There is no definitive consensus on what groups of substances comprise “natural products”,
with some authors restricting them to small molecule secondary metabolites [179], and oth-
ers more broadly stating that an NP is any chemical substance produced by a living organ-
ism [178]. For the purpose of this review, we adopt the latter of these two definitions: that
natural products include all classes of chemical substances that are produced or recruited by
living organisms, and have the ability to be isolated and reused by humans. This definition
includes an incredibly diverse range of compound types; therefore, it is crucial to understand
the different subgroups of NPs, along with their characteristics. These classes of NPs fre-
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quently overlap and have vaguely defined boundaries, but they are nevertheless useful for
understanding the methods that can be applied to them.
Phytochemicals
Phytochemicals—chemicals synthesized by plants—encompass an broad range of NPs, in-
cluding members of many of the other classes described later in this section. Phytochemicals
can be toxic, they can provide important dietary nutrients (such as amino acids, antiox-
idiants, and dietary fiber), or they can be inert in humans. For most research purposes,
however, phytochemicals are limited to primary and secondary metabolites in plants, which
can be generally divided into phenolic acids, stilbenes, and flavonoids (which, themselves, can
be further subdivided into more specific subclasses), all of which are small molecules (rather
than macromolecules, which tend to be prevalent in many of the other classes we discuss) [88].
These chemicals have been the source of many traditional and modern medicines, famous
examples of which include the analgesic acetylsalicylic acid (aspirin), the heart medication
digoxin, and the chemotherapy drug paclitaxel [173].
Fungal metabolites
Fungal metabolites serve a relatively similar role to plant metabolites, so much so that they
share some of the same subclasses (perhaps most notably the flavonoid compounds). Like
plant metabolites, fungal metabolites can treat a wide variety of diseases and conditions, but
they are perhaps most famous as a source of many successful antibiotics. Other areas of suc-
cessful application include antimalarials (antiamoebin), immunosuppressants (ciclosporin),
statins (mevastatin, lovastatin), and more [244].
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Toxins
Toxins are substances that can potentially harm or kill. They include poisons and venoms,
and are (by definition) produced by living organisms. Poisons are toxins that cause harmful
effects when swallowed, inhaled, or absorbed through the surface of the skin, while venoms
are toxins that cause harm when actively injected via a sting or a bite.
Poisons are produced by members of many major clades of organisms, including plants,
fungi, bacteria, and most groups of animals. Natural poisons are usually used for defensive
purposes, although some species have adapted them for more complex roles [123]. They can
include members of all classes of molecules, and although many tend to consist of relatively
small molecular structures, macromolecules such as proteins, large cabohydrates, and lipids
can be poisonous as well. NP poisons include many chemotherapy drugs, particularly when
their toxic effects act more selectively on cancer cells than healthy cells. Some examples
include paclitaxel (from Taxus brevifolia) and vinblastine (from Catharanthus roseus) [244].
Venoms are complex mixtures of chemicals produced by animals for either defensive
or offensive purposes (or, sometimes, both in the same species). An individual species’
venom can include hundreds of unique chemical compounds, many of which are proteins
that act on specific molecular targets. Venoms are highly evolutionarily optimized to fit
organisms’ biological niches [52], but due to interspecies homology, the effects of individual
venom components have led to numerous therapeutic applications, including FDA-approved
treatments for hypertension, diabetes, neuropathic pain, and more [141]. Like poisons,
venoms have also demonstrated potent anti-cancer effects, and their high target specificity
has made them of particular interest for applications of precision medicine, particularly for
rare or aggressive cancer types [206,267].
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Antibodies
Components of the immune system—particularly antibodies—have long been attractive
for drug discovery and design. Their primary function is recognition and inactivation of
pathogens, including bacteria and viruses, but biotechnologists have repurposed them for
many ‘unintended’ uses, including the targeted treatment of various diseases. One approach,
known as immunotherapy, involves the design and application of monoclonal antibodies that
bind specifically to certain cells or proteins related to the disease of interest. Naturally, these
are often autoimmune diseases, such as rheumatoid arthritis [222] and allergies [114], but
they have also been applied to diverse diseases such as viral infections [140] and multiple
sclerosis [100]. Recently, substantial attention has been given to immunotherapy treatments
for cancer, exemplified by the 2018 Nobel Prize in Medicine being awarded for research in
this area [108, 136, 209]. The second approach involves using antibodies as delivery agents
for therapeutic compounds, which is also being explored extensively for cancer, due to its
capacity to mitigate off-target effects [11]. Interestingly, this delivery method has attracted
specific attention for the delivery of chemotherapeutics that are, themselves, NPs [157].
It should be noted that—in spite of the substantial accomplishments described above—
antibodies have failed to deliver on several therapeutic applications that originally held
promise, often for characteristics that are inherent to antibodies in general. One example
involves the treatment of Alzheimer Disease (AD) using monoclonal antibodies. Antibody-
based treatments for AD performed strongly in mouse models [13] and in early-phase clinical
trials [99], but in phase-2 trials and beyond, they have failed to deliver [241]. Multiple theories
have been posed, but the two leading hypotheses for failure have been that (1) antibodies
are limited in their ability to cross the blood-brain barrier, and (2) certain degenerative
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diseases require early treatment for antibodies to be effective, far before patients begin to
show symptoms [231]. Other failures in antibody therapy are related to the activity of
antibodies themselves—drugs like theralizumab (designed to treat leukemia and rheumatoid
arthritis) failed in human trials due to inciting a life-threatening ‘cytokine storm’ in all
healthy volunteers [67]. Nonetheless, much research on new antibody therapies is being
conducted to treat the same diseases associated with these early failures [223].
NPs with limited therapeutic potential
The classes of NPs described above cover substantial breadth. However, to provide a more
complete image of drug discovery in terms of NPs, it is also important to consider classes with
only limited—or at least presently unknown—therapeutic potential. For the purposes of this
review, we focus on whether a compound is reactive enough in living systems to potentially
perturb that system. If it is, then there exists an opportunity to exploit the perturbations
for potentially therapeutic outcomes. The largest group of NPs that falls short in this
regard is those with purely structural purposes, including materials like wood, biopolymers,
and excretions like spider silk, which suggests that the drug discovery methods discussed in
subsequent sections of this review are unlikely to generate many new lead compounds.
Nonetheless, biology is rife with exceptions to every rule, and even these groups of
NPs have occasionally yielded compounds with therapeutic use. Wood creosote has been
used for centuries as a treatment for diarrhea, and is currently marketed in Japan under the
trade name Seirogan [98]. Biopolymers have not resulted in drugs themselves, but have been
used many times to successfully deliver drugs within living systems [183]. Even spider silk
has shown potential in drug delivery [232], and has been bioengineered to have antibiotic
23
1.3 INFORMATICS METHODS IN NATURAL PRODUCT DRUG DISCOVERY
properties [91]. For this reason, we hesitate to say that any class of NPs has no therapeutic
potential. In a practical sense, these observations are most useful in a cost-benefit analysis
scenario, when it is necessary to balance research budget with scientific risk, highlighted
by Dickson and Gagnon as one of the major factors influencing the total output of the
pharmaceutical industry [60].
1.3.2. Cheminformatics methods
Cheminformatics methods can generally be classified according to the types of characteristics
they exploit: either direct measures of chemical activity (e.g., chemical constants, reactive
groups, or ADME measurements), or indirect measures (e.g., structural motifs, compound
class membership, or other higher-order observations). These techniques can be further sub-
divided; for example, structural comparisons can be applied either before or after promising
chemical activity is known (which we refer to here as prospective and retrospective structure
mining, respectively). Prospective structure mining is conducted in a supervised manner,
where known chemical activity of well-characterized compounds is compared to the struc-
tures of query compounds to predict the therapeutic potential of the queries. Retrospective
structure mining, on the other hand, is more analogous to unsupervised learning techniques,
where other screening techniques first identify a compound of interest (referred to as a “hit”),
and then seek to expand the number of candidate compounds by searching for structures
that are similar to the hit compound.
Many traditional cheminformatics methods are challenging to adapt to certain classes
of NPs, particularly when the NPs consist of large chemical structures (like venoms, anti-
bodies, or other protein-based NP drug candidates). For example, generating combinatorial
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libraries of large polypeptides is currently intractable, due to the massive search space.
However, additional characteristics that are unique to these classes of NPs enable either
simplifying assumptions to be made or the invention of entirely new approaches for predict-
ing bioactivity [104]. Here, we divide cheminformatics into 3 major categories of methods
that have been used to success with NPs, providing discussion of the caveats that must be
considered for NPs in particular.
Natural product QSAR analysis
Quantitative Structure Activity Relationship (QSAR) analysis is a widely used—if often
ambiguously defined—technique in cheminformatics for predicting a response variable given
a set of structural, chemical, and or physical input variables (known as molecular descriptors).
Generally, the goal is to learn a function of the form
yˆ = f(x) + 
where x = (x1, . . . , xN) is the vector of N input variables, yˆ is the estimated response
(continuous in the case of regression, and integer-valued in the case of classification), and  is
an error term. f can be any appropriate model; common choices include logistic regression,
support vector machines, random forest, artificial neural networks, and others. Recently,
deep learning has shown to be particularly effective for predicting a wide variety of responses,
including solubility, probe-likeness, and others [126]. A number of free and commercial
software implementations of QSAR are available for a variety of use cases [19, 246], and
approaches for adapting generic statistical and machine learning models for QSAR are readily
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available [135].
QSAR has been applied fairly widely to different classes of NPs, where specific classes
tend to dictate the chosen molecular descriptors. Typical choices for non-NP applications
include symbolic (1- or 2-D) descriptors, 3-D spatial organization, higher-order (e.g., time-
dependent or ligand-bound) conformational characteristics [196], experimental measurements
(partition coefficient, polarizability, refractivity, etc), and many others. For a detailed review
of these and similar descriptors, see [42]. Additional characteristics that can be used for
small-molecule NPs include categorical (‘one-hot’) variables indicating class membership
(e.g., alkaloid, terpenoid), species of origin (or more general taxonomic clades), and other
biological features. Macromolecular NPs are substantially more restricted in terms of the
types of descriptors that can be used effectively. Generally, 3-D conformational descriptors
and binding data function best for these NPs, and yield good results [58, 171]. QSAR has
performed adequately for predicting binding affinity of antibodies to proteins—Mandrika et
al. describe a model consisting of 26 physicochemical descriptors (covering hydrophobicity,
polarity, electronegativity, etc.) at each amino acid position in a library consisting of single
chain monoclonal antibodies [156]. While this model has not yet been applied to NP drug
discovery, it seems to be a feasible way forward.
Molecular docking and dynamics
QSAR is a useful statistical method for predicting potentially therapeutic interactions, but
it is often desirable to directly model the chemical or physical interaction that is being inves-
tigated. Molecular docking is an approach that seeks to predict if and how two compounds
(usually a target and a ligand) physically interact. This is usually performed in two steps:
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(1) searching for potential conformational fits, and (2) scoring those fits. Molecular dynamics
is a particular simulation technique that can be applied to docking, and is popular in drug
development. From a high level, molecular dynamics performs a computational simulation
of the atoms and molecules (often including solvents) present in a putative reaction, and
allows the molecules to interact for a period of time. The technical details and algorithms
for docking and dynamics are well summarized elsewhere [118, 189]—we will instead focus
on broad caveats, issues, and innovations in applying these to NPs.
The class of NP compound tends to dictate the role (target vs. ligand) that the com-
pound plays in docking simulations. Typically, small molecule NPs and relatively short
polypeptides (e.g., peptide toxins and venom components) act as ligands, while larger pro-
teins and protein complexes act as targets (although exceptions are common). This distinc-
tion is important, especially when the goal is screening many candidate compounds: usually,
the target is held fixed, while the ligand can be drawn from libraries of many compounds.
Therefore, it is computationally feasible to perform docking of many small molecule com-
pounds when a specific molecular target is already known [121, 137, 151]. Conversely, if a
macromolecular NP is suspected of interacting with endogenous small-molecule metabolites
(e.g., in human cancer cells), docking simulations can be used to mine which metabolites
could bind to the NP [194]. If both a target and a ligand are already predicted by other
means (e.g., QSAR or other methods described in this review), docking is commonly used as
a secondary validation method. In spite of their large molecular weight, antibodies are rela-
tively easy to screen in large numbers via docking, due to their specific structural and binding
constraints that can substantially reduce computational complexity of simulations [1, 252].
Molecular dynamics is an important technique for characterizing physical interactions
27
1.3 INFORMATICS METHODS IN NATURAL PRODUCT DRUG DISCOVERY
of putative drugs with their targets, but due to computational challenges it cannot be used
with current technologies in a data-driven manner to screen very large numbers of NPs
against similarly large numbers of potential targets simultaneously [217]. However, it has
proven incredibly valuable in uncovering specific therapeutic mechanisms of NPs (venom pro-
teins in particular). An early and influential example of this came in 1995, when Albrand et
al. combined molecular dynamics with NMR to explain how Toxin FS2 (from Black Mamba
venom) blocks L-type calcium channels, causing potent cardiotoxic effects [3]. Additionally,
there are noteworthy success stories that have emerged from screening relatively small NP
databases against specific drug targets: The compound ellagic acid—which has shown both
antiproliferative and antioxidant properties—was identified by Moro et al. by screening a
proprietary database of 2,000 NPs against the oncoprotein casein kinase 2 [50]. Similarly, Fu
et al. identified Jadomycin B—another molecule with anticancer effects—by screening 15,000
microbial small molecule metabolites against the oncoprotein Aurora-B kinase [78]. These
examples illustrate the feasability of molecular dynamic studies for discovering new thera-
peutic NPs, and suggest that overcoming associated computational challenges will enable
their widespread application in diverse and data-driven contexts.
Computational mutagenesis and library construction
One of the most common techniques for identifying drug candidates is to generate massive
libraries of compounds that can be screened in parallel, with the understanding that only a
very small fraction will result in ‘hits’ (potential therapeutic activity). There are many ways
such libraries are generated, many of which fall under the umbrella term of combinatorial
chemistry (i.e., enumerating chemical structures using combinatorics) [242]. NPs provide
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some advantages over traditional (non-NP) classes of candidate compounds, namely that
such ‘libraries’ already exist in nature. General purpose online databases of chemical com-
pounds (such as PubChem and ChEMBL) [81, 142] contain many NPs that are annotated
by compound class, while other, more specific databases (such as ArachnoServer, VenomKB,
and the Dictionary of Marine Natural Products) provide even more granular annotations for
aggregating NP libraries with various characteristics of interest [192,204].
Computational mutagenesis is a related class of techniques that has shown efficacy in
certain classes of NPs. This method involves specifying a template (e.g., a certain antibody
with putative therapeutic activity that requires optimization), and then sequentially mu-
tating locations in the template’s structure to generate a library of candidate compounds.
These libraries can then be screened in silico (e.g., using molecular docking simulations as
described in §1.3.2) to find structures that can be engineered in the lab. Antibodies, in
particular, are particularly well-suited to computational mutagenesis, by modifying amino
acids in binding regions [226, 262]. The feasability of mutagenesis techniques in the context
of NP drug discovery was demonstrated by Chen et al., who generated a library of analogues
of the 7-residue NP peptide HUN-7293 to optimize its inhibitory effects on cell-adhesion [40].
It should be noted that one of the advantages of working with NPs is the potential of
avoiding library screening entirely, under the assumption that nature has optimized it for
biological activity. This point is expanded on in §1.3.3.
1.3.3. Bioinformatics methods
Bioinformatics methods for drug discovery include anything related to the biological func-
tion of potentital drug candidates, including sequence-based characteristics, interactions with
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body structures (metabolites, proteins, cells, tissues, etc.), pathway perturbations, and toxi-
city, among others. Multi-omics and high-throughput sequencing are also major areas within
bioinformatics. Most subdisciplines of bioinformatics can be applied in some way to the drug
discovery process [244,261].
In the case of NPs, researchers are able to make use of an entire range of techniques
related to the organisms that produce the compounds. In particular, phylogenetics and
evolution provide many routes for various drug discovery activities. Closely related organ-
isms often produce similar proteins and metabolites, so when one natural compound with
promising activity has an unsuitable therapeutic index for human use, libraries of similar
compounds can be easily constructed by searching in organisms within the same genus. How-
ever, these techniques must be applied with caution: members of some groups of natural
compounds (such as venom proteins) are heavily optimized to fit a very particular biological
niche, so even members of the same species may have entirely unique metabolic profiles with
respect to compounds of interest. One prominent example of this was found in the rat-
tlesnake species Crotalus oreganus helleri, where members of the species living on different
sides of a mountain range produced entirely separate venom profiles [237].
Gene expression perturbation
The rise of multi-omics approaches to uncovering mechanisms of disease has led to multitudes
of ways to assess the effect that putative drugs have on cells. In particular, gene expression
perturbation—quantified using RNA-sequencing and transcriptomics—has led to a number
of innovative breakthroughs in drug discovery for diseases associated with gene disregulation,
including cancers and various other diseases with complex genetic etiologies [225,234]. Along
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with environmental exposures, structural abnormalities, and other influencing factors, these
diseases often can be attributed in part to abnormalities in gene expression, including the
systems-level effects of expression perturbation in the larger context of cell signaling and
metabolic networks [47, 182]. More accurately, differential expression can be treated as a
phenotypic signal that arises from underlying disease etiology. Accordingly, drugs and drug
candidates that effectively invert such deleterious effects are potential therapies for these
diseases.
This technique is particularly well-adapted for use in NP drug discovery, as vast num-
bers of compounds from all classes of NPs are specifically optimized to have roles in cell
signaling or metabolic networks, and are already known to be relatively biologically sta-
ble [141]. Compounds used in Traditional Chinese Medicine (TCM) have been particularly
well utilized in this area. In a 2014 study, researchers uncovered likely mechanisms by which
the TCM compound berberine exhibits anti-cancer activity, using publicly-available expres-
sion data for berberine-perturbed human cells taken from the Connectivity Map (CMap)
project [138]. Another important recent example by Lv et al. provides differential gene ex-
pression profiles in response to 102 different TCM compounds, presented as a framework
from which to base future systematic research on the activities of TCMs [149].
A separate but related approach involves analysis of differential expression in the or-
ganisms producing the NPs (rather than the organisms that NPs act upon). An investigation
by Amos et al. discovered previously unknown NPs—as well as putative mechanisms describ-
ing their functionality—by comparing transcriptome profiles of different bacterial species in
the genus Salinispora [5], underscoring the diversity of emerging multi-omics techniques that
can be employed within NP drug discovery.
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Modeling protein structure and function
Although the size and complexity of proteins is often prohibitive to structure-based analyses
designed for small molecules, other drug discovery approaches leverage the unique character-
istics of proteins and other macromolecules to perform discovery in ways that are otherwise
impossible. Since many classes of NPs are comprised of proteins, these techniques can often
be adapted to NP drug discovery with relative ease.
Some methods use supervised machine learning algorithms trained on protein structures
(and motifs) with known activity to predict activity in previously uncharacterized proteins;
this is essentially traditional QSAR designed to work on proteins. The FEATURE frame-
work [85] does this using 3-dimensional spatial orientation of atoms to predict activity at
numerous “microenvironments” within a larger macromoleucle, and is therefore generalizable
to diverse proteins with conserved functional activity. Other research teams have designed
similar frameworks based on other machine learning models, including deep learning models
like convolutional neural networks [243,245]. For further details on learning protein function
from structure, we refer the reader to [190].
Still other protein functional modeling approaches rely on input variables that behave
like “abstractions” of raw molecular characteristics, including amino acid or DNA structure
(along with sequence alignment algorithms) [250], ontology annotations (see §1.3.4 for more
details) [177], and biomarker response [75].
Using evolution to discover drug candidates
The fact that NPs are derived from living organisms implies that they either serve a spe-
cific purpose in the context of that organism, or they are a byproduct of an important
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process [233]. Therefore, we can use evolution and taxonomy as tools for both discover-
ing new compounds and their effects, as well as for generating libraries of similar natural
products [160].
The simplest—and most common—use of phylogenetics in natural product drug dis-
covery revolves around the axiom that closely related species produce similar NPs. This can
be used to predict the structures of NPs, given structures for similar NPs in related species
are already known [273]. Following a pattern akin to QSAR modeling (described in §1.3.2),
phylogenetics can also be repurposed to predict other characteristics of closely related NPs,
including molecule classes, toxicity, stability, and others, where instead of using molecular
descriptors as observed features of the NP, you instead use evolutionary characteristics to
build a predictive model. A noteworthy example is given by Malhotra et al., who used
discriminant function analysis (DFA) to classify and predict functions of over 250 phospho-
lipase A2 proteins from viperid snakes, where aligned amino acid sequences alone were used
to construct the input features for the DFA model [154].
Other uses of evolution in drug discovery employ phylogenomics to discover associ-
ations across more distantly related species (e.g., between humans and microbes). This
includes efforts to catalog the entire breadth of various classes of natural products to create
comprehensive NP class libraries (see §1.3.2 for more details) [208]. In 2016, Rudolf et al.
showed that comparative genomics in diverse microbial species could identify 87 distinct
gene clusters across 78 bacterial species corresponding to a class of putative NP anticancer
drugs known as enediynes [213]. By finding instances of NP coevolution in distantly related
species, studies have uncovered compounds that play keystone roles in metabolic processes,
leading to therapeutic solutions in analogous processes in humans. A noteworthy and so-
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phisticated example is shown in the CSMNA method [271], which is based on the hypothesis
that similarities between human and plant metabolic networks can be used to guide phy-
tochemical drug discovery. The authors validate their drug discovery algorithm by showing
that similarities between the plant Halliwell-Asada (HA) cycle and the human Nrf2-ARE
pathway underlie antioxidant activity of HA cycle molecules on proteins in the Nrf2-ARE
pathway.
Some caveats need to be kept in mind when using evolutionary approaches. Cer-
tain classes of NPs are under evolutionary pressures that complicate phylogenetic analysis.
Venom proteins, in particular, can be highly divergent even among species within the same
genus [36], a phenomenon attributed to the high metabolic cost of venom production, and
the highly targeted nature of many venom proteins to specific prey species.
1.3.4. Semantic (knowledge-based) methods
Cheminformatics and bioinformatics are two of the major disciplines within biomedical
informatics, and comprise two of the primary fields involved in translational research and
drug discovery. We now turn our focus to a set of methods that emerged from semiotics,
linguistics, and library science, but have been adapted to serve broad functions in computer
science and artificial intelligence—known as knowledge-based or semantic (i.e., relating to
human-interpretable meaning) methods. In general, these are methods involving the applica-
tion of various knowledge representations, such as ontologies and structured terminologies.
Some activities within this group include rule-based natural language processing, certain
types of clinical data mining, knowledge extraction, semantic data normalization, and oth-
ers. Especially in the context of drug discovery, knowledge-based methods are frequently
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applied in coordination with bioinformatics and/or cheminformatics methods, and serve as
one of the main approaches to combining and unifying findings and intermediate results
spread across separate research activities.
Perhaps the most well-utilized resource in knowledge-based approaches to drug discov-
ery is the Gene Ontology [8], which classifies conceptual biological entities into 3 groups:
molecular functions, cellular components, and biological processes (each of which is impor-
tant in various stages of the drug discovery process). Researchers have created multitudes
of data resources to assist in drug discovery, and many of these are mapped to the Gene
Ontology to assist with in silico aggregation and preliminary validation of putative hypothe-
ses. Some of these linked resources include DrugBank [261], UniProtKB/Swiss-Prot (and
associated annotation programs like ToxProt) [113], and ChEMBL [81], all of which catalog
compounds that may confer some therapeutic effect.
Still other tools have been created to map unstructured data relevant to drug dis-
covery (such as journal article abstracts in PubMed) to more structured representations.
MetaMap, SemRep, and Semantic Medline from the National Library of Medicine, as well
as the NCBO Annotator from the National Center for Biomedical Ontology identify ontol-
ogy and terminology terms within free text (usually pulled from journal articles) at various
levels of abstraction. These tools have been used to successfully perform ontological infer-
ence across multiple levels of evidence for many discovery tasks, including drug discovery.
For further details, we refer the reader to the original paper describing Swanson’s Fish Oil-
Raynaud’s Syndrome hypothesis [238], which explains how structured knowledge and graph
algorithms can be used to discover informative associations fragmented across otherwise
unrelated publications [38].
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Other levels of knowledge representation (e.g., not formally controlled at the concept
level) also have important roles in drug discovery; tools like OMIM can be used to map
newly discovered drug-gene associations to diseases that are modulated by that gene or set
of genes. For comprehensive listings of the various ontologies, knowledge representations,
and similar tools with proven roles in drug discovery, we refer the reader to a number of
existing reviews [79,150,244].
While the number of ontologies and similar resources relevant to drug discovery are
vast, advanced applications of these resources are relatively scarce. This trend is even more
striking in regards to NP drug discovery. As of now, most therapeutic associations between
NPs and disease are discovered serendipitously rather than through systematic, rigorous
applications, although earlier sections of this review describe notable exceptions to this trend.
In light of the fact that advanced use of semantic methods is rare in NP drug discovery, we
will additionally consider applications of ontologies and terminologies used for drug discovery
that could be applied to NPs, based on current knowledge.
Literature mining
Literature mining—the process of using text mining on scientific literature databases—is
one of the most common usages of semantic biomedical knowledge resources. The MED-
LINE/PubMed database contains over 26 million biomedical text citations, many thousands
of which contain knowledge related to NPs, and possibly describing characteristics of those
NPs that provide direct or indirect evidence of therapeutic activity. There are generally
two ways to automatically extract such knowledge from biomedical publications: (1) Using
existing ontology/terminology annotations, or (2) using natural language processing (NLP)
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techniques that discover such annotations.
Medical Subject Headings (MeSH) are one terminology resource designed to structure
the content of PubMed articles, and are applied manually by expert annotators at the US
National Library of Medicine (NLM) to new articles shortly after indexing in PubMed [145].
MeSH terms cover a diverse range of biomedical concepts, arranged in a hierarchical fashion,
and cover various classes of NPs. MeSH can be used to aggregate PubMed articles describing
certain types of NPs, and can be refined using additional terms (e.g., “Drug Discovery”)
or qualifiers (e.g., “/therapeutic use”). MeSH terms can link journal entities to struc-
tured external databases by either using cross-mappings (including via the NLM’s Unified
Medical Language System (UMLS)) or annotations in external databases directly to MeSH
terms [211]. MeSH terms have been used to summarize components of plant genomes [18],
demonstrating potential paths forward in discovering novel NPs (rather than using the terms
to gather knowledge about known NPs).
A limited number of databases provide access to curated sets of articles describing
NPs. VenomKB provides articles annotated to venom components as well as literature
predictions describing the putative therapeutic effects of those components and mappings
to other external databases [205] (we will examine VenomKB in depth in Chapter 2).
Similarly, the NPASS database presents chemical characteristics of a broader range of NPs
and provides references to PubMed entries describing manually-curated biological activity
measurements in a range of organisms (including humans) [270]. Other databases, including
MarinLit and NAPRALERT, provide commercial and paid access to curated NP literature
data.
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Electronic health record mining
Similarly to literature mining, we can apply knowledge retrieval techniques to observational
data sources. As far as drug discovery is concerned, observational data provides a method
for assessing the effects compounds have on humans in the absence of rigorously controlled
clinical research studies. This style of data analysis offers several major advantages over
clinical trials, including avoidance of exposing new patients to potentially harmful treat-
ments, and mitigating certain types of bias associated with eligibility and patient selection.
Observational data can often produce larger cohorts than clinical trials. Various sources of
observational data can be utilized for drug discovery, but here we will focus on electronic
health records (EHRs), due to their prevalence and proven utility for many translational
research tasks. Although privacy concerns, data fragmentation, and standardization have
traditionally hampered access to EHR data—particularly for research teams without clinical
expertise or affiliation with a large academic medical center—rapidly growing efforts such
as Observational Health Data Sciences and Informatics (OHDSI) [103] and the Electronic
Medical Records and Genomics (eMERGE) network [166] are breaking these barriers in ways
that will increase access to data covering the breadth of the translational spectrum.
EHR data are complex, multimodal, and subject to many unique biases and ethical/le-
gal constraints [255]. In addition to free text (recorded by health care providers), a number
of structured data types are also present (including claims data, medication orders, labora-
tory measurements, patient demographics, and others). As of now, no major applications of
EHR data mining to NP drug discovery have been reported, but a number of related areas
provide hints as to its feasibility. A review by Yao et al. highlights 3 specific ways that EHRs
can aid drug discovery: (1) Finding relationships between diseases for the purposes of drug
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repurposing, (2) evaluating the usage patterns and safety of drugs and/or drug candidates,
and (3) discovering phenotype–genotype associations that can lead to the discovery of new
drug targets for specific diseases [268]. Relevant caveats of each of these can be discussed
from the perspective of NP drug discovery, including specific advantages and disadvantages
that NPs provide when compared to non-NP drugs and drug candidates.
Drug repositioning involves taking an existing drug and using it to treat a different
disease than what it is currently intended for [7]. EHRs have been used for a number of drug
repositioning approaches. The most common repositioning strategy involves discovering
similarities between diseases, and then using those similarities to imply new treatments.
This is based on the assumption that diseases with similar etiologies will produce similar
signals in the EHR, and that similar etiologies may imply similar treatments. An important
example by Rzhetsky et al. showed unexpected similarity between bipolar disorder and breast
cancer [215]. Recently, it has been demonstrated that the breast cancer drug tamoxifen may
be useful for treating the symptoms of bipolar disorder [130].
EHR data can also be used to assess the safety of drugs (or putative drugs), by de-
termining whether exposure to the drug increases risk of adverse effects [221, 240]. This is
easiest for approved drugs that have coded representations in the EHR software (e.g., those
with ATC codes or similar—experimental and unapproved drugs generally do not have a
structured representation in EHR databases), but natural language processing can identify
experimental and putative drugs with reasonable efficacy [25]. This suggests that NP drug-
candidate safety surveillance could be performed on free-text notes in the EHR, especially
when treated as environmental exposures rather than physician-prescribed interventions.
The feasibility of this approach was demonstrated by Zhang et al., who showed that herbal
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and natural supplements (which are usually considered NPs) could be identified in medica-
tion lists using natural language processing, and quantified the gap between structured drug
representations and these compounds [272]. Two of the main gaps in need of resolution to
realize this goal include specifying a standardized nomenclature for NPs [57], and identifying
where (geographically) hospital patients may be exposed to the NPs being investigated.
Discovering new drug targets is not strictly the same thing as drug discovery, but it
does provide an essential starting point for identifying new drug leads. Recent decades have
seen a steady decline in the discovery of new targets, and previous reviews on the topic have
called for new and innovative strategies to address this issue [143, 230]. Using EHR data
and clinical biobanks to conduct Genome Wide Association Studies (GWASs) and Phenome
Wide Association Studies (PheWASs) are touted as solutions [268], by providing associative
links between diseases and specific genetic loci, which can then be used as targets for new
precision drug therapies [167, 258]. NPs, in particular, come into play when considering
their unique abilities to target certain genes and gene products that are poorly targeted by
small molecules. Both monoclonal antibodies and protein-based therapeutics are known for
their ability to target individual cell types, especially useful in cancers with specific genetic
signatures [2,49]. GWAS and PheWAS are relatively new compared to the drug discovery and
development timeline, but we will likely see many NP drugs emerging from clinical trials that
used EHR- and biobank-enabled analyses for target discovery in the coming decades [244].
Linking HTS data to putative disease treatments
Until now, we have discussed ways that ontologies and terminologies can be used to retrieve
and structure knowledge, but another important role semantic techniques play in biomedicine
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is integrating disparate data sources in ways that otherwise require massive amounts of man-
ual interpretation and annotation to apply at scale. This is important for many reasons,
including experimental validation, increasing statistical power and inferential capacity, and
even to discover new knowledge entirely. A particular application that has experienced rapid
growth and major methodological advancements in drug discovery is linking new types of
high-throughput sequencing (HTS) data to clinically-meaningful associations. Previously
mentioned techniques such as gene expression perturbation (§1.3.3) yield results consisting
of signals that have biological meaning, but no explicit connection to clinical phenotypes.
Important early examples of data-driven drug discovery from gene expression formed thera-
peutic associations between cimetidine and lung adenocarcinoma [225], as well as topiramate
and inflammatory bowel disease [64], but these examples required manual curation of many
phenotype-linked expression profiles from which discovery could be performed. Knowledge
representations provide a method for making these connections automatically, when correctly
leveraged.
Successful knowledge integration of this type requires links to be formed between (a.)
sets of genes (or, more specifically, groups of probe sets) and metabolic pathways, as well
as (b.) links between pathways and phenotypes. A number of well-established and richly
annotated gene-pathway databases (including Reactome and KEGG) [70,117] already exist,
and are used widely by the biomedical research community. Resources linking pathways to
phenotypes are considerably less prevalent (and less complete), due largely to a limitation of
available, relevant data, but ongoing efforts in the translational bioinformatics community
are changing this. Integrating differences in gene expression and phenotypic response at the
cell- and tissue-level with pathway data has shown particular promise in this area [86, 87].
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A recent review by Oellrich et al. outlines emerging and established tools for computational
phenotyping [187].
Similar studies are, however, nearly absent from the realm of NP drug discovery. The
unique characteristics of different NP classes (especially those described earlier in this re-
view) can facilitate the phenotyping process. Metabolomics data provides clues as to NPs’
original functions in their source organisms, which can often be extended to their effects
when applied to humans [264, 266, 271]. Phylogenomics can highlight similarities between
the genetic epidemiologies of complex diseases in humans versus model organisms, possibly
suggesting species from which to mine compounds that can treat these diseases [207]. Even
the predator/prey adaptations of NP-producing species can suggest the biological function
of NPs [54, 169]; the discovery that the cone snail Conus geographus hunts fish by releasing
insulin into the surrounding water (resulting in rapid hypoglycemic shock in the prey) led to
the identification of a powerful insulin-receptor-binding motif that has shown considerable
promise for future treatments of diabetes [168]. Some recent studies focusing on discovery
from TCM data show promise: Cui et al., for example, created a TCM chemical structure
database that they screened against acetylcholinesterase (ACE) inhibitors, both via dock-
ing simulations with the known structure of ACE, as well as similarity to existing ACE
inhibitors retrieved from BindingDB [51]. Conceivably, ontology resources could be used to
adapt these methods into an automated approach for screening many drug classes with little
to no manual curation.
Linking HTS data to disease phenotypes is only one application of semantic knowledge
resources that could be a boon for NP drug discovery. There are many other conceivable
uses for linking evidence between clinical datasets, drug terminologies, literature-mined as-
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sociations, and organismal biodiversity data, any of which could lead to potentially valuable
discoveries and improved evidence for unproven hypotheses.
1.3.5. Gaps and opportunities in NP drug discovery
Computers have revolutionized the way medicine and biomedical research are conducted,
and the same applies to drug discovery. In doing so, it is critical to consider all of the ways
in which computers can assist the discovery process in order to maximize the return on
research efforts. In terms of natural product drug discovery, this review reveals that while
some branches of informatics are being utilized extensively, other methods have not been fully
explored. By summarizing 9 representative groups of informatics methods (see Figure 1.4
and Table 1.1), we highlight these disparities and, by extension, areas of opportunity for
future research.
Pharmacologists and the pharmaceutical industry have championed the use of ad-
vanced cheminformatics techniques in concert with cutting-edge biotechnology innovations.
Although NP drug discovery has always been a hallmark activity in pharmacology, phar-
maceutical researchers have only applied these cheminformatic techniques to NPs rather
recently. Both QSAR (§1.3.2) and docking simulations (§1.3.2) are standard practice for
studying the therapeutic potential and mechanisms of NPs. There is also a fair number of
NP library studies (§1.3.2) that have been used to success—especially when focused on anti-
bodies [101]—leading to the discovery of drugs such as adalimumab [109], ecallantide [163],
and others [184]. As computing power improves, it is likely that we will see similar attention
be paid to more challenging NP classes, such as venom peptides and other macromolecular
compounds.
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Bioinformatics demonstrates a similar trend, albeit somewhat earlier in its development
(with regards to NP drug discovery) than cheminformatics. The bioinformatics methods
covered in this review are intriguing in that each is a technique originally intended for uses
other than drug discovery. Differential gene expression analysis (§1.3.3) was originally used
to explore differences between cell lines and disease states rather than the effects of drug
perturbation, although the conceptual jump in applying expression analysis to drug discovery
is arguably an obvious one. However, due to this technique’s relatively recent emergence,
few examples using NPs (as opposed to non-NP small molecule candidates) currently exist
in the literature, none of which are truly data-driven (i.e., agnostic to both specific diseases
and specific NP drug candidates). Nonetheless, analyses targeted towards specific diseases
compared against the Connectivity Map dataset have resulted in two substantial discoveries
based on plant metabolites: Celastrol as a treatment for acute myeloid leukemia [92], and
gedunin as a treatment for prostate cancer [97]. Therefore, the preliminary groundwork for
truly data-driven drug discovery for NPs via perturbational differential expression analysis
has already been established. For further examples of the successes of the Connectivity Map
approach to data-driven drug discovery overall, we direct readers to a previous review by
Musa et al. [176]. Phylogenetics (§1.3.3)—one of the earlier uses for computers in biology—
has become known for its diverse areas of application, including drug discovery. Since NPs
come from organisms that can be studied in a phylogenetic context, bioinformaticians have
realized just how valuable of a tool this can be for NP drug discovery, and a number of
completed and ongoing research initiatives capitalize on this.
Semantic methods have been used much less frequently for drug discovery than the
other branches of informatics, and even less so for NPs. Only a few sparse examples of
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literature mining applications (§1.3.4) exist for NP drug discovery. A few studies show that
ontologies and similar methods that link experimental evidence to HTS data and structured
knowledge representations (§1.3.4) could easily be adapted to perform preliminary validation
for expensive and time-consuming manual experimentation to prove therapeutic activity in
NPs, but the actual use of these methods for this purpose is also virtually nonexistent.
EHRs and other clinical data resources are in a similar situation—as far as we can tell, there
are currently no published examples of clinical data mining (§1.3.4) being used to discover
therapeutic associations from NPs.
1.3.6. Data needs for NP drug discovery
Throughout this review, we have touched upon computational and informatics methods with
varying data needs, and have naturally mentioned several data resources that are dedicated
to (or have strong relevance to) NP drug discovery. Just as certain discovery methods are
enabled by characteristics specific to NPs, certain data types and dimensions are as well.
This includes taxonomic/evolutionary data [48, 132], primary (i.e., “intended”) targets and
functions of NPs in nature [22], the crude composition of NPs (often leading to synergistic
effects, analogous to drug combination therapies) [29, 39], and others specific to particular
classes of NPs. A more comprehensive description of NP databases is presented in a review
by Xie et al. [265], but here we will cover some of them in brief as they pertaining to specific
data needs.
The diversity and complexity of data types relevant for NP drug discovery research
poses challenges in storing, representing, and exchanging these data. An immediate con-
sequence is that many NP databases are limited to a narrow range of closely related NPs,
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which results in data fragmentation for the sake of completeness [259]. ConoServer [116] and
ArachnoServer [192] are two NP databases with rich and highly descriptive data, but each
only applies to toxins produced by a single clade of species. One partial solution to this
problem is to form dedicated efforts within larger, more general purpose databases that are
dedicated to improving the representation of NPs, which is the approach taken by the Tox-
Prot manual annotation program within UniProtKB/Swiss-Prot [113]. However, this does
not completely resolve the greater issue of being able to leverage all important data types
that are unique to certain classes of NPs. One other advantage that larger database efforts
have over smaller, specialized NP databases is the presence of APIs and other tools that
enable computational access. Many of the specialized databases do offer the ability to down-
load data in bulk, but these can be incomplete and out-of-date. Furthermore, APIs can assist
in making databases interoperable—an integrated network of specialized and well-annotated
databases that can exchange semantic knowledge solves the issue of adequately representing
granular characteristics while providing many of the benefits of larger data repositories.
Fragmentation of NP databases has also led to issues in maintaining those databases
in the event of funding inconsistencies and institutional career changes—an issue that is
at least partially safeguarded against when data resources are maintained by larger teams
with more robust operating budgets. Three examples of now-defunct NP databases are the
Traditional Chinese Medicine Systems Pharmacology (TCMSP) database [210], the Animal
Toxin Database (ATDB) [93], and the SuperNatural database [65]. Smaller NP databases
can also suffer from issues like having unwieldy and non-descriptive URLs, such as that for
the Tea Metabolome Database (found at http://pcsb.ahau.edu.cn:8080/TCDB/f) [269].
Furthermore, if ownership of such a database changes, or if the principle investigator moves
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to a new institution, the URL would likely break, creating issues in finding the database
when reading the manuscript that describes it—a phenomenon sometimes referred to as
“link rot” [164].
Taking into account these and related issues, a wealth of opportunity is available for
informatics researchers and data scientists to improve the quality, quantity, and intercon-
nectedness of NP databases and knowledge representations. In the following section, we
will reiterate these and other areas of importance for the near future, as elucidated over the
course of this review.
1.4. Semantic knowledge resources
1.4.1. Knowledge representations
Computers are, fundamentally, devices that read series of arithmentic and/or logical instruc-
tions and then carry those instructions out. By combining and layering these instructions in
increasingly complex ways, computer programmers ascribe meaning to the operations in ways
that correspond to human knowledge [260]. Knowledge—the meaningful understanding of
something or someone, acquired through perceiving or learning—implies forming logical con-
nections between concepts and the real-world objects and/or phenomena that those concepts
represent. The computers of today cannot truly obtain knowledge in the strict understand-
ing of the word, but they can be taught the associations between real-world concepts that
define their meaning, and in doing so, can achieve a convincing approximation of knowledge
about concepts. Semantics (specifically, formal semantics) is the branch of logic concerned
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with defining the meaning of concepts through logical axioms and relationships with other
concepts, and it provides the toolkit needed to represent knowledge in a way that can be
serialized and reasoned over by computer systems.
There are different types of semantic knowledge representations that can be used to
represent biomedical data and/or knowledge, each of which has advantages and disadvan-
tages in different scenarios. These vary in their level of expressiveness as well as formality.
More expressive representations of knowledge can be thought of as conveying more mean-
ing. Formal knowledge representations are those that strictly follow a well-defined system of
thought based on logical axioms that link a finite set of symbols, such as unique identifiers
or names.
The least formal type of knowledge representation is a database, which contains data
records that follow a consistent, ordered structure, and cannot be used for inference. Struc-
tured terminologies provide additional expressivity, by arranging entities in a configuration
that specifies subsumption relationships between those entities (also known as IS A relation-
ships.) A semantic network is similar to a structured terminology in that links define their
meaning, but the links are not necessarily directed, and they typically assume additional
meanings instead of only subsumption (e.g., ‘John HAS DIAGNOSIS type-2 diabetes’). An
ontology is the most expressive form of knowledge representation. Although the definition
of an ontology somewhat varies, they generally consist of a semantic network that defines
entities and their relations, along with additional formally defined data annotations attached
to those entities. Additionally, they usually contain both hierarchical and nonhierarchical re-
lationships. Ontologies closely resemble class hierarchies from object-oriented programming
languages, and can contain many similar features. The most common variation of ontology
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in practical applications today is known as an OWL (Web Ontology Language) ontology. In
OWL ontologies, classes group together similar entities that have the same set of attributes
and the same relations to entities of other classes, and specific instances of these entities are
known as individuals. The links between entities are called object properties, while annota-
tions to direct pieces of data are called data properties. OWL ontologies comprise a major
feature of the so-called ‘semantic web’, and they can be developed and interacted with using
software such as Prote´ge´.
1.4.2. Constructing and using ontologies
In practical terms, the process of building an ontology usually consists of first specifying
the ontological commitment, which is a definition of the extent of the ontology’s intended
capabilities, in terms of the domain of knowledge it covers. Once this is determined, the
builder then defines the class hierarchy, adds nonhierarchical relationships, specifies data
annotations and their correct data types, and then fills in individuals for each class. Finally,
ontology reasoning software should be used to ensure that the individuals are defined cor-
rectly and have all of the required object and data properties as required by the specifications
laid out in the class hierarchy.
Rich semantic knowledge representations like OWL ontologies allow for many useful
types of inference to be performed on data. Since they define links between real-world entities
in a way that computers can process, they can be used to automatically answer complex
questions that convey both meaning and new knowledge. Aside from the reaserch I discuss
in Chapters 2 and 4, there is no such suitable representation for venom data. The only
existing ontologies that contain any terms regarding venoms (such as the Gene Ontology and
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Figure 1.5.: Screenshot of an OWL ontology (specifically the Venom Ontology—see §2.2.3)
in the Prote´ge´ ontology editor. The ontology’s class hierarchy is in the leftmost panel, with
the class Organism selected. Members of that class are listed in the second panel from the
left. The remaining panels show annotations and other properties acanthaster planci, an
individual that is a member of the class Organism.
SNOMED-CT) have too broad ontological commitment, and therefore have limited coverage
and value. Scenarios such as that described by Don Swanson in 1986 (in which literature
mining illuminated a link between fish oil supplements and Raynaud’s syndrome) could be
commonplace in venom data, and using ontologies to integrate new venom data with existing
data could provide many hypotheses for drug discovery purposes.
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1.5. Data-driven discovery from gene expression data
1.5.1. Data-driven science
The traditional paradigm for scientific investigation involves posing a hypothesis, and then
attempting to disprove that hypothesis. Well-established scientific theories are based on
failing to disprove similar hypotheses many times, under varying experimental conditions.
Usually, hypotheses are made using some amount of prior supporting knowledge. For ex-
ample, the observation that Conus geographus (geography cone snail) venom suppresses the
sensory circuitry of prey fish in a way that mimics hypoglycemic shock led to the (now well-
established) hypothesis that this venom contains specialized insulins that could be used for
therapeutic applications in humans [168,216]. This approach to scientific discovery provides
many substantial advantages to the scientific process, largely by reducing certain types of
bias and by allowing a methodical approach to building important research on many layers
of supporting prior evidence, theoretically increasing both the precision and the recall of new
discoveries.
One of the most substantial disadvantages to hypothesis-driven science is that it re-
quires researchers to conceive of scientific phenomena (or at least the outcomes of those
phenomena), which limits scientific discovery primarily to concepts and applications that
are at least peripherally being focused on by existing investigations. The main exception to
this is serendipitous discovery, where some new phenomenon is initially observed or hinted at
as a matter of coincidence. A widely known example of this is the discovery of the antibiotic
properties of Penicillium mould, as reported by Alexander Fleming in 1929, when he noticed
that cultures of staphylococcal bacteria cleared in the area surrounding mould spores that
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Figure 1.6.: Hypothesis-driven vs. data-driven science. a.) Hypothesis-driven science fol-
lows a linear path, where previous studies build a basis for formulating new hypotheses.
b.) In data-driven science, data are collected and then mined for statistically significant
patterns, which can then be used as the foundation for hypothesis-driven lines of research.
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accidentally contaminated the plate [74]. Although this initial discovery was made by mat-
ter of accident, it led to a careful and highly impactful line of research—supported by many
subsequent hypothesis-driven investigations—that would ignite the modern era of antibiotic
treatment, saving countless lives and becoming one of the major pillars supporting today’s
pharmaceutical industry [239].
A compromise between hypothesis-driven science and exploratory analyses that can
uncover entirely novel discoveries is a relatively new approach known as data-driven science,
which is summarized in Figure 1.6. In data-driven science, rather than posing a single hy-
pothesis and then seeking to disprove that hypothesis, investigators instead collect large sets
of data and use statistical techniques to highlight patterns in the data that may correspond
to nonrandom scientific phenomena. Subsequently, researchers can then gather these pat-
terns and convert each of them into traditional hypotheses that can be explored individually,
using the well-established hypothesis-driven paradigm.
Data-driven science shows up in two parts of this dissertation: (1) In VenomSeq, we use
data-driven methods to find new associations between venoms and drug classes / disease,
and (2) VenomKB is meant to be a tool that facilitates data-driven approaches to discovery
from venom data, both by providing that data in a structured form where venom-related
entities can be compared to one another easily, and by presenting tools to the users that
help provide supporting evidence to accompany putative discoveries that are uncovered by
data driven methods (either using data from VenomKB/VenomSeq or from elsewhere).
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1.5.2. Differential expression analysis
The human genome contains some 20,000 protein-coding genes, in addition to a vast number
of regulatory elements and other stretches of DNA with unknown functions. While each
cell in the human body contains the same genes (with some exceptions), differences in cell
types (functional and morphological) are largely the result of those genes being expressed
in different amounts—and in different combinations—based on the characteristics and the
needs of the cell. Beyond differences in cell and tissue type, gene expression can be altered
at the level of individual cells due to specific chemical and physical influences, such as injury,
disease (e.g., viruses that use cells for reproduction), hormone signaling, and perturbation by
exogenous chemicals, including toxins, dietary nutrients, and pharmaceutical drugs. When
these types of perturbations initiate a specific, targeted mode of action (rather than global,
nonspecific cellular processes, such as DNA damage resulting from exposure to ionizing
radiation), the effects on differential expression tend to be reproducible and correlated with
the underlying changes in the cell.
From a broader perspective, differential expression analysis is generally used for the
following purposes:
1. Determining differences in gene expression between cell lines or tissue types.
2. Determining differences in gene expression between healthy and diseased cells.
3. Determining differences in gene expression between perturbed (e.g., by drugs or genetic
alterations) and non-perturbed cells.
The last of these (perturbed vs. non-perturbed cells) can be further divided into applications
for learning the mechanisms of certain perturbagens, as well as discovering new drugs or drug
candidates that have a ‘therapeutic-like’ effect on expression.
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Aside: Platforms for gene expression analysis
Changes in expression can be measured (technically, estimatated, since we do not directly
count every transcript in a cell) via a number of different approaches. DNA microarrays are
one of the most widely used of these, due to their ease of use and relatively low cost [124].
DNA microarrays are glass slides with a large number of short nucleotide oligomers (small
fragments of DNA) arranged in a grid. In microarray analysis, mRNA (i.e., actively tran-
scribed genes) extracted from a population of cells are reverse transcribed into cDNA which
is then fragmented and labeled with fluorescent tags. These labeled fragments are passed
over the surface of the microarray, and the fragments bind to their complementary sequences
on the array. After binding, the intensity of each probe’s fluorescence is proportional to the
level of expression of the corresponding mRNA sequence in the cell population of interest.
While microarray experiments have proven to be very successful for many purposes (espe-
cially when performing high-throughput screening of many cell populations simultaneously),
it suffers from a number of limitations, most notably that quantifying fluorescence instead
of counting the number of transcripts directly results in an additional contributing factor to
estimation error [43].
A more expensive technique with higher resolution is RNA sequencing (RNA-Seq),
which involves collecting and reverse-transcribing mRNA in a sample (like with microar-
rays), but then performing sequencing on the cDNA fragments to obtain individual reads
corresponding to a particular isolated mRNA fragment [188]. Computational techniques
(some of which are described in §3.4.4) are then used to determine the number of reads for
each gene being measured, yielding a random sample of the actual transcripts, rather than
a fluorescence value that is merely proportional to this number. The processed results of
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RNA-Seq are counts for each gene in the human genome.
A third and arguably less popular approach uses an experimental procedure known as
quantitative polymerase chain reaction (qPCR). qPCR is an older technique, and is the most
low-throughput of the three I have discussed. In qPCR, mRNA is amplified using polymerase
chain reaction, and then separated into individual transcripts via electrophoresis. The bands
are then isolated, and then by allowing hybridization with probes and detection via autora-
diography, the researcher is able to determine the identity and the relative abundance of the
transcript in that band [249]. Obviously, this method is extremely laborious and unsuitable
for analysis of many different transcripts (e.g., entire transcriptomes), since each transcript
is handled in a distinct experiment.
PLATE-Seq
As I suggested in the previous section, one of the primary barriers to wide adoption of RNA-
Seq for exploratory analysis is cost. In recent years, a number of innovative biotechnology
and informatics approaches have been designed to address this issue. One of these—a pro-
tocol named PLATE-Seq—was developed as a joint effort in the Califano and Sims labs
at Columbia University [32]. Whereas traditional RNA-Seq involves isolating transcripts
and performing individual sequencing runs on each sample, PLATE-Seq instead pools many
samples together in a single sequencing run, after using barcoded primers unique to each
sample in the reverse transcription process. After performing sequencing on the single pooled
sample, the reads are then matched back to their original sample based on the identity of
the barcoded adapter at the end of the sequence. PLATE-Seq is the specific sequencing
technology we use with VenomSeq, which is described in Chapter 3.
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The PLATE-Seq approach is primarily limited by a decrease in resolution (quantified
by the average depth of any given transcript) over traditional RNA-Seq, resulting from the
fact that any single sample (pooled or otherwise) has a technical limit on the number of to-
tal reads in that sample that can be sequenced2. Therefore, it is more challenging to assure
sufficient coverage over all areas of the genome, particularly at high enough frequencies to
ensure detection of sequencing errors. However, recent analyses have demonstrated that the
resolution of PLATE-Seq is plenty sufficient for all but the most stringent clinical applica-
tions, where the goal is to obtain high confidence estimates for a small number of transcripts
(e.g., discovering specific mutations occurring in a certain gene). In applications that aim to
identify large-scale trends (such as disregulation of large sets of functionally related genes),
this limitation is relatively inconsequential.
Additionally, the authors of PLATE-Seq have been involved in developing additional
tools to augment the results in ways that compensate for the decreased number of reads.
One of the most importance of these is an algorithm known as VIPER (Virtual Inference
of Protein activity by Enriched Regulon Analysis) [4]. The VIPER algorithm accepts gene
expression data (such as those returned by PLATE-Seq) and a previously determined network
of gene regulation specific to the cell line used for producing the PLATE-Seq data. Using
network inference, the expression levels of master regulators for that cell line can be estimated
within known bounds, ‘filling in the gaps’ left by the lower resolution data.
2This limit varies based on the sequencing platform used, but is present in all currently available platforms.
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We begin by introducing VenomKB—an online knowledge base that is designed to facilitate
the emergence of computational techniques to investigate therapeutic uses for venom com-
pounds. As of its first release (v1.0), VenomKB consisted of three database tables. The
first is a manually curated list of putative and active (i.e., in clinical use) venom therapies.
The second and third detail the outputs of two different algorithms (VExtractor and Seman-
ticVExtractor) that were used to automatically extract (by natural language processing or


































Figure 2.1.: MeSH was used to identify a core set of relevant articles, which were then passed
to three methods of knowledge extraction (manual review, the VExtractor algorithm,
and the SemanticVExtractor algorithm). The outputs of these three methods were then
collected and assembled as VenomKB.
scientific literature. A schematic outlining the processes of data collection and curation in
building v1.0 is shown in Figure 2.1. VenomKB is an open-source and publicly accessible
resource for researchers and other individuals interested in venom therapeutics and may be
accessed at the project’s official website (http://www.venomkb.org). The website contains
a tabular interface for searching, sorting, and viewing the different records in each database
table, and data records of interest may be selectively downloaded in CSV, XML, and JSON
formats, as desired. Additionally, a “frozen” copy of the data as it exists at the time of v1.0’s
publication can be found on FigShare (see §2.1.6 for individual data citations). At this time,
the knowledge base contained 42,723 unique records.
The original goals of VenomKB were twofold: (1) to make it easier to discover proposed
or suggested venom therapies for a disease of interest (or vice-versa), and (2) to facilitate the
identification of studies on established venom therapies in order to guide the study of newly
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Figure 2.2.: Image shows the first 8 records of the ‘Manually Curated Venoms’ table.
The top bar has links to the knowledge base home page and each of the three current
database tables. Search filters are in the frame entitled ‘Filters’ on the right side of the
interface. Download links (for CSV, XML, and JSON format) and pagination functionality
are located at the bottom of the page, out of range of the screenshot.
discovered or newly classified venoms. Since the discipline of computational approaches
for discovering venom therapies is emergent, we expected VenomKB to grow rapidly in the
future. We encourage interested users to monitor additions and changes to the knowledge
base by viewing the website’s home page (http://www.venomkb.org), which will be updated





The MEDLINE biomedical literature repository contained 22,376,811 searchable titles and
abstracts as of its 2014 release (when v1.0 of VenomKB was first assembled). We used
this resource to extract all venom therapies, established or hypothetical. We found 5,117
relevant articles using the Medical Subject Heading (MeSH) term Venoms/therapeutic use.
We saved the abstracts in MEDLINE format—a text-based format that includes the article
titles, abstracts, and important metadata records for each article. We then applied three
separate methods for extracting data regarding putative venom therapies on these data—the
first of these was manual review and curation of journal articles and the second and third
were computational algorithms that automatically extracted relevant knowledge from the
pre-filtered set of MEDLINE articles.
To manually curate the abstracts, we first randomized the order of the 5,117 journal
articles (to avoid bias by only selecting articles from a short span of time) and selected
the first 275 records that describe putative venom therapies. We skipped articles that were
incorrectly tagged with the MeSH term Venoms/therapeutic use or where the proposed
venom therapy was unclear or subjectively deemed insignificant. We also ignored articles
that described venom immunotherapy—a technique that involves reducing sensitivity to
venoms (typically bee venoms) by administering small dosages of the venom over time in
order to desensitize the immune response [6]. For abstracts that we determined contained
valid putative venom therapies we recorded the data in the following format:
〈venom〉 | 〈physiologic effect〉 | 〈PubMed ID (PMID)〉
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In the first of the two automatic knowledge extraction methods, called VExtractor (see
Appendix D; filename vextractor.py), we used the NCBO BioPortal Annotator API to
extract ontology terms from the text of the title and abstract for each of the 5,117 entries.
We then filtered the annotations by chosen ontologies and Unified Medical Language System
(UMLS) semantic types that have a high likelihood of selecting venom compounds and
physiological effects of the compounds on the human body. The ontologies and semantic
types we used are documented in full in the repository listed in Appendix D (filename
vextractor ontologies and semtypes.txt). We selected these ontologies and semantic
types based on knowledge of ontology contents and a trial-and-error process of manually
altering the filtering strategy and observing if the algorithm was able to precisely identify
venom compound names and physiological effects as was determined for five of the manually
reviewed articles, selected randomly. Finally, VExtractor then sorts these terms into the
appropriate data structures (see below) and returns them as output. The NCBO annotator
can identify more than one venom compound and/or physiologic effect, so all were recorded
for loading into the knowledge base. This application was run for each of the 5,117 originally
identified journal articles as input—a task facilitated by the ability of VExtractor to accept a
list of PMIDs and run the script for each one, returning the results as two comma separated
value (CSV) text files, in the following format:
〈PMID〉 | 〈venom compound〉
〈PMID〉 | 〈physiologic effect〉
In this format, the results could be interpreted as a list (0 or more) of both potential venom
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compounds and effects. The outcome is greater flexibility in interpretation of the knowledge
contained in a given article, at the expense of potentially losing resolution if multiple venom
compounds—each with unique effects on the human body—are discussed in the same journal
article. Finally, we combined these two lists using a Ruby script (see Appendix D; filename
make vextractor table.rb) into a single list with records in the format:
〈venom compound〉 | 〈physiologic effect〉 | 〈PMID〉
We performed the second automated knowledge extraction method (a workflow we
named ‘SemanticVExtractor’) using a program named ‘SMDB Search’ (see Appendix D;
directory smdb search/). SMDB Search is a utility that connects to a local copy of the new
Semantic MEDLINE (SemMedDB) resource—a database that enables searching MEDLINE
by semantic concept rather than a traditional search query—and extracts semantic predicates
for either a given list of PMIDs or a certain UMLS or Gene Ontology (GO) term. For
the purposes of this study, we used all of the PMIDs that returned valid records in the
VExtractor procedure (i.e., all for which at least one possible venom compound and at
least one effect) as input for SMDB Search. The output of SMDB Search was a list of
Java Script Object Notation (JSON) formatted data structures. It should be noted that
instead of recording the output values as ‘potential venoms’ and ‘effects’ (as was done for
the previous two knowledge extraction methods), we recorded them as ‘subject’ and ‘object’,
since venoms and effects can occur in either order (e.g., venom x treats condition y versus
condition y treated by venom x)—see §2.1.3 for further explanation. In addition to the
subjects and objects, we recorded the predicate phrase and the UMLS semantic types for
each the subject and the object, to allow for more detailed analysis of data results in future
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Table 2.1.: UMLS Semantic Types for filtering SemanticVExtractor output.
UMLS Semantic Type 4-letter abbreviation
Amino Acid, Peptide, or Protein aapp
Amino Acid Sequence amas
Biologically Active Substance bacs
Body Substance bdsu
Chemical chem
Chemical Viewed Functionally chvf




Hazardous or Poisonous Substance hops
Hormone horm
Immunologic Factor imft
Nucleic Acid, Nucleoside, or Nucleotide nnon




additions to VenomKB. Finally, we used these semantic types to filter the output values
of SemanticVExtractor—only data records with subject semantic types listed in Table 2.1
were retained, because those semantic types are the ones that logically may be assigned
to venom compounds. Like with the VExtractor method, we designed SemanticVExtractor
with the ability to return 0 or more data records for each journal article. In order to remove a
large number of the false positives identified by the two automated methods, we performed a
manual review of the database contents, removing obviously erroneous entries. This included
compounds that are not related to venom compounds (e.g., ‘insulin treats type-2 diabetes




2.1.3. Description of data in VenomKB v1.0
The results of the data collection methods described above are all available on the knowledge
base website (http://www.venomkb.org/), as well as in a public FigShare repository (see
individual data citations below) for the purposes of data permanence and reproducibility
of data integrity analyses that we have performed (see §2.1.4). While the data records on
FigShare are static, the content of the knowledge base itself will change over time as data
records are validated/invalidated and as new knowledge extraction methods are developed
for the emerging field of computationally-predicted venom therapies. To create the data files
on FigShare, we exported the complete contents of the three relevant PostgreSQL tables as
CSV-formatted files, where the first line of the file consists of the headers describing each
data field, and each line thereafter represents a single data record. All of the tables include
the following records: id (a unique numerical identifier), pmid (the PubMed identifier for an
article supporting the data record), created at (the date and time at which the record was
added to the database), and updated at (the date and time at which the record was most
recently modified, which is identical to the contents of created at in many cases). Each of
the three individual files is described below, with the addition of the other fields that are
unique to each table.
The manually vetted putative venom therapies (‘Manually Curated Venoms’) are stored
in a file named manual venoms.csv (see §2.1.6; Data Citation 1). A sample of the first three
records is shown in Table 2.2. This table contains two unique fields: venom and effect.
venom is the name of the venom compound. These names may or may not be a trade name,
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Table 2.2.: Sample data from ‘Manually Reviewed Venoms’ table.
ID venom effect PMID
1 bombesin gastric secretion 11996
2 ancrod claudication 66429
3 ancrod deep vein thrombosis 80632
. . . . . . . . . . . .
n [venom n] [effect n] [PMID n]
a compound name, or some other name, but they reflect the name used in the associated
journal article. It should be noted that this is not an arbitrary design decision—since there
is no standardized naming format or classification system for venom components (e.g., the
compound EMD 121974—a modified snake venom protein—is almost ubiquitously referred
to by the trade name Cilengitide), the most methodical approach is simply to preserve the
name(s) given by the author of the journal article. effect is the primary purported physio-
logic, molecular, or phenotypic effect or target of the venom. However, this is not explicitly
qualified—for example, a venom compound that is reported as effect being ‘Parkinson’s
disease’ likely intends to mean that the venom treats Parkinson’s disease, not that it causes
the disease. Although this introduces some ambiguity into the database, it was a design
choice made to facilitate easy searching for diseases and molecular targets via the web inter-
face. The data for the first automated knowledge extraction algorithm—which utilizes the
NCBO Annotator API; named VExtractor—is contained in the file named vextractor.csv
(see §2.1.6; Data Citation 2). A sample of the first three records is shown in Table 2.3.
Aside from the common fields mentioned above, these data records have two additional fields:
venom and effect. Like with the other methods, venom describes the venom or venom com-
ponent being discussed. Since these terms were automatically extracted and standardized to
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Table 2.3.: Sample data from ‘VExtractor’ table.
ID venom effect PMID
1 ceruletide tachyphylaxis 11996
2 ceruletide gastric secretion 11996
3 ceruletide pancreatitis 2717605
. . . . . . . . . . . .
n [venom n] [effect n] [PMID n]
the terms contained in the UMLS, the naming scheme is more consistent than in the Man-
ually Curated Venoms table. effect is similar to the equivalent field in Manually Curated
Venoms, but it is more commonly a disease or an observable physiological effect rather than
a molecular mode of action or molecular target. Likewise, although the effect is often listed
as a disease name, it should usually be interpreted as treating that disease rather than caus-
ing it. This should, however, be done with regard to context: venom compounds in many
situations may in fact be the cause of particular generalizable diseases (e.g., pancreatitis as a
result of Tityus trinitatis scorpion envenomation [14]). For this reason, we urge users to refer
to the supplied PubMed IDs when looking at individual VenomKB records. The label for the
column was not chosen to be treats because the field does not always describe a treatment.
If there is any ambiguity in a data record of interest, it is strongly recommended to view the
cited PubMed article to determine the exact context of the therapeutic effect of the venom.
Formatted output from the second automated method—using the SMDB Search utility;
named SemanticVExtractor—is contained in a file named semantic vextractor.csv (see
§2.1.6; Data Citation 3). A sample of the first three records is shown in Table 2.4. Unlike
the prior database tables, this one contains three fields of interest: compound, predicate,
and object. These three fields describe the three components of a predication stored in
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Table 2.4.: Sample data from ‘SemanticVExtractor’ database table.
ID compound predicate object pmid
1 bombesin isa tetradecapeptide 11996
2 bombesin augments gastric 11996
3 caerulein affects acidification 11996
. . . . . . . . . . . .
n [compound n] [predicate n] [object n] [pmid n]
the SemMedDB database—a subject, a predicate, and an object. A predication describes a
relationship between two entities (the subject and the object), and its predicate defines the
type of relationship. The order 〈subject〉 | 〈predicate〉 | 〈object〉 has the advantage of being
similar to the structure of an English language sentence, so the semantic concept under-
lying the predication can be easily read by a human. For example, if the predication is
caerulein | augments | pancreatic juice secretion, it is easily understood as equiv-
alent to the phrase, ‘The (venom-derived) compound named caerulein augments the secretion
of pancreatic juice.’ In this context, the subject of the predication is always a chemical com-
pound, so the subject field of SemanticVExtractor output was renamed to compound upon
loading into the knowledge base. However, the venom component being referred to is not
always the subject—it could also be the object of the predication. For instance, one of
the predications in this table could be compound ‘X’ | inhibited by | bombesin’. This
predication describes the effect of bombesin on compound X, yet bombesin is the object of
the predication. In this table, compounds and objects are always either UMLS terms or GO
terms, and ‘predicates’ are the predicates that are contained within the SemMedDB database
(specifically contained in the PREDICATION table of the database). A parallel bar chart of
the 10 most frequent semantic types in Semantic VExtractor is shown in Figure 2.3. To
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improve the utility of VenomKB beyond that of a purely static knowledge resource, indi-
vidual web pages describing the data records contain links to their cited PubMed articles,
as well as links to search queries for compounds and other terms on a number of external
databases/ontologies. Since there is no structured terminology or naming scheme for venoms
and/or venom derived compounds, we cannot guarantee that all records in VenomKB will
return useful search results—this is something that we intend to improve upon in the future
by creating a hierarchical terminology of venoms that can be used to standardize the con-
tents of VenomKB, and generate cross-mappings to other knowledge resources regardless of
synonym variation.
2.1.4. Technical validation of VenomKB v1
The manually reviewed and curated list of putative venom therapies was considered the ‘gold
standard’ against which the two automated methods of knowledge extraction were validated.
We validated the ability of the two automated methods to identify venom compounds and
their purported effects on the human body. It was assumed that the precision of the two
automated methods would be low, since there is no UMLS semantic type or other unique
identifier with which venom compounds are annotated in a consistent manner in the scientific
literature. As a result, many of the identified compounds are not venoms at all, but belong
to the same UMLS semantic types as venoms and venom components. However, we designed
the two algorithms to be highly sensitive. In essence, we expected to see a high occurrence
of false positives but a substantially lower occurrence of false negatives.
In order to determine percent recall of the two algorithms, we selected 100 records at
random from the table of manually reviewed venom therapies. For each of those selected
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Figure 2.3.: The top 10 most frequent UMLS semantic types represented in the Seman-
ticVExtractor data output, plotted by total counts.
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data records, we then manually recorded whether the same venom compound and effect were
identified by each of the two algorithms for the MEDLINE article associated with the respec-
tive PMID. For this measurement, VExtractor exhibited a 76% recall with respect to the
gold standard, and SemanticVExtractor exhibited a 67% recall. Additionally, we recorded
whether the 〈venom〉 | 〈effect〉 pair was found in any record, regardless of PMID. For this
second measurement (where the ‘PMID’ field was disregarded), VExtractor had a recall of
89% (a change of +13%) and SemanticVExtractor had a recall of 84% (a change of +17%).
These data support the conclusion that the two algorithms have a relatively high degree of
sensitivity for correctly extracting venoms and their purported effects, and the false nega-
tives (〈venom〉 | 〈effect〉 pairs not identified by one of the two algorithms) are substantially
offset by the ability of the algorithms to identify equivalent 〈venom〉 | 〈effect〉 pairs elsewhere
in the scientific literature. We calculated the specificity of each of the two algorithms by
selecting 100 random records and determining whether those records describe a venom or
a venom compound, and also whether they describe a physiologic target or effect of that
venom compound. Prior to pruning obvious false positives from each of the two database
tables, VExtractor demonstrated a precision rate of 66%, and SemanticVExtractor demon-
strated a precision rate of 52%. After pruning false positives, we resampled the two database
tables and recomputed precision. Each of the two values improved substantially: VExtractor
demonstrated a new precision rate of 82% (a change of +16%), and Semantic VExtractor
demonstrated a precision rate of 80% (a change of +28%), empirically demonstrating the
value of manually filtering ‘bad values’. These values (both recall and precision) are shown
in Table 2.5, and the specific data records used to conduct the validation are available on
FigShare (see §2.1.6; Data Citation 4). Although these rates for precision are relatively high
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Table 2.5.: Percent recall rates of the ‘VExtractor’ and ‘SemanticVExtractor’ algorithms
as compared to the gold standard (manually reviewed venoms), using 100 randomly selected
records from the ‘Manually Reviewed Venoms’ table. Reported precision was computed after






VExtractor 35,240 76% 89% 82%
SemanticVExtractor 7,208 66% 84% 80%
for a novel knowledge discovery pipeline, they do raise the question of how to minimize false
positives in a maintainable fashion, rather than via manual review and culling of erroneous
records within very large database tables. As mentioned below (in §2.1.5), VenomKB allows
for users to ‘flag’ individual records for removal. This method of ‘crowd sourcing’ the removal
of erroneous records will continue to improve in its robustness as VenomKB gains content
and new users.
False negatives are another important concept to consider. Our method for identify-
ing relevant PubMed articles involved searching for the MeSH term Venoms/therapeutic
use, but since MeSH terms are manually curated annotations, there is no way to ensure
full coverage of relevant articles. Furthermore, a lack of structured terminological resources
for studying venoms and venom components makes more complex methods of knowledge re-
trieval (e.g., using alternative machine learning techniques that incorporate semantic knowl-
edge of venom compounds) nearly impossible. To this end, we are planning a follow-up study
that involves the creation of an ontology for venoms and their contained compounds, as well
as synthetic derivatives that are already used therapeutically. After creating the ontology,
we should be able to devise novel methods for identifying false negatives—those records
erroneously omitted from the database due to a lack of complete MeSH term annotation.
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2.1.5. VenomKB v1 usage notes
Any internet enabled device using a modern web browser should be able to access the knowl-
edge base and download data from both the knowledge base itself (at http://www.venomkb.
org) and from the FigShare repository (See Data Citations in §2.1.6). No user account is
necessary to access or download the data records, but a number of community editing and
contribution features do require users to create a private profile. Users have the ability to
add or edit records on the manually-curated portion of the knowledge base. Deletion priv-
ileges are not publicly available, in order to prevent abuse. However, if a user feels that a
particular record was included erroneously, there is a button on the data record’s page that
allows the user to ‘flag’ the record for review by site administrators. Once flagged, adminis-
trators are notified, after which they decide whether to remove the item or not. Users can
see on the index page whether individual items have been flagged or not. Furthermore, users
may contribute to a ‘comment’ thread on each data record, given that they have logged in to
an account. Comment threads are visible on the pages for each individual database record.
Major changes to the knowledge base are announced on the knowledge base website when
they occur. As mentioned previously, data records may be selected and downloaded in one
of three software formats: CSV, XML, and JSON. Although these may be manipulated and
analyzed by most modern programming languages and data analysis software packages, we
performed technical validation of the data sets using the standard libraries of the Python
and Ruby programming languages. Intermediary data files (prior to loading into a relational
database) were structured as to make them ‘self documenting’ (i.e., key-value pairs include
descriptive key labels). A GitHub repository with all of the scripts used to analyze and pro-
cess the data is linked to in Appendix D. Within the knowledge base, numerical identifiers
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for individual records were assigned arbitrarily based upon the order in which they were
added to the database.
As mentioned previously, VenomKB will change and grow as new records are added.
In particular, we plan to expand the ‘manually curated venoms’ database by identifying
additional relevant MeSH terms that may also refer to therapeutic uses of venoms (aside from
Venoms/therapeutic use). Furthermore, we plan to closely monitor new studies regarding
novel venom therapies, adding them to the knowledge base as we come across them.
Since VenomKB is intended to grow into a collaborative, public resource on compu-
tational analysis and prediction of putative venom therapies, we encourage suggestions and
comments regarding new additions and revisions. Up-to-date contact information can be
found from the homepage of the knowledge base website, or alternatively, readers can con-
tact the corresponding author for this study as listed below.
A final note to users regards data records that appear to be irrelevant at first glance, yet
actually do describe a property of a venom compound being used for therapeutic purposes.
For example, consider entries in the VExtractor database for PMID 22098810. The database
contains 4 entries for this PMID, all referring to a venom compound named hypoglycemic
agent, which treats obesity. Upon inspecting the journal article referenced by this PMID,
it can be seen that the hypoglycemic agent in question is actually the venom compound
exenatide, which does treat both type-2 diabetes mellitus and obesity [153]. As mentioned
previously, we plan to build a structured terminology for venom compounds that can be
used to resolve relatively uninformative descriptors (such as hypoglycemic agent) into their
actual specific venom compound names, but since such a resource currently does not exist, we
suggest that users follow links to the PubMed pages to validate the compound(s) themselves.
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2.1.6. VenomKB v1 Data Citations
The following citations point to persistent copies of the data as referred to in the preceding
text:
1. Romano, J.D., & Tatonetti, N.P. Figshare
[http://dx.doi.org/10.6084/m9.figshare.1287000] (2015).
2. Romano, J.D., & Tatonetti, N.P. Figshare
[http://dx.doi.org/10.6084/m9.figshare.1286999] (2015).
3. Romano, J.D., & Tatonetti, N.P. Figshare
[http://dx.doi.org/10.6084/m9.figshare.1287001] (2015).




Perhaps the most fundamental issue standing in the way of modern translational research
for venom-based drug discovery is the almost complete lack of an informatics infrastructure
uniting our existing knowledge on venoms. In this study, we present a novel ontology of
venoms and related concepts that addresses this problem systematically. Biomedical ontolo-
gies allow for consistent and unambiguous naming of entities (in this cases, venoms, venom
components, and the species from which they are sourced) and how they are interconnected.
We also present a number of initial investigations regarding venom biodiversity across the
tree of life, and explore how they can inform the discovery and refinement of novel therapeutic




Building the Venom Ontology
We used Prote´ge´ (ver. 4.2) [186] to create the class structure of the Venom Ontology using
domain knowledge: By our definition, every venomous species has exactly one venom, and
every venom has one or more molecular components that can be classified by the class of
molecule they are (e.g., peptide, carbohydrate, inorganic cofactor). Recent reports suggest
that Conus geographicus modifies its venom based on whether it is used defensively or of-
fensively [66], but for the purposes of this ontology they can be grouped together as a single
venom. If a venom component is a peptide, it has a canonical amino acid sequence. Each of
the entities may have one or more other pieces of metadata, including links to other ontologies
and structured terminologies. After defining the class structure of the ontology, we popu-
lated the ontology with individuals (specific instances of the ontology’s classes) sourced from
UniProtKB/Swiss-Prot’s Tox-Prot database [113]. This database is a manually curated list
of venom peptides containing numerous annotation tags including species of origin, amino
acid sequences, full taxonomic lineage, and automated cross-mappings to other online re-
sources. However, the structure of Tox-Prot does not support semantic reasoning. Due to
the large number of individual records in the Tox-Prot database (6,092 at the time of creating
the ontology), we added the contained information programmatically by first exporting the
ontology from Prote´ge´ to an RDF-formatted XML file [17], and then using Apache’s Jena
framework [165] to parse the venom records and insert relevant data into the appropriate
spot within the ontology’s class hierarchy.
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Exploratory analysis of venom ontology data records
To demonstrate some potential applications of Venom Ontology, we performed three ex-
ploratory analyses of its contained data. The first of these involved assessing the similarity
of amino acid sequences for venom peptides produced by species of the same genera. To
accomplish this, we grouped species (stored as “Organisms” in the ontology) by genus, along
with their derived peptide compounds. We then selected 2 genera that are well represented
in the data set, and built “sequence similarity networks” for each of them. In selecting these
genera, we looked for ones that are prolific enough within the ontology to generate infor-
mative (non-trivial) networks, yet not so prolific as to be unwieldy in terms of visualization
or computation. In practice, we looked for two genera with approximately 20 species in
the ontology. For each genus selected, we used BLASTp [37] to align all pairs of peptides
within the genus. We constructed the networks using peptide sequences as nodes, and the
alignments between them as edges. We transformed the BLAST scores (which represent the
percent coverage of the alignments; denoted S)for alignments using the following equation:
S ′ = 1
eS
which allows us to define a “distance” between two peptide sequences (i.e., smaller values
of S ′ indicate higher similarity), used as edge weights in the final networks. S ′ is a value in
the interval (0; 1], and is generally very small (e.g., < 1 ∗ 10−15). Finally, we filtered edges
by setting a maximum expect value (“e-value”—a normalized p-value defining confidence
that the alignment is non-random) threshold of 1 ∗ 10−50. Alignments that fell below this
maximum cutoff almost certainly signify evolutionarily related sequences, and are therefore
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informative for the purposes of constructing these networks. For visualization purposes, we
rendered the networks in Cytoscape [224] using the prefuse force-directed layout [96], and
colored nodes (individual peptides) by the species from which those peptides were sourced.
Our second analysis was a basic exploration of the distribution of both species and
individual peptides in the ontology across the tree of life. We defined common groupings
of animals (cnidarians, molluscs, insects, arachnids, fish, amphibians, reptiles, birds, and
mammals) that may contain venomous species. From these large classes, we used NCBI’s
Taxonomy database [72] to determine the highest-level taxa common to all members of those
groups (grouping multiple taxa for paraphyletic groups, such as “fish”). For each of these
taxa, we searched for their frequency of occurrence in the set of all species present in the
database. We also enumerated the number of total sequences in the database for the groups
listed.
The third and final analysis consisted of observing the complexity of venoms within
the ontology. In this context, we simplistically define complexity as the number of distinct
peptide components within the venom (e.g., a venom containing 20 peptide components is
more complex than a venom containing only 10). We investigated the distributions of venom
complexity for each of the taxonomic groups mentioned in the previous paragraph, making
note of features such as mean number of peptide components per venom, standard deviation,
and skewness (i.e., lack of symmetry, computed as the estimated third standardised moment
E [x3]).It should be noted that the results of these analyses are subject to systematic biases
depending on how well the data in Tox-Prot is representative of the totality of venoms that
exist in nature (refer to §2.2.4 for further discussion).
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Figure 2.4.: A schematic diagram of classes and class relationships in the Venom Ontology.
Blue arrows denote is a relationships, while other colors denote object property relation-
ships. Diagram automatically generated by the Prote´ge´ plugin “OBO Graph View”.
2.2.3. Results
All code and data files used in this study are available for public use on GitHub at (http:
//github.com/JDRomano2/venom_ontology_code). The ontology is available online, hosted
both on BioPortal (http://bioportal.bioontology.org/ontologies/CU-VO) and on the
project’s homepage, at http://venomkb.tatonettilab.org/ontology. A visualization of
the ontology’s class hierarchy and object property associations is shown in Figure 2.4.
Venom ontology
Venom Ontology presently contains 614 known venomous species, and 6,092 curated peptides,
each of which has a known amino acid sequence. There are correspondingly 614 “whole venom
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extract” entities, arising from the following axiom:
Organism ⊇≥ 1has Venom.WholeVenomExtract∩ ≤ 1has Venom.WholeVenomExtract
which states that every organism has exactly one whole venom extract. Due to our data
source being peptide-centric, each whole venom extract (and, correspondingly, each organ-
ism) currently included in the ontology has at least one peptide, although this is not de-
fined as necessary (i.e., the ontology allows for whole venom extracts to contain zero or
more peptides). We added a small number of synthetic venom compounds (all clinically
approved drugs) to the ontology by manually entering them as individuals for the “Syn-
thetic Venom Derivative” class. This is a tractable approach presently, but as venom-derived
therapeutic agents continue to be discovered and are coerced into a structured format, an
automated means for adding them will become necessary—this point is elaborated on below,
in §2.2.4. Venom Ontology was validated using the FaCT++ reasoning engine [248].
Analysis of the ontology’s contained data
Our analysis of venom peptide sequence similarity for a number of well-represented genera
highlights some noteworthy features of venoms that have significant implications for drug
discovery. In Figure 2.5, we show two sequence similarity networks—one for genus Lox-
osceles (widow spiders) and one for Bungarus (kraits—a genus of venomous snakes)—yet our
methods could be applied to any other taxonomic group that is present in the ontology. Since
we only kept alignments with strong statistical support (low e-value—see §2.2.2 for details),
the graphs are not fully connected. Small connected components (e.g., the “islands” seen
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Figure 2.5.: Two sequence similarity networks for venom peptides within the same genus.
a.) shows peptides from species in genus Loxosceles, and b.) shows peptides from species
in genus Bungarus. Relative node size is based on the degree of the node, and length of
the edges is based on the inverse BLASTp score (see eq. (1)). Nodes of the same color are
peptides from the same species of animal. Red arrows indicate “clusters” with high species
diversity (i.e., similar peptides found in a number of closely related species).
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around the periphery of the networks) as well as clusters within larger connected components
can be interpreted as groups of peptides that are likely to be closely related on a structural
level. Although we originally expected sequences from a given species to segregate together,
there are clusters in each of the networks that contain a diverse mixture of sequences from
numerous species (denoted in the Figure 2.5 by red arrows). The smaller connected com-
ponents tend to be more homogeneous in terms of their species composition (e.g., they have
higher cluster purity). Subjectively, it is also noteworthy that the networks do not display
the properties of “scale-free” networks (characterized primarily by few nodes of very high
degree, and many nodes of very low degree), which are arguably the most prevalent family of
networks that arise from biological phenomena [12]. While speculation as to why this occurs
is beyond the scope of this exploratory analysis, it would be an interesting topic to pursue
in a follow-up study.
The distribution of species and sequences by higher taxonomic groupings is shown
in Table 2.6. Both “fish” and “reptiles” are common names that consist of multiple
clades (i.e., they are paraphyletic). It should be noted that 5 species, containing a total
of 1,348 sequences, are not classified within any of these groups. While this only makes up
0.81% of the total number of species, it contains 22.13% of the total number of sequences
found in the ontology. This seems to be the result of numerous sequences that have poorly
formed or absent “taxonomic lineage” annotations in Tox-Prot (meaning that some of the
‘orphaned’/unclassified sequences likely come from already classified species that are in-
cluded in the larger taxonomic groups). After looking at properties of venoms exposed by































































































































































































































































































































































































Table 2.7.: Distribution of venom complexity across the tree of life, by common taxonomic
groups. A venom’s complexity is defined as the number of known distinct peptide components
it contains.
Common name Minimum Median Mean Maximum Skewness1
Molluscs 1 4 11.230 118 3.638
Insects 1 2 3.101 15 2.211
Arachnids 1 4 13.020 293 6.576
Fish 1 2 2.800 6 1.517
Amphibians 1 1.5 1.500 2 n/a
Reptiles 1 4 9.496 64 2.271
Mammals 6 6 6.000 6 n/a
All species 1 4 9.922 293 7.987
Table 2.8.: Mann-Whitney U test results for all pairs of venom complexity distributions.
A p-value of less than 0.05 signifies that two distributions are statistically different.
Arachnids Fish Insects Mammals Molluscs Reptiles
Amphibians 0.117 0.417 0.439 0.667 0.167 0.126
Arachnids 0.155 1.85e−7 0.842 0.909 0.725
Fish 0.732 0.366 0.216 0.170
Insects 0.194 2.74e−5 2.20e−7
Mammals 0.858 0.813
Molluscs 0.878
the ontology at the genus level, we investigated the distribution more generally across the
tree of life. Distributions of venom complexity are shown in Table 2.7. In this portion of
the data analysis, we only show the common taxonomic groups from Table 2.6 that have
at least 1 venom and 1 peptide. The final row of the table shows the distribution across all
species present in the ontology. Additionally, Figure 2.6 shows a graphical representation




























Figure 2.6.: Violin plots showing distributions of venom complexity in 7 common taxonomic
groups. Numeric summary statistics are listed in Table 2.7 for each of the groups shown.
Complexity is measured as the number of venom peptides in Venom Ontology for a single
species—the vertical axis is the complexity measure for a given species, and the widths of
individual plots correspond to the density of the distribution at that complexity measure.
Individual species are shown as transparent dots—they are spread horizontally (“jittered”)




Some ontology classes possess no individuals, yet are still informative
The Venom Ontology contains several terminal classes that do not have any members (“in-
dividuals”), classes Carbohydrate, and Inorganic Molecule. The rationales for their in-
clusion are threefold: (1) The ontology is meant to convey computable semantic knowledge
of venoms, and with the current structure ontology reasoning software is able to understand
that venoms may contain a number of different components, of which only some may be
peptides. (2) Since future revisions to the ontology may incorporate new data sources, we
hope to be able to populate these classes with informative instances in a future release. (3)
We hope to be able to generate members for these classes using machine learning methods
that don’t require a curated dataset of venom components (such as “ontology learning from
text”) [263]. Another class—“Synthetic Venom Derivative”—seems to be specific enough to
allow for manual population using domain knowledge of existing synthetic versions of venoms
used as pharmaceuticals. However, existing synthetic venom derivatives are more numerous
than it would initially seem. For example, a number of conantokins (a specific sub-class
of conotoxins—sourced from snails in the genus Conus) have been modified and produced
synthetically, yet none have received approval for clinical use [45, 202]. For this reason, a




Grouping venom peptides by genus reveals clusters of similar venoms across species
As briefly alluded to in §2.2.3, the networks in Figure 2.5 show clusters of venom pep-
tides that contain members from a number of closely related species. This suggests a novel
approach for discovering libraries of therapeutic venom-derived peptides with a similar ther-
apeutic effect. During drug development, having a large number of drug candidates available
improves the likelihood of finding a molecule that simultaneously has the greatest therapeu-
tic effect while minimizing toxic effects (a notoriously challenging obstacle in repurposing
venoms for clinical use). This proposed approach provides a data-driven framework for
discovering venom-derived therapeutic agents, which is an improvement over traditional
methods that are almost entirely based on serendipitous discovery or borrowed from ancient
traditional medicine [141].
Non-reptile venomous species are underrepresented in existing data
Recent analyses of venom biodiversity reveal surprising patterns, including that the preva-
lence of venomous fish is far higher than in any other major taxonomic group, including
reptiles [229]. Table 2.7, however, shows a strong bias towards venomous reptiles in avail-
able data (fish peptides make up only 0.23% of venom sequences in the Tox-Prot dataset,
while reptilian peptides make up 37.72%). Other discrepancies are also apparent: for ex-
ample, only one venomous mammal is included in the database: Ornithorhynchus anatinus
(duck-billed platypus). While it is uncommon for mammals to be venomous, reviews on the
subject have identified numerous others aside from O. anatinus, including multiple shrews,
bats, and certain species of loris (taxonomic family Lorinae).
By knowing about these discrepancies, we can prioritize future venom research to
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include presently underrepresented categories of animals, which should in-turn increase the
likelihood of discovering novel compounds that have diverse therapeutic effects.
Apparent complexity of venoms varies across the tree of life
Venoms usually consist of a complex mixture of organic and inorganic molecules, each of
which has a particular effect. If we define “complexity” as the number of distinct peptide
components in a venom, our results show that venom complexity is highly variable across the
tree of life. In Table 2.7 we list summary statistics for venom complexity distribution across
7 common taxonomic groupings. These data are additionally visualized in Figure 2.6 as a
violin plot. The plot, shown with number of peptides per venom on a logarithmic scale, high-
lights that there are many outliers in the dataset—species with extremely complex venoms
compared to the mean of 9.922 peptides per venom. Furthermore, each of the taxonomic
groups has its own unique distribution. Although the sizes of some groups in the ontology are
too small to result in viable statistical inferences (e.g., mammals and amphibians), variable
distributions of venom complexity suggest that complexity is regulated in some manner that
is conserved by evolution—otherwise, all of the distributions would converge. In particular,
insects seem to have venoms that are relatively simple compared to arachnids, molluscs,
and reptiles. Interestingly, arachnids have the largest number of outlier species that have
extremely complex venoms. Reptiles, by far the most well-represented group in the dataset,
have notably fewer highly complex outliers than either molluscs or arachnids. As an example
of a quantitative approach to comparing these distributions, Table 2.8 shows the p-values of
the Mann-Whitney U test applied pairwise to all of the distributions shown in Figure 2.6.
These observations may be an artifact of data completeness (see §2.2.4), but if not, they can
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help to guide research towards more rich libraries of venoms that may include important
therapeutic compounds.
Using venom ontology in conjunction with VenomKB to support drug discovery
In §2.1, we described VenomKB v1.0—a knowledge base cataloguing putative therapeutic
uses of venoms and venom-derived compounds, constructed via manual literature review
and automated knowledge discovery techniques applied to MEDLINE [205]. Linking these
two separate data resources may optimize the process of computational drug discovery by
implying a polyhierarchical structure on many of VenomKB’s data records (specifically, ones
that map to instances in Venom Ontology). For example, if a record in VenomKB describes
the therapeutic effect of a compound produced by species X, we may be able to find highly
similar (and possibly more efficacious) molecules by using Venom Ontology to identify venom
peptides from species that are in the same genus as species X. In the future, we intend to add
a component to the ontology that resolves venom names with their synonyms, which could
allow us to identify venoms with multiple therapeutic effects, as well as increase confidence in
therapies when multiple studies corroborate the same effect. We plan to fully integrate these
two resources, so that VenomKB can be browsed by navigating the hierarchical structure of
Venom Ontology, and vice versa.
Limitations—structured data on venoms are largely incomplete
It is important to remember that these studies necessarily omit data on venoms from many
clades of venomous animals. Since (a.) venom data are sparse even for most known venomous
species, and (b.) we only have discovered a small handful of the vast number of venomous
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species believed to exist (and have actually studied even a smaller number), we treat the
Tox-Prot dataset as a “best approximation” of venom diversity based on available data. This
obviously introduces various sources of systematic bias into the inferences that are made from
the ontology’s contained data.
In §2.2.2, we mention this limitation in regards to our definition of venom complexity
(the relative number of peptide components contained within a venom). We analyze our
data under the assumption that the Tox-Prot data set does not prioritize certain species
for “completeness”—in other words, that the ratio of the actual number of peptides to the
number that are in the data set remains consistent for all species. However, this may not
be the case. The available data for some species may be substantially more complete than
for others. Also, it may be more challenging to run proteomic analyses on some species
than others. Each of these factors would affect the consistency of completeness across the
dataset. A future goal that could help eliminate these potential sources of bias would be
only to populate the ontology with complete proteomic surveys of species’ venoms.
We intend for the Venom Ontology to be one of the first major steps towards system-
atically and consistently coercing newly discovered venoms and venom components into a
standardized format. The ontology’s structure suggests numerous ways to define a consistent
vocabulary for these semantic concepts.
2.3. VenomKB v2
We then completely rewrote VenomKB to take advantage of the semantic structure provided
by the Venom Ontology: In its revised form, VenomKB v2.0 is a resource for aggregating
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and representing venom knowledge including molecular characteristics, biodiversity data,
manually- and automatically-identified literature data, and a standardized ontological rep-
resentation for these different data types. VenomKB v2.0 is a complete rewrite of a previous
toxinology resource aimed specifically at literature data [205], the contents of which are in-
cluded in v2.0 in a more controlled and robust format. VenomKB is built with a modern and
intuitive interface along with a REST API to make all data elements programmatically avail-
able. This knowledge base is the most complete public resource for computational toxinology
research to-date, and it stands to become a major resource for toxinologists, informaticians,
molecular biologists, and educators interested in venoms and/or their components.
2.3.1. Results
VenomKB can be accessed online at http://venomkb.org/. The original version of the
knowledge base is still available for use, and can be accessed via a link on the home page of
the URL above.
Size and structure of VenomKB
VenomKB currently catalogues 6,236 venom proteins from 632 venomous species of animals.
VenomKB also contains 5 genomes from venomous animals, which—at the time of writing—
is the entirety of publicly available venomous animal genomes known to the authors. 5
FDA-approved venom-derived drugs are included, as well as the targets that those drugs
(and the venom peptides from which they are derived) are known to act upon. The major
data types in the knowledge base are summarized in Table 2.9. Figure 2.9 shows counts
of the various data types contained in VenomKB.
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Figure 2.7.: Image of the home page for VenomKB (v2.0). Users can access data and
informational pages via the navigation bar or in the main body of the website. A “News














































Figure 2.8.: UML class diagram showing the class hierarchy of Venom Ontology when used
in VenomKB v2.0. Note the addition of several new ontology classes to accomodate new
features not supported by the original version of the Venom Ontology, including Effect
(and its descendents) and Genome. Red class names indicate classes that have dedicated
data pages in the VenomKB v2.0 web application, and green class names indicate classes
that are rendered as subcomponents on data pages for other classes.
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Table 2.9.: VenomKB size and data types




Disease/condition annotations 1,065 E
Approved venom-derived drugs 5 D
Literature predications 14,710 –
Gene Ontology annotations 18,677 –
Each of the previously described data types is structured according to the Venom On-
tology [206], which provides a formal description of the different types of data related to
venoms, along with the types of relationships that exist between them. Every data record in
VenomKB is assigned a unique, permanent identifier that consists of one alphabetical char-
acter followed by seven digits. The first character indicates the data type (see Table 2.9),
and the seven digits are randomly assigned.
We sourced all non-inferred data in VenomKB from other publicly available resources.
A large number of the protein data were adapted from UniProtKB/Swiss-Prot’s Tox-Prot
annotation system [113], which is a major effort to identify and manually curate animal
toxin peptides (including venom components) in UniProtKB. The number of proteins (6,236)
currently in VenomKB is equal to the number of venom components in Tox-Prot at the time
of constructing the database.
VenomKB also contains 39,179 literature annotations that describe a venom or a venom
component treating a disease or health condition, which we transferred from VenomKB v1.0.
Of these, 275 were manually curated, and 33,284 are normalized semantic predications ex-
tracted from the Semantic MEDLINE database using a knowledge discovery approach, which
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is described in a previous study [205]. We automatically mapped 14,710 of these predica-
tions to both species and individual proteins using ontological inference; these predications
are shown in both the Species and Protein data pages, as well as the raw JSON representa-
tions of these data types.
Figure 2.9.: Barplot of counts of data types in VenomKB v2.0. Genomes, Species, and
Proteins are ‘primary’ data types represented as instances of Venom Ontology classes; Disease
annotations, Literature predications, and GO annotations are ‘secondary’ data types that
are represented as properties of primary data types.
Web application description
The home page for VenomKB is shown in Figure 2.7. From the home page, users can
access most components of the web application, as well as a link to the VenomKB v1.0
application, for backwards compatibility. The main interface for exploring data is located
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at http://venomkb.org/data, or from links on the home page. The interface is shown in
Figure 2.12, for reference. Users can filter data records in several ways, including by name,
data type (e.g., proteins, species, or genomes), annotation score (1 to 5 stars, explained
below), or by disease/condition annotations. Data types not included in this interface (such
as literature predications and other annotations) are embedded within the structure of their
corresponding documents. The search interface allows sorting by column. When users
Figure 2.10.: Venom complexity by major taxonomic groups. ‘Complexity’ is defined as
the number of proteins present in VenomKB for a specific venomous species. The relatively
low complexity of insect venoms compared to arachnids, reptiles, and molluscs could be
informative for the purposes of drug discovery.
find a data record of interest, they can view it by clicking on its corresponding VenomKB
ID (VKBID), or by navigating to ‘http://venomkb.org/{VKBID}’. An image of a protein
detail page is shown in Figure 2.13. The detail page for individual data records presents
information that is not available in the data search interface (e.g., for proteins, this includes
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amino acid sequence information, Gene Ontology annotations, literature predications, related
articles from PubMed, a link to the species the venom is from, and others). Since literature
predications are highly redundant and often uninformative for most uses, the web interface
collapses duplicate predications and highlights those likely to be clinically relevant (based
on the UMLS semantic types of the subject and object concepts). Additionally, tabs at the
top of the data detail page allow the user to view the record in JSON (JavaScript Object
Notation) format or download the record as a JSON text file. Users can run BLAST on the
amino acid sequences for protein data records, and we plan to add other external analysis
tools in the near future. Whenever possible, species pages provide a complete taxonomic
lineage for the venomous species being described (the major exception to this is for some
species of scorpion, which are interestingly underrepresented in ITIS—the public database we
used to source taxonomies). Where appropriate, an image is displayed showing the current
data element. At the bottom of each page is a list of external identifiers corresponding to the
element currently being viewed. If users find an error in any given data element, a button
allows them to report the issue to the website’s administrator.
Since VenomKB focuses largely on characteristics of venoms related to drug discov-
ery, pages corresponding to venom proteins that have led to the development of approved
drugs also contain information about those drugs and the endogenous human structures that
these proteins (and, by extension, their derived drugs) target. An example of these website
components is shown in Figure 2.11.
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Figure 2.11.: Example of a venom-derived drug and a venom protein target, taken from
the page for Exendin-4 (VenomKB ID: P5730495). Similar components are included in
VenomKB for all venom proteins that have led to the development of an approved drug, and
more will be added in the future, as experimental drugs reach the market.
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Table 2.10.: Version differences; VenomKB v1.0 vs. v2.0
VenomKB v1.0 VenomKB v2.0
Web framework Ruby on Rails Node.js + React + Express
Database back-end PostgreSQL MongoDB
Database structure 3 unstructured SQL tables Structured documents mapped
to Venom Ontology
API None REST API, implemented
in Mongoose.js
Legacy support n/a VenomKB v1.0 rows
mapped to v2.0 documents
VenomKB augments existing knowledge using ontological inference
There are generally two types of ontological inference in VenomKB, both of which are de-
pendent on the structure of the Venom Ontology: 1.) Inferred data types and 2.) inferred
data associations. Currently, the only inferred data type in VenomKB is “Systemic Ef-
fects”, which are diseases and conditions that are either associated with or resulting from
the administration of a venom or venom component to the human body. Another inferred
data type that we plan to add in the future is “Molecular Effects”, which are the specific
effects that venoms and their components have on biomolecular structures at the cellular or
sub-cellular level in the human body. By using the structure of the Venom Ontology, we
can use class assertions to infer and validate the molecular effects associated with diseases
and conditions, and potentially discover new disease/condition associations for venoms and
venom components.
In Figure 2.10 we illustrate a specific example of the type of observation that can be
made using a combination of VenomKB’s data and ontological inference. Here, we define
99
2.3 VENOMKB V2
venom complexity as the number of unique protein components in a species’ venom. By
grouping species in VenomKB using the available taxonomic hierarchy and then counting
the number of linked protein records for those species, we can plot distributions of venom
complexity for major taxonomic clades, such as reptiles, insects, molluscs, and others. In
addition to highlighting the relative lack of mammals, fish, and amphibians in VenomKB
(and, by extension, other databases containing venom data), these distributions highlight
that insect venoms seem to be of lower complexity than arachnid, reptile, and mollusc
venoms. This observation may be useful for the purposes of drug discovery—for example,
it could suggest that components of insect venom tend to be less specific in their molecular
targets, perhaps so they have activity in a wider range of species (which is well-supported
in the literature of evolutionary toxinology) [125,219].
Heuristic annotation scores provide a relative measure of data quality
A major aspect of creating publicly available databases for science is to provide methods for
assessing the quality of the data. Data quality can be assessed using two general approaches:
task-based assessment, and by performing intrinsic tests on the data records. Intrinsic as-
sessments of data quality are challenging, especially when designing inferred data types that
lack a baseline reference. One noteworthy example of addressing this issue is in the UniProt
database, where data elements are given scores that indicate completeness and confidence in
the assertions made by that element. However, few structured databases outline an objective
approach to assigning quality scores.
We defined heuristic annotation scores for each data record in VenomKB, which are
designed to provide a means for comparing the quality of VenomKB data entities relative to
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Figure 2.12.: Interface for graphically searching and browsing data in VenomKB. Users can
search by string, data type, data quality score, and by disease/condition annotation. The
query results page allows sorting by various fields. To access a particular data record, click
on the VenomKB ID corresponding to the entry of interest.
all other entities of the same data type. These scores are represented as integers in the range
[1 . . 5], inclusive, and are displayed as ‘star’ icons on the data browse and data detail pages in
the web application. To ensure that these quality measures are well-distributed within each
data type, we balanced the number of elements attaining each of the five possible scores. The
procedure we used to create these annotation scores is described in Experimental Procedures.
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Data availability and programmatic access to VenomKB
All data and code related to VenomKB are freely and publicly available online. A version-
controlled Git repository for a.) generating the database back-end and b.) the VenomKB
web application itself can be accessed at http://github.com/jdromano2/venomkb. The
code used to generate the database is written in the Python programming language, and
it uses the PyMongo library to populate a MongoDB database instance with the generated
data. The web application is written in JavaScript (using the React library to design the user
interface and Redux to represent the internal state of the data model), and communicates
with the MongoDB back-end via a REST API (Application Programming Interface) that is
also accessible for programmatic access by end-users. The API functionality is documented
on VenomKB’s website at http://venomkb.org/about/api.
Table 2.11.: Data sources used in VenomKB v2.0.
Data source Used for
ToxProt Most molecular data in “Protein” records
NCBI Taxonomy Species nomenclature data
ITIS Species taxonomic hierarchies
Protein Databank (PDB) Protein images
Wikimedia Commons Species images
MEDLINE / SemMedDB Structured semantic predications
VenomKB v1.0 Raw semantic predications




Advantages of VenomKB over existing venom databases
To our knowledge, VenomKB is one of five public databases focused on venoms and their
components. In designing VenomKB, we aimed to improve on a number of characteris-
tics that make these databases unsuitable for many tasks. The other four databases are
UniProtKB/Swiss-Prot’s Tox-Prot dataset [113], ConoServer [115, 116] and ArachnoServer
[192] databases, and the Animal Toxin DataBase (ATDB) [94]. ConoServer and Arach-
noServer are each focused on specific clades of venomous animals (cone snails and arachnids,
respectively). Tox-Prot is a relatively small component of the much larger UniProtKB, and
therefore does not have the ability to support many of the characteristics unique to venoms.
ATDB seems to no longer be available for public use, at the time of writing.
VenomKB seeks to address each of these shortcomings. Of particularly critical impor-
tance is VenomKB’s inclusion of several datatypes that are present in none of the alternative
venom databases. This includes inferred disease/condition associations, explicit representa-
tions of the animal species from which the proteins are derived, publicly available genome
data, and the semantic predications extracted from previous scientific publications. As de-
scribed by [77], types of data like these are critical to the drug discovery process. For example,
if a protein has a known therapeutic effect but is too toxic to administer to humans, similar
species may synthesize less toxic alternatives.
VenomKB is not limited to certain clades of venomous species. In addition to improving
the coverage of the data, this also allows users to compare characteristics of venoms that have
similar properties despite coming from unrelated species. However, it does limit its focus to
venoms and concepts related to venoms, which allowed us to structure the knowledge base
around the Venom Ontology and exploit the unique semantic features of venoms in a way
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to make inferences that would otherwise be challenging. We specifically host VenomKB on
its own domain (venomkb.org) instead of on an institutional website: Since institutional
websites and affiliations tend to change, having a dedicated domain name improves the site’s
sustainability model.
Extending the VenomKB technique beyond venoms
Although VenomKB was designed specifically to manage venoms and venom component data,
it is reasonable to assume that our techniques could be extended to other similar domains
of interest. Plant metabolites, in particular, provide an interesting target, especially given
that they already comprise a major source of approved therapeutics worldwide [56, 181].
The process of translating the structure of VenomKB to another domain would essentially
involve three steps: (1) redefining the ontology on which the knowledge base is built (e.g.,
creating an appropriate plant metabolite ontology), (2) finding the appropriate data sources
for populating the knowledge base, and (3) making inferences to define new data types where
possible.
VenomKB as a model for open access of scientific data
As mentioned in the previous section, all code and data related to VenomKB are freely
accessible to the public. These resources are maintained under the open-source GNU General
Public License v3 [247], which permits use, reuse, and modification under limited terms. A




VenomKB is limited by a general lack of availability of venom data. Given that scientists
believe there may be millions of venomous species on the planet [229], the 632 species rep-
resented in VenomKB comprise only a miniscule fraction of the total. This disparity is
even more apparent when viewed from the perspective of whole-genome sequencing data:
VenomKB only contains 5 species’ whole genomes (which, as stated before, is the entirety
of publicly available genomes from venomous species, at the time of writing). This issue
is exacerbated further by the fact that it is often challenging to tell whether a species is
venomous or not—for example, it was only discovered in 2009 that the common octopus
(Octopus vulgaris) is venomous, since the octopus is neither aggressive, nor is the venom
appreciably toxic to humans [212].
Although VenomKB contains novel data in the form of literature predications and
automatically inferred disease/condition associations (as well as the ontological relationships
between datatypes), much of the knowledge base is aggregated from previously compiled data
sources, such as UniProtKB, NCBI, and others. However, in the near future, VenomKB will
soon include novel experimental data in the form of human gene expression profiles that
capture transcriptional responses to being exposed to specific animal venoms.
Future additions to VenomKB
VenomKB is—and likely will remain—a work in progress. Our goal is to provide a compre-
hensive knowledge resource for computational toxinology, but due to both the breadth of
venom data types (experimental, clinical, molecular, etc.), and the rapid generation of new
venom data, it is unlikely that any venom data resource will ever be truly comprehensive.
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To address this challenge, a crucial aspect of VenomKB is a map of current and planned
features that grows with and adapts to the evolving needs of the toxinology and drug dis-
covery communities. This feature map is available to view at http://venomkb.org/about/
features/. Aside from the novel gene expression profile data that was mentioned previously,
important additions in the near future include the following:
• Important pharmacokinetic and biochemical measures (when known), such as IC50,
Ki, and molecular mass
• Additional gene-level data, including nucleotide sequences, protein isoforms, and gene
families
• Annotations to clinical trials exploring particular venom compounds
• Metrics related to whole genomes, such as total size and sequencing methods used
• Species-level data related to natural uses of venoms, such as predation/defense, venom
delivery, and target species
Furthermore, we strongly encourage input from researchers who could benefit from additional
features. Contact methods for the authors are provided on the VenomKB website, at http:
//venomkb.org/contact.
2.3.3. Methods
The original version of VenomKB was written using the Ruby on Rails web framework for
the Ruby programming language, but for v2.0 we rewrote the entire web application in
JavaScript, using the React.js library to implement the interactive user-interface, and the
Mongoose library to construct the data model for the REST API. The differences between
v1.0 and v2.0 are summarized in Table 2.10. We maintain the database back-end for
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VenomKB on a MongoDB server that is separate from the web application for security and
performance.
We constructed the database using an iterative approach, starting with data aggregated
from existing databases and then transitioning to the addition of inferred and novel data
types. To serve as a starting point for building the database, we treat the ToxProt venom
protein annotation program as a gold-standard, being arguably the most complete existing
venom database that is not constrained to a certain set of taxa. First, we retrieved all
venom peptides in the ToxProt database and extracted core attributes relevant to VenomKB
(such as amino acid sequences and cross-references to other databases). We then retrieved
taxonomy data for all species with at least one peptide, and used both the NCBI Taxonomy
database [72] and the Integrated Taxonomic Information System (ITIS) to build taxonomic
lineages and to retrieve other species-level data, such as common names, synonyms, and
external identifiers.
To link literature annotations and predication data from VenomKB v1.0 to the new
knowledge base, we used expert-identified literature references provided by the ToxProt
program. For each PubMed identifier in ToxProt, we retrieved corresponding VenomKB
v1.0 predications, and linked them to both their respective protein and species data records.
Since many literature annotations are duplicated both within a single document and between
multiple documents, we merged duplicate records.
In VenomKB, we represented data provenance using the PROV-DM data model stan-
dard [170]. Data provenance is a representation of the sources of each data type in VenomKB
along with the methods employed to manipulate and restructure data. Beyond accountabil-
ity and reproducibility, provenance allows for data quality assessment [89]—data aggregated,
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created, or validated by more rigorous methods generally are deemed to be of better quality
than otherwise. The provenance model for VenomKB can be downloaded from the website,
at http://venomkb.org/download.
Generating balanced heuristic annotation scores
In Results we explain the use of heuristic annotation scores to provide a method for compar-
ing data quality and completeness relative to VenomKB’s other data elements of the same
type. We accomplished this task by first assigning raw (unscaled) scores to each instance of
each data type based on presence and absence of certain elements. For example, the raw score
of a protein was increased by 0.05 for each literature predication, and decreased by 0.2 if it
had no literature predications. A species’ raw score was increased by 3.2 if a complete taxo-
nomic lineage was present, and decreased by 1.0 if no image of that species was available. The
complete details for assigning raw scores is outlined in the VenomKB code repository—the
following Python code sample (from generate annotation scores.py) shows the scoring
function for a Protein:
def score_protein(p):
""" Score a protein.
Keyword arguments:
p -- The protein , as an encoded JSON document.
Returns:
Floating point value >= -4.0"""
score = 0.
if ’pdb_structure_known ’ in p.keys ():
if p[’pdb_structure_known ’] == True:
score += 3
if ’pdb_image_url ’ in p.keys ():




if ’None ’ in p[’pdb_image_url ’]:
score -= 4
if ’description ’ in p.keys ():
score += 1.
score += (len(p[’out_links ’]) * 0.1)
if ’literature_predications ’ in p.keys ():
score += 0.2
score += (len(p[’literature_predications ’]) * 0.05)
return score
After computing raw scores, we then adjusted the scores for each data type to a discrete








where |x| denotes the number of elements of data type x, x(i) is the vector of order statistics
for the raw scores of data type x, and x′ is the vector of transformed scores. This procedure
produces five evenly sized bins from 1 to 5 for each data type in VenomKB.
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Figure 2.13.: Example of a page containing a single venom protein. Userschoose the way
that they view data using the tabs at the top of the interface. The user is presented with an
image of the protein, descriptive information, a link to the species from which the protein
was discovered, amino acid data (with links to external tools such as BLAST), and gene
ontology annotations. Other fields are out of view, including literature predications, links to
external databases, and related publications from MEDLINE.
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Chapter 3.
A transcriptomic approach for generating
therapeutic effect data from venoms
3.1. Introduction (VenomSeq)
In Chapter 1, we introduced VenomSeq as a new platform for creating new next-generation
sequencing data from venoms that can be used to discover therapeutic associations. Briefly,
VenomSeq involves exposing human cells to dilute venoms, and then generating differential
expression profiles for each venom, comprised of the significantly up- and down-regulated
genes in cells perturbed by the venom. We then compare the differential expression profiles to
data from public compendia of perturbational gene expression data and gene regulatory data
corresponding to disease states. VenomSeq works in the absence of any predefined hypotheses,
instead allowing the data to suggest hypotheses that can then be explored comprehensively
using rigorous traditional approaches.
3.1.1. Enrichment analysis
A major challenge in working with large scale -omics datasets lies in finding parametric rep-
resentations for higher-order biological phenomena that allow us to assess their statistical












Figure 3.1.: Graphical abstract outlining the VenomSeq workflow.
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(GWAS) often assess the significance of individual single nucleotide polymorphisms (SNPs)
with statistical tests that assume normality in the distribution of the target trait, in spite of
this usually being unrealistic [33]. When performing transcriptomic research, the relation-
ships between expression levels of individual genes and varying states of cellular perturbation
are even more complex, being dependent on vast numbers of overlapping regulatory processes
and signaling cascades [139], as well as naturally-occurring randomness [120]. To circumvent
this issue, biostatisticians instead turn to nonparametric hypothesis tests, which make no
assumptions about the underlying distribution of the data. These usually rely on statistics
(which are just functions of a sample and therefore nonparametric) to derive a measure of
significance. For example, the Mann-Whitney U test is a nonparametric test that rely on a
statistic U that is derived from the sum of ranks within a group of interest.
One of the most valuable classes of nonparametric statistical tests for transcriptomic
and gene expression analyses is known as enrichment analysis, popularized in 2004 in a
method named gene-set enrichment analysis (GSEA) [235]. Briefly, the goal is to determine
whether a subset S of members in a larger set G (e.g., genes involved in a constrained
metabolic pathway within the set of all genes in the human transcriptome) tend to occur
closer to the front or the back of a list that orders the members of the set with respect to
some value of interest (e.g., relative expression level). Enrichment analysis deserves special
consideration in this dissertation, since it shows up in no fewer than three of the algorithms
described in this chapter (connectivity score computation, msVIPER, and enrichment of
phenotypes in DisGeNET—all described in §3.4.6).
The key statistic in enrichment analysis is known as an enrichment statistic or enrich-
ment score (ES), which is itself derived from a nonparametric test named the Kolmogorov–
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Smirnov test (or KS test). The procedure for finding the ES is as follows:
1. Construct a vector of ranks L with respect to the measure of interest (e.g., relative
expression) over all members of G.
2. Traverse the elements of L from the front to the back.
3. Maintain a running score, where at each element l ∈ L you either add a quantity (if
l ∈ S) or subtract a quantity (if l /∈ S)1.
4. Set ES to the value of the running score with the greatest magnitude.
ES can be positive or negative—a positive ES indicates a shift towards the front of
the ranked list (i.e., ‘enriched’), while a negative ES indicates a shift towards the back of the
ranked list (i.e., ‘depleted’). Statistical significance of the ES can be assessed in one of two
ways: (1) Via comparison to a critical value determined analytically using the Kolmogorov–
Smirnov distribution (related to Brownian motion and based on the idea that ES should
behave like a “random walk” under the null hypothesis), or (2) by comparing ES empirically
to a null model generated by randomly permuting either the samples or the features of the
dataset a large number of times. In practice, most studies use the permutation approach
rather than the analytical approach.
While permutation tests such as these are criticized for reduced statistical power over
analytic alternatives [185], the approach does provide one crucial advantage in the context of
VenomSeq: since we use a chain of algorithms where the input to one is the set of statistically
significant elements identified by the previous (creating a kind of “stacking” of statistical
models), finding a closed form of an analytical solution would be substantially more complex
1The quantity to add or subtract changes based on the specific task. It can range from a fixed quantity to
a quantity whose magnitude is different for each l ∈ L.
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MAPK signaling pathway enrichment in P53 mutant cell line
Figure 3.2.: Example of of enrichment analysis using GSEA, with a null model consisting
of 1000 iterations of phenotype permutation. The analysis indicates depletion of MAPK
signaling pathway gene expression in P53-mutant cells, but does not pass the significance
threshold. Notice that ES increases by a magnitude determined by rank correlation of the
gene with the phenotype.
and error-prone than simply performing permutation tests at each stage in the process2.
3.2. Results (VenomSeq)




Table 3.1.: Statistics for S. maurus growth inhibition data.









In order to optimize the exposure concentrations of each venom, we performed growth in-
hibition assays on human cells exposed to varying concentrations of the venoms. This is
necessary to minimize the impact of toxicity while ensuring the venom is in high enough
concentration to exert an effect on the human cells. Since each venom is comprised of many
(largely unknown) molecular components, we performed the assays on samples of venom
measured in mass per volume, rather than compound concentration (molarity). We used
GI20—the concentration of a venom at which it inhibits growth of the human cells by 20%—
as the effective treatment dose in all subsequent experiments.
The experimental GI20 values and complete dose-response data for each of the 25
venoms are provided in Appendix A (Table A.1), a sample of which is reproduced (for
S. maurus) in Table 3.1. The resulting growth inhibition curves for all venoms are shown in
Figure 3.3. Venoms from L. colubrina, D. polylepis, S. verrucosa, S. horrida, C. marmoreus,
O. macropus, and P. volitans did not demonstrate substantial growth inhibition at any tested
concentration, so for those venoms we instead performed sequencing at 1.0µg µl−1, which is
the highest concentration used in the growth inhibition curves.
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2.0 1.5 1.0 0.5 0.0
L. colubrina
6 4 2 0
GI80: 1.93E-03
M. xanthina
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D. polylepis






2.0 1.5 1.0 0.5 0.0
GI80: 7.94E-03
Atractaspis sp.
6 4 2 0
GI80: 3.65E-03
M. gigas
2.0 1.5 1.0 0.5 0.0
GI80: 1.25E-01
L. fallax






2.0 1.5 1.0 0.5 0.0
GI80: 1.09E+00
A. lobata
2.0 1.5 1.0 0.5 0.0
S. verrucosa
2.0 1.5 1.0 0.5 0.0
S. horrida















2.0 1.5 1.0 0.5 0.0
GI80: 9.49E-01
L. quinquestriatus
2.0 1.5 1.0 0.5 0.0
GI80: 9.26E-02
S. maurus
6 4 2 0
GI80: 1.78E-04
B. bufo
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GI80: 1.58E-01
B. variegata
2.0 1.5 1.0 0.5 0.0
GI80: 2.42E-02
A. mellifera
2.0 1.5 1.0 0.5 0.0
GI80: 8.38E-01
V. crabro






2.0 1.5 1.0 0.5 0.0
C. marmoreus
2.0 1.5 1.0 0.5 0.0
GI80: 7.10E-01
C. imperialis
2.0 1.5 1.0 0.5 0.0
O. macropus





log10 venom concentration (mg/ l)
Figure 3.3.: Growth inhibition plots for each of the 25 venoms. GI80 values are provided,
unless growth inhibition was not observed (in which case sequencing was instead performed
at 2 mg µl−1).
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Table 3.2.: Experimental conditions for RNA-Seq.
Venoms 25 species
Cell line IMR-32 (Human neuroblastoma)
Dosage GI20 for each venom
Time points 6/24/36 hours post-treatment
Replicates 3 per time point per venom
Controls 12 water controls, 9 untreated
Solvent Water
3.2.2. mRNA sequencing of venom-perturbed human cells
After determining appropriate dose concentrations for each venom, we performed RNA-
Seq on human IMR-32 cells exposed to the individual venoms. Table 3.2 summarizes the
experimental conditions used for sequencing. After transforming the raw sequencing reads
to gene counts (see §3.4.4), we compiled the results into a matrix, where rows represent
genes, columns represent samples, and cells represent counts of a gene in a sample. For
detailed quality control data, refer to Appendix A, which includes links to related files.
The raw (i.e., FASTQ files produced by the sequencer) and processed (i.e., gene counts per
sample) data files are available for download and reuse on NCBI’s Gene Expression Omnibus
database; accession GSE126575.
3.2.3. Differential expression signatures of venom-perturbed human
cells
We constructed differential expression signatures for each of the 25 venoms as described
in §3.4.5, where each signature consists of a list (length ≥ 0) of significantly upregulated
genes, and a list (length ≥ 0) of significantly downregulated genes. The specific expression
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Table 3.3.: Partial differential expression signature for O. macropus. Most of the signifi-
cantly differentially expressed genes (35 of 41 total) are omitted for brevity.
Gene Base mean log2-FC Wald statistic p-adj
SPRY4 37.38 -2.27534 -3.3084 0.0991
REPIN1 38.30 -0.95256 -4.3326 0.0061
DUSP14 33.88 -0.91311 -3.3327 0.0991
... ... ... ... ...
BRD3 130.81 1.37645 4.115 .0096
RSRC1 63.48 1.38140 4.2042 0.0091
BAZ1B 120.05 1.69463 5.0846 0.0003
signatures are available on FigShare at https://doi.org/10.6084/m9.figshare.7609160.
An excerpt from the expression signature for O. macropus is shown in Table 3.3. The
total number of differentially expressed genes for each venom ranges from 2 genes (Laticauda
colubrina and Dendroaspis polylepis polylepis) to 1494 genes (Synanceia verrucosa). Note that
these signatures are specific to IMR-32 cells—we expect that the same procedure applied to
other cell lines would yield substantially different expression signatures.
Gene-wise statistical significance is a function of both log2 fold change and the number
of observed counts. This relationship is illustrated in Figure 3.4, which is derived from the
same data shown in Table 3.3 (for O. macropus).
3.2.4. Associations between venoms and existing drugs
Using publicly-available differential expression profiles for existing drugs—many with known
effects and/or disease associations—we were able to identify statistically significant associ-
ations between venoms and classes of drugs. These associations are based on the methods
designed by the Connectivity Map (CMap) team [131], and utilize their perturbational differ-
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O. macropus vs. untreated
Figure 3.4.: MA plot showing genewise relationship between log2 fold change and mean of
normalized counts in samples corresponding to O. macropus venom. Each point represents







Figure 3.5.: Connectivity analysis results. a.) Heatmap of τ -scores between the 25 venom
perturbations and the 500 Connectivity Map signatures with the highest variance across all
venoms. A distinct hierarchical clustering pattern is evident across the venom perturbations,
although it does not conform to any obvious grouping pattern of the venoms. b.) Principle
component analysis of the 25 venom perturbations, where features are all τ -scores between
the venom and signatures from the Connectivity Map reference database. 4 distinct outliers
are labeled—these venoms correspond to outliers in the heatmap. Also shown are the ratios
of variance explained by each of the first 21 principle components—after the first principle
component, the distribution is characterized by a long tail, suggesting that much of the
variance is spread across many dimensions, underscoring the complexity of the connectivity
score data. c.) Barplot showing the number of significant differentially expressed genes for
IMR-32 cells exposed to each of the 25 venoms.
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ential expression data as the “gold standard” against which to evaluate the venom expression
data. In short, this approach uses a Kolmogorov-Smirnov–like signed enrichment statistic to
compare a query signature (i.e., venoms) to all signatures in a reference database (i.e., known
drugs), normalizing for cell lines and other confounding variables, and finally aggregating
scores of ‘like’ signatures (i.e., drug MoAs) using a maximum-quantile procedure. Complete
details of these methods are provided in §3.4.6.
Different venoms yield different profiles of connectivity scores based on the genes
present in their differential expression signatures. For example, all connectivity scores be-
tween B. occitanus and CMap perturbagens are zero, and all connectivity scores between
S. horrida and CMap perturbagens are negative, which suggest that these venoms either
behave like no known perturbagen classes, or that the venoms have no therapeutic activity
on IMR-32 cells. Kernel density plots of the connectivity scores for each venom are shown
in Figure 3.6. In Figure 3.5, we show several visualizations of the connectivity analysis
results that highlight characteristics of the data. Interestingly, when hierarchical clustering
is performed on the connectivity scores by venom perturbation, the venom perturbations
form robust clustering patterns that persist across multiple non-overlapping subsets of the
connectivity data. This suggests that the clustering corresponds to meaningful characteris-
tics of the venom perturbations in comparison to known drugs, although these characteristics
are not readily apparent (i.e., the clustering does not reproduce taxonomy, or other obvious
traits of the venoms).
The associations we identified are shown in Table 3.4. As we anticipated, only some
venoms show strong associations to any classes of drugs. Interestingly, only one venom
(S. subspinipes dehaani) was linked to an ion channel inhibition MoA—venoms, in general,
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Table 3.4.: Venom–drug class associations.
Venom Drug class (MoA)
Synanceia horrida ATPase inhibitor
CDK inhibitor
DNA synthesis inhibitor
Scolopendra subspinipes dehaani T-type Ca2+ channel inhibitor
Pterois volitans Topoisomerase inhibitor
Argiope lobata ATPase inhibitor
PI3K inhibitor
PPARγ agonist
Scorpio maurus FGFR inhibitor
Rhinella marina HIV protease inhibitor
tend to have powerful ion channel blocking or activating effects. However, this may be due
to a preponderance of non-ion channel MoAs in the CMap data rather than an actual lack
of ability to identify ion channel activity.
Many of these MoAs comprise either well-established or emerging classes of cancer
drugs. Some that have been used extensively as chemotherapeutic agents include CDK
inhibitors (palbociclib, ribociclib, and abemaciclib), topoisomerase inhibitors (doxorubicin,
teniposide, and irinotecan, among others), and DNA synthesis inhibitors (mitomycin C,
fludarabine, and floxuridine). Meanwhile, PI3K inhibitors and FGFR inhibitors are classes
of “emerging” chemotherapy drugs, each recently leading to many high-impact research
studies and early-stage clinical trials.
The other classes are indicated for a diverse range of diseases, including circulatory and
mental conditions (calcium channel blockers), and cardiac abnormalities (ATPase inhibitors).














































































































Normalized connectivity score (NCS)
Figure 3.6.: Kernel density plots of normalized connectivity scores (NCSs) for each of the
25 venoms. Note the tendency to introduce sparsity by setting NCS to zero if the quantities
a and b have opposite signs (see §3.4.6). Text labels indicate proportion of NCSs for a
single venom that are negative, zero, or positive. Each plot is based on 473,647 NCSs (all
differential expression profiles in GSE92742 [234]).
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mation, and cholesterol disorders.
We are in the process of validating several of the associations listed in Table 3.4
using targeted, cell-based assays, the results of which will be documented in subsequent
publications.
VenomSeq technical validation
Following the procedures described in §3.4.7, we used a secondary PLATE-Seq dataset of 37
existing drugs (with known effects) tested on IMR-32 cells to assess whether the sequencing
technology (PLATE-Seq) and cell line (IMR-32) employed by VenomSeq are compatible with
connectivity analysis and the CMap reference dataset. In this dataset, we were able to map
20 of the 37 drugs to a single existing CMap perturbational class (PCL). The drugs, their
modes of action, and the PCLs of which they are members are listed in Table 3.5.
VenomSeq technical validation: Recovering connectivity by integrating cell lines When
we aggregated all connectivity scores between a known drug and members of the same PCL
in the CMap dataset, irrespective of cell line, the connectivity scores are significantly greater
than those in a null model in 12 out of 20 instances, which indicates that drugs within
the same functional class tend to have more similarities in the query and reference datasets
than if the compounds are chosen at random. In all 20 cases, the average effect size3 was
positive, regardless of statistical significance. These—and their corresponding measures of
3Effect size is defined as the average difference between connectivities within the expected PCL and the
null model of random connectivities for the same query
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VenomSeq data Validation data CMap reference data
Technology PLATE-Seq PLATE-Seq L1000
Measurement type Gene counts Gene counts Gene relative abundance
Human cell line(s) IMR-32 IMR-32 9 core cell lines
Exposure 
compounds
25 crude venoms 37 small molecule 
drugs
19,811 small molecule 
compounds
E ects known No Yes Some
Drug class 
annotations







Figure 3.7.: Results of applying the VenomSeq sequencing and connectivity analysis work-
flow to 37 existing drugs with known effects, to validate the compatibility of PLATE-Seq
and IMR-32 cells with the connectivity analysis algorithm and dataset. a.) Scatter plot
showing validation drugs that are members of a CMap PCL and the mean differences be-
tween within-PCL connectivity scores and a null distribution of random connectivity scores
for the same drug (Table 3.6). Verticle axis shows the p-value of a Student’s t-test compar-
ing the within-PCL and null connectivity score distributions (corrected for multiple testing).
Statistically significant drugs are labeled by name. b.) Summary of the validation strategy,
showing that the validation dataset bridges certain gaps between the VenomSeq data and the
CMap reference data. c.) Distributions of rank percentiles of expected (“true”) PCLs within
the list of all PCLs ordered by average connectivity score (Table 3.7), aggregated by CMap
dataset cell lines, and d.) validation drugs. Green distributions indicate a shift towards the
front of the rank ordered list, indicating stronger compatibility with the PLATE-Seq/IMR-32
query data, based on expected connections, and “*” indicates statistically significant shifts.
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Table 3.5.: Drugs used to validate PLATE-Seq and the IMR-32 cell line for connectivity
analysis. Not all compounds of a given mechanism of action will necessarily map to that
mechanism’s associated PCL—PCLs consist of compounds that are members of the same
functional class and also have high transcriptional impact.
Drug Mechanism of Action CMap perturbagen class (PCL)
Mibefradil T-type Ca2+ channel inhibitor CP T TYPE CALCIUM CHANNEL BLOCKER
Isradipine L-type Ca2+ channel inhibitor CP CALCIUM CHANNEL BLOCKER
Nifedipine L-type Ca2+ channel inhibitor CP CALCIUM CHANNEL BLOCKER
Diltiazem Ca2+ channel inhibitor CP CALCIUM CHANNEL BLOCKER
Verapamil Ca2+ channel inhibitor CP CALCIUM CHANNEL BLOCKER
Fendiline Ca2+ channel inhibitor CP CALCIUM CHANNEL BLOCKER
Topiramate Na+ and Ca2+ channel modulator CP SODIUM CHANNEL BLOCKER
Ionomycin Ca2+ channel signal inducer
1-EBIO Ca2+-gated K+ channel activator CP POTASSIUM CHANNEL ACTIVATOR
Forskolin Adenylyl cyclase activator
Pregabalin Increases GABA biosynthesis
Gabapentin Increases GABA biosynthesis
Baclofen GABAB-receptor agonist
Memantine Glu-receptor inhibitor
Acamprostate Glu-receptor inhibitor CP GABA RECEPTOR ANTAGONIST
MTEP Glu-receptor inhibitor
Ivermectin Glu-gated Cl− channel inhibitor
Carbenoxolone Glucocorticoid metabolism inhibitor
Mifepristone Glucocorticoid receptor inhibitor CP PROGESTERONE RECEPTOR ANTAGONIST
Dexamethasone Glucocorticoid receptor agonist CP GLUCOCORTICOID RECEPTOR AGONIST
Aldosterone Mineralocorticoid receptor agonist
Spironolactone Mineralocorticoid receptor inhibitor
Olanzapine Dopamine receptor inhibitor CP DOPAMINE RECEPTOR ANTAGONIST
Eticlopride Dopamine receptor inhibitor CP DOPAMINE RECEPTOR ANTAGONIST
Ondansetron 5-HT3 serotonin receptor inhibitor CP SEROTONIN RECEPTOR AGONIST
Naltrexone Opioid receptor inhibitor
Disulfiram Acetaldehyde dehydrogenase inhibitor
Cerlitinib ALK inhibitor
Crizotinib ALK inhibitor
Sirolimus mTOR inhibitor CP MTOR INHIBITOR
Manumycin a Farnesyltransferase inhibitor CP NFKB PATHWAY INHIBITOR
Vorinostat HDAC (I/II/IV) inhibitor CP HDAC INHIBITOR
Prazosin Adrenergic receptor inhibitor CP BETA ADRENERGIC RECEPTOR AGONIST
Rolipram Phosphodiesterase-4 inhibitor
Minocycline NOS inhibitor
Pioglitazone PPARγ/α inhibitor CP PPAR RECEPTOR AGONIST
Fenofibrate PPARα agonist CP PPAR RECEPTOR AGONIST
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significance—are shown in Figure 3.7 and Table 3.6. Overall, these data are congruent
with those made by the Connectivity Map team in [234]—namely, that expected connections
between query drugs and reference compounds can be recovered for some PCLs, but not for
others. Importantly, in both our observations and the observations in [234], PCLs related to
highly conserved core cellular functions perform better under this approach.
VenomSeq technical validation: Impact of reference cell lines and query drugs on ex-
pected PCL percentile ranks Since IMR-32 cells are not present in the CMap reference
dataset, we were particularly interested in seeing which cell lines present in the reference
dataset (if any) performed better than others at the task of recovering expected connections.
Using the PCL ranking strategy described in §3.4.7, 7 of the 9 core cell lines show at least a
moderate tendancy to place the true PCL towards the front of the ranked list of all PCLs,
indicating that at least some of the ability to recover expected connections is retained when
looking at those 7 cell lines individually. PCL rankings stratified by drug (rather than cell
line) show a similar pattern—15 of 20 PCL-annotated drugs tend to have the expected PCL
ranked towards the front of the list (“enrichment”), while 5 tend to have the expected PCL
show up towards the back of the list (“depletion”). Of these 20, the only It should be noted
that—due to the rather small number of profiles in the reference dataset that are annotated
to PCLs—these two analyses were limited in terms of statistical power, and deserve a follow




Table 3.6.: Enrichment of strong connections in expected PCL annotations . p-values cor-
respond to independent, two-sample Student’s t-tests between “within-PCL” connectivities
and a null model of randomly sampled compound connectivities (see text) for the same
query drug, and are corrected for multiple testing using the Benjamini-Hochberg procedure.
Effect size is the difference of means between those two groups, such that larger effect sizes
correspond to higher expected connectivity scores between the query drug and members of
its same drug class. Note that effect sizes are relatively small in most cases—this is due in
part to the sparsity of connectivity scores.
Drug PCL p-value Effect size
Topiramate CP SODIUM CHANNEL BLOCKER 1.018e-31 13.168
Vorinostat CP HDAC INHIBITOR 5.952e-22 1.717
Sirolimus CP MTOR INHIBITOR 2.240e-17 1.232
Eticlopride CP DOPAMINE RECEPTOR ANTAGONIST 1.278e-11 4.175
Olanzapine CP DOPAMINE RECEPTOR ANTAGONIST 8.117e-09 2.640
Fenofibrate CP PPAR RECEPTOR AGONIST 1.012e-07 1.775
Pioglitazone CP PPAR RECEPTOR AGONIST 1.158e-07 3.252
Manumycin a CP NFKB PATHWAY INHIBITOR 4.124e-07 5.983
Dexamethasone CP GLUCOCORTICOID RECEPTOR AGONIST 2.741e-06 2.462
Prazosin CP BETA ADRENERGIC RECEPTOR AGONIST 2.476e-02 2.083
Acamprosate CP GABA RECEPTOR ANTAGONIST 4.290e-02 2.260
Mibefradil CP T TYPE CALCIUM CHANNEL BLOCKER 6.871e-02 0.355
1-EBIO CP POTASSIUM CHANNEL ACTIVATOR 2.573e-01 2.597
Fendiline CP CALCIUM CHANNEL BLOCKER 2.854e-01 2.636
Diltiazem CP CALCIUM CHANNEL BLOCKER 2.929e-01 5.719
Isradipine CP CALCIUM CHANNEL BLOCKER 4.062e-01 0.683
Nifedipine CP CALCIUM CHANNEL BLOCKER 4.100e-01 1.932
Mifepristone CP PROGESTERONE RECEPTOR ANTAGONIST 4.309e-01 3.160
Verapamil CP CALCIUM CHANNEL BLOCKER 5.404e-01 5.880
Ondansetron CP SEROTONIN RECEPTOR AGONIST 5.710e-01 2.659
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Table 3.7.: Correct PCL ranks aggregated by cell line. Mean rank percentile is the mean
rank of the correct (“true”) PCL, aggregated over all query drugs and divided by the total
number of PCLs (92), reported by cell line.










3.2.5. Associations between venoms and disease regulatory networks
Direct observations of expressed genes (via mRNA counts) provide an incomplete image
of the regulatory mechanisms present in a cell. To complement the CMap approach that
focuses on perturbations at the gene level, we designed a parallel approach that uses cell regu-
latory network data to investigate perturbations at the regulatory module (e.g., pathways and
metabolic networks) level; an approach we refer to as master regulator analysis. In master
regulator analysis, the ARACNe algorithm [162] is used to obtain regulatory network data
for our cell line of interest (in this case, IMR-32), consisting a list of regulons—overlapping
sets of proteins whose expression is governed by a master regulator (e.g., a transcription
factor). The msVIPER algorithm [4] is then used to determine the activity of each regu-
lon by computing enrichment scores from observed expression levels of the genes/proteins
contained in that regulon (here, using the RNA-Seq results described in §3.2.2).
We matched the significantly up- and down-regulated master regulators for each venom
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to diseases using high-confidence TF-disease associations in DisGeNET [193]—a publicly
available database of associations between diseases and gene network component. This
approach is based on the idea that diseases caused by disregulation of metabolic and signaling
networks can be treated by administering drugs that “reverse” the cause (i.e., abnormal
master regulator activity) of disregulation. Since we are interested in discovering associations
with multiple corroborating pieces of evidence, we specifically filtered for diseases where two
or more linked TFs are disregulated when perturbed by the venom. The complete list of
associations are provided on figshare at https://doi.org/10.6084/m9.figshare.7609793;
here, we describe a handful of interesting observations.
The most prevalent class of illness (comprising 19.7% of all associations across all
venoms) is DISEASES OF THE NERVOUS SYSTEM AND SENSE ORGANS. This is not surprising,
considering many of the 25 venoms have neurotoxic effects, and IMR-32 is a cell line derived
from neuroblast cells. One source of bias in these results is that similar diseases tend to
be associated with the same regulatory mechanisms [236]. For example, associations be-
tween a venom and schizophrenia will often be co-reported with associations to other mental
conditions, such as bipolar disorder and alcoholism.
3.3. Discussion (VenomSeq)
3.3.1. Venoms versus small-molecule drugs
In the connectivity analysis portion of VenomSeq, we demonstrated that these techniques
have the ability to identify novel venom–drug class associations, and corroborate known
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venom activity. One distinct advantage of performing queries against the CMap reference
dataset is their inclusion of manually-curated PCLs, which allow for normalization of data
gathered from multiple perturbagens and multiple cell lines, aggregated at a class level that
corresponds approximately with drug mode of action. For this reason, hypotheses generated
by the connectivity analysis portion of VenomSeq are often testable at the protein level.
One important caveat is that venom components have a tendency to interact with
cell surface receptors (e.g., ion channels or GPCRs), inciting various signaling cascades and
therefore acting indirectly on downstream therapeutic targets. While this is certainly the
case for many drugs as well (GPCRs are considered the most heavily investigated class of drug
targets [102]), small molecules often can be designed to enter the cell and interact directly
with the downstream therapeutic target. This has important implications regarding assay
selection for in vitro validation of associations learned through the connectivity analysis. For
example, if the MoA of interest is inhibition of an intracellular protein (e.g., topoisomerase),
a cell-based assay should be considered when testing venom hypotheses, since the venom
likely is not interacting directly with the topoisomerase (and, therefore, the effect would not
occur in non-cell based assays).
3.3.2. Venoms versus human diseases
The master regulator analysis portion of VenomSeq discovers associations between venoms
and the diseases they may be able to treat, rather than to drugs. This could be especially
useful for discovering treatments to diseases with no or few existing indicated drugs (or
drugs that are not present in public differential expression databases). Additionally, since
the master regulator approach is sensitive to complex metabolic network relationships, it is
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(theoretically) more sensitive to patterns, as well as more suited to diseases with complex
genetic etiologies that are not explainable by observed gene counts alone.
Currently, the primary drawback to the master regulator approach is that criteria for
statistical significance are not well established. Therefore, it is challenging to determine
which venom-disease associations are most likely to reflect actual therapeutic efficacy. As a
temporary alternative, we used several heuristics to ensure there are multiple corroborating
sources of evidence for the reported associations.
As discussed previously, the connectivity analysis produces hypotheses that are rel-
atively straightforward to validate experimentally, using affordable, widely available assay
kits and reagents. Since the master regulator workflow gives hypotheses at the disease
level (where the underlying molecular etiologies can be unknown), validation instead needs
to be performed at the phenotype level, either using animal models of disease, or carefully
engineered, cell-based phenotypic assays that measure response at multiple points in disease-
related metabolic pathways (e.g., DiscoverX’s BioMAP® platform [21]).
3.3.3. Biologically plausible therapeutic hypotheses
VenomSeq contains multiple types of data analysis for two reasons: (1) It allows us to cover
diseases with a wider array of molecular etiologies, and (2) it provides a means for obtaining
multiple pieces of corroborating evidence for a given hypothesis. If a link between a venom
and a drug/disease is suggested by both connectivity analysis and master regulator analysis,
and there is additional literature evidence that lends biological or clinical plausibility, this
increases our confidence that the suggested therapeutic effect is “real”.
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Argiope lobata venom versus cardiopulmonary and psychiatric diseases
A. lobata is a species of spider in the same genus as the common garden spider. The species
is relatively understudied, largely due to its lack of interaction with humans, in spite of being
distributed across Africa and much of Europe and Asia. The venom from species of Argiope
spiders contain toxins known as argiotoxins [198], which are harmless to humans, in spite
of having inhibitory effects on AMPA, NMDA, kainite, and nicotine acetylcholine receptors,
which have been implicated in neurodegenerative and cardiac diseases. VenomSeq provides
supporting evidence for therapeutic activity in each of these classes.
Connectivity analysis links A. lobata venom to ATPase inhibitor drugs (see Figure 3.8),
which include digoxin, ouabain, cymarin, and other cardiac glycosides, and are used to treat
a variety of heart conditions. Another venom-derived compound—bufalin (from the venom
of toads in the genus Bufo) [133]—is considered an ATPase inhibitor, and has demonstrated
powerful cardiotonic effects. Connectivity analysis also links the venom to PPAR agonist
drugs, which are used to treat cholesterol disorders, metabolic syndrome, and pulmonary
inflammation. Interestingly, PPARγ activation results in cellular protection from NMDA
toxicity. Given the known inhibitory effect of argiotoxins on NMDA receptors [172], this is
striking and biologically plausible evidence for toxin synergism, where two or more venom
components target multiple cellular structures with related functions in order to incite a
more powerful response [134].
Master regulator analysis supports these findings, as well. We found that A. lobata
venom is associated with a number of circulatory diseases, including hypertension, heart
failure, cardiomegaly, myocardial ischemia, and others. Additionally, it reveals strong as-
sociations with an array of mental conditions, such as schizophrenia, bipolar disorder, and
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Figure 3.8.: Structure of digoxin (left), a cardiac glycoside that inhibits the function of
the Na+/K+ ATPase (ATP1A; right) in the myocardium, which causes a decrease in heart
rate [129]. A. lobata venom has similar differential expression effects to those of digoxin and
other ATPase inhibitor drugs, based on connectivity analysis. Diagram from Reactome [70].
psychosis. These associations are supported by recent research into argiotoxins (and other
polyamine toxins), showing that their affinity for iGlu receptors can be exploited to treat
both psychiatric diseases and Alzheimer disease [198].
Scorpio maurus venom for cancer treatment via FGFR inhibition
S. maurus—the Israeli gold scorpion—is a species native to North Africa and the Middle
East. Its venom is not harmful to humans, but it is known to contain a specific toxin,
named maurotoxin, which blocks a number of types of voltage-gated potassium channels—an
activity that is under investigation for treatment of gastrointestinal motility disorders [24].
Our connectivity analysis suggests an additional association with FGFR inhibitor
drugs. FGFR inhibitors are an emerging class of drugs with promising anticancer activity,
and much research focused on them aims to understand and counteract their adverse effects
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Figure 3.9.: Diagram of FGFR signaling pathways. FGFR inhibitors target 1 of the 4
types of FGFR complexes, abnormal activity of which are involved in angiogenesis. VenomSeq
suggests therapeutic similarity between S. maurus venom and existing FGFR inhibitor drugs.
Pathway diagram from Reactome [53].
136
3.3 DISCUSSION (VENOMSEQ)
(see Figure 3.9). Although there is no prior mention of FGFR-related activity from this or
related species of scorpions, descriptions of unexpected side effects of S. maurus venom on
mice provides evidence that such activity could be true. In particular, the venom has been
shown to have biphasic effects on blood pressure: when injected, it causes rapid hypoten-
sion, followed by an extended period of hypertension. The fast hypotension is known to be
caused by a phospholipase A2 in the venom, but no known components elicit hypertension
when administered in purified form [69]. The observed FGFR inhibitor-like effects on gene
expression suggest that an unknown component (or group of components) may cause the hy-
pertensive effect via FGFR inhibition. We are currently performing experimental validation
of this link, and will report results in future revisions of this manuscript.
3.3.4. Accessing and querying VenomSeq data
VenomSeq is designed as a general and extensible platform for drug discovery, and we en-
courage secondary use of both the technology as well as the data produced using the 25
venoms tested on IMR-32 cells described in this manuscript. We maintain the data in two
publicly-accessible locations: (1.) a “frozen” copy of the data, as it exists at the time of writ-
ing (on figshare, at https://doi.org/10.6084/m9.figshare.7611662), and (2.) a copy
hosted on venomkb.org, available both graphically and programmatically, and designed to
be expanded as new data and features are added to VenomKB.
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3.3.5. VenomSeq data analysis software
To encourage reuse and reproducibility, we provide an open-source Python package con-
taining all of the data structures and algorithms used in the data analysis portion of
VenomSeq. The software can be downloaded from its source code repository on GitHub at
https://github.com/jdromano2/venomseq, or from the Python Package Index at https:
//pypi.org/project/venomseq. The package contains documentation and example code
for reproducing the results and figures from this chapter. Several auxiliary datasets (such as
the Connectivity Map expression profiles) must be downloaded from their original sources
in order to reproduce certain segments of the pipeline, but these are documented where
applicable.
3.3.6. Transitioning from venoms to venom components
VenomSeq is a technology for discovering early evidence that a venom has a certain thera-
peutic effect. However, most successful approved drugs derived from venoms make use of
the activity of a single component within that venom, rather than the entire (crude) venom.
As previously mentioned, venoms can be comprised of hundreds of unique components, each
with a unique function and molecular target. We are in the early stages (in collaboration
with the Holford lab at CUNY–Hunter College) of applying VenomSeq individually to pu-
rified samples of each of the peptides from the venom of a snail in the family Terebridae.
The goal of this project will be twofold: (1) To demonstrate the use of VenomSeq to screen
individual venom components rather than crude venoms, and (2) to determine which of these
venom components actually exerts transcriptomic effects on human cells. Each of these ques-
tions provides opportunities to understand better how specific venoms can cause therapeutic
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changes in human cells.
Even though most existing venom-derived drugs consist of a single component, crude
venoms in nature use the synergistic effects of multiple components to cause specific pheno-
typic effects [134]. Therefore, testing each venom component individually using the VenomSeq
workflow might fail to capture all of the clinically beneficial activities demonstrated by the
crude venom. A brute-force solution is to perform VenomSeq on all combinations of the
isolated venom components, but doing so requires a massive number of experiments (2n− 1,
where n is the number of components in the venom). Therefore, it will be necessary to estab-
lish a protocol for prioritizing combinations of venom components. One potential solution is
to fractionate the venom (i.e., using gel filtration) and perform VenomSeq on combinations
of the fractions, but this will need to be tested. Alternatively, integrative systems biology
techniques could be used to predict which components act synergistically, via similarity to
structures with well-established activities.
3.3.7. Applying VenomSeq to other natural product classes
VenomSeq was, obviously, designed for the purpose of discovering therapeutic activities from
venoms, but it could be feasibly extended to other types of natural products, including
plant and bacterial metabolites, and immunologic components. Venoms provide a number
of advantages and simplifying assumptions that were useful in designing the technology, but
once VenomSeq becomes more proven it should be possible to relax these assumptions with
some minor modifications to experimental protocol and data analysis. We foresee a few of
these as the following:
• Venoms’ targeted nature makes it easy to assume they will have some effect in animals;
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other natural products may be inert.
• Venom components are intentionally delivered as a mixture; other natural product
mixtures might only be easy to collect as a mixture, in spite of unrelated biological
activities.
• Venoms are usually soluble in water, while other natural products often are not.
• Non-venom toxins may have less-targeted MoAs, disrupting biological systems indis-
criminantly (e.g., by interrupting cell membranes regardless of cell type).
• The kinetics of non-venom natural products may be more subtle than venoms, which
tend to have powerful binding and catalytic protperties.
3.3.8. Interpreting connectivity analysis validation results
In §3.2.4, we described the results of the connectivity analysis procedure applied to PLATE-
Seq expression data from IMR-32 cells treated with 37 existing drugs that have known
effects, many of which are members of Connectivity Map perturbagen classes (PCLs). Since
VenomSeq uses an expression analysis technology that is different from the Connectivity
Map’s L1000 platform, as well as a cell line that is not present in the Connectivity Map
reference dataset, this is crucial for establishing that one can discover meaningful associations
between crude venoms and profiles in the reference data within the VenomSeq framework.
Overall, the findings of our analysis are congruent with those made by the Connectivity
Map team in [234]. Specifically, PCLs that affect highly conserved, core cellular functions
(such as HDAC inhibitors, mTOR inhibitors, and PPAR receptors) tend to form strong
connectivities with members of the same class regardless of cell line. Therefore, associa-
tions discovered between crude venoms and these drug classes are likely “true associations”,
even when using IMR-32 cells in the analysis. Furthermore, by virtue of leveraging data
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corresponding to drugs with known effects, but using a new cell line and different assay
technology, we have made the following novel findings:
• Although IMR-32 is not present in the reference dataset, similarities between IMR-
32 and cell lines that are present in the reference data can be leveraged to select
reference expression profiles that are more likely to reproduce true associations. For
example, HA1E and A375 cells produce expression profiles that form reasonably strong
connectivities between IMR-32 query signatures and members of the same drug classes.
• More cell lines need to be included in the Connectivity Map data in order to better
understand correlation structures in cell-specific expression, as well as to better capture
therapeutic associations that are specific to cell types underrepresented in current
datasets.
• Similarly, continued effort should be devoted to adding new PCL annotations. Cur-
rently, only 12.3% of compound signatures in the reference dataset are annotated to
at least one PCL, and some PCLs contain only a few signatures. A more rigorous
definition of what specifically comprises a PCL would allow secondary research groups
to contribute to this effort, ultimately improving the utility of the CMap data and
increasing the sensitivity of the algorithms used to discover new putative therapeutic
associations.
In spite of the large degree of corroborating evidence these results provide (e.g., every
drug in our validation set produced a positive average effect on within-PCL connectivities
versus corresponding null distributions), we cannot confidently predict that the associations
discovered for crude venoms are true associations, rather than simply data artifacts. Al-
though our confidence in the novel associations would be greatly improved by more PCL
annotations to allow our analyses to attain greater statistical power, the ultimate test is to
perform in vitro and (eventually) in vivo tests for these predicted therapeutic mechanisms
of action. Aside from larger quantities of reference data against which to run the validation
analyses, we also hope to employ other data science techniques involving network analysis
and more advanced applications of master regulator analysis (see, e.g., §3.2.5) to further un-
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derstand the dynamic interactions between cell types, gene expression, and perturbational
signals that underly therapeutic processes.
3.4. Methods (VenomSeq)
Obtain 25 crude venoms
Human (IMR-32) cells
Expose cells to venoms Reverse transcribe,
















Figure 3.10.: RNA-Seq strategy for VenomSeq. Crude venoms are extracted and lyophilized.
IMR-32 cells in culture are then treated with predetermined dosages of reconstituted venoms,
and the PLATE-Seq method [32] is used to isolate, sequence, and count reads corresonding
to cellular mRNA.
3.4.1. Reagents and materials
We performed growth inhibition assays and perturbation experiments using IMR-32 cells [200]—
an adherent, metastatic neuroblastoma cell line used in previous applications of PLATE-Seq
and VIPER—grown in Eagle’s Minimum Essential Medium (EMEM) supplemented with fe-
tal bovine serum. All venoms were provided in lyophilized form and stored at −20 ◦C. Since




3.4.2. Obtaining 25 venoms
VenomSeq is designed to apply to all venomous species across all taxonomic clades. Accord-
ingly, we validated the workflow using 25 venoms sampled from a diverse range of species
distributed across the tree of life. We selected the 25 species based on availability and compli-
ance with international law, and sought to balance maximal cladistic diversity with minimal
expected cytotoxicity (e.g., snakes in the genus Bitis are known for inducing tissue death
and necrosis, and are therefore challenging to use for drug discovery applications [197]). We
purchased the 25 venoms from Alpha Biotoxine in lyophilized form, and obtained prior ap-
proval from the US Centers for Disease Control (CDC) through the Federal Select Agent
Program [83] for importing venoms containing α-conotoxins. The 25 venoms we selected
are shown in Table 3.8. Note that we assigned a numeric identifier to each venom for
convenience—these numbers show up numerous places in the data for VenomSeq. We also
have included a rooted cladogram of the 25 species in Figure 3.11.
3.4.3. Growth inhibition assays
A major challenge in generating differential gene expression data for discovery purposes is
finding appropriate dosages for the compounds being tested. This is done to ensure the
compound is in sufficient concentration to be exerting an observable effect on the cells, while
also mitigating processes that result from toxicity (e.g., apoptosis). In practice, determining
an appropriate dosage concentration usually makes use of previous experimental evidence
and/or biochemical constants, but since these are generally not available for crude venoms,
we instead determined dosages based on growth inhibition.
We prepared 2-fold serial dilutions of each venom, using a starting concentration of
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Table 3.8.: 25 venoms used to validate the VenomSeq workflow. Numbers in the right
column are used as placeholder names for the venoms in data files.
Species name Common name Venom number
Naja nivea Cape cobra 1
Laticauda colubrina Banded sea krait 2
Montivipera xanthina Ottoman viper 3
Dendroaspis polylepis polylepis Black mamba 4
Crotalus scutulatus scutulatus Mojave rattlesnake 5
Atractaspis sp. Burrowing asp 6
Macrothele gigas Japanese funnel web spider 7
Linothele fallax Tiger spider 8
Poecilotheria fasciata Sri Lanka ornamental spider 9
Argiope lobata — 10
Synanceia verrucosa Reef stonefish 11
Synanceia horrida Estuarine stonefish 12
Buthus occitanus Common yellow scorpion 13
Leiurus quinquestriatus Deathstalker 14
Scorpio maurus Large-clawed scorpion 15
Bufo bufo Common toad 16
Rhinella marina Cane toad 17
Bombina variegata Yellow-bellied toad 18
Apis mellifera Western honey bee 19
Vespa crabro European hornet 20
Scolopendra subspinipes dehaani Vietnamese centipede 21
Conus marmoreus Marbled cone snail 22
Conus imperialis Imperial cone snail 23
Octopus macropus Atlantic white-spotted octopus 24



































































































Figure 3.11.: Rooted cladogram showing the 25 species used in VenomSeq. Clades corre-
sponding to major taxonomic groups are labeled as indicated.
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2.0 mg µl−1. We seeded 96-well plates with IMR-32 cells and exposed them to the serial
dilutions of the venoms after 24 hours of incubation. 48 hours after exposure, we quantified
growth inhibition of the IMR-32 cells via cell viability luminesence assays.
For each venom, we fit these data to the Hill equation:
y = Bottom + (Top− Bottom)1 + 10(logGI50−x)×h
where x is venom concentration, y is response (i.e., percent growth compared to untreated
cells), Top and Bottom are the maximum and minimum values of y, respectively, and h is a
constant that controls the shape of the sigmoidal curve. We used the resulting GI20 values
(i.e., the value of x such that y = 100%−20% = 80%) as the venom exposure concentrations
for the following sequencing experiments. Since some of the curves had very steep slopes
(indicating rapid loss of total cell viability after miniscule changes in venom concentration),
we confirmed the accuracy of the GI20 concentrations via secondary viability assays using
the exact GI20 values extrapolated from the growth inhibition curves.
3.4.4. mRNA Sequencing
We prepared samples of human IMR-32 cells in 96-well cell culture plates, allowing for 3
replicates at each of 3 time points (6, 24, and 36 hours post-treatment) for each of the 25
venoms. The layout of the samples across 2 96-well plates is available in Appendix A.
We reconstituted the crude venoms in water, and treated the samples with corresponding
venoms at the previously determined GI20 values. We additionally prepared 12 control
samples treated with water only, and 9 control samples that were untreated. Following
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total mRNA extraction, we carried out the PLATE-Seq protocol [32] to obtain gene counts
for each sample. All sequencing was performed on the Illumina HiSeq platform. We used
STAR [61] to (1) map the demultiplexed reads to the human genome (build GRCh38 [220])
and (2) count the reads mapping to known genes. For detailed quality control data for the
sequencing experiments, refer to Appendix A.
3.4.5. Constructing expression signatures
We constructed differential gene expression signatures using the DESeq2 [146] library for
the R programming language. DESeq2 fits observed counts for each gene to a negative
binomial distribution with mean µij and dispersion (variance) αi, which we find to be a
more robust model than traditional approaches based on the Poisson distribution (i.e., by
allowing for unequal means and dispersions). In practice, users can substitute any method
for determining significantly up- and down-regulated genes from count data. We filtered
for genes with an FDR-corrected p-value < 0.05, and recorded their respective mean log2-
fold change values, noting whether expression increased (up-regulated) or decreased (down-
regulated).
3.4.6. Comparing venoms to known drugs and diseases
Comparing to known drugs using connectivity analysis
We retrieved the most recently published Connectivity Map dataset from the Clue.io Data
Library (GSE92742), which contains 473,647 perturbational signatures, each consisting of
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Figure 3.12.: Strategy for discovering new associations from VenomSeq data. After ob-
taining processed gene counts per sample, we generated differential expression signatures for
each venom, and then used the signatures in two parallel analyses: connectivity analysis,
and master regulator analysis.
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12,328 genes, along with relevant metadata [234], including cell line annotations, dosages,
time elapsed post-exposure, replicate numbers, and membership in manually-curated drug
classes. We then used the procedure described by the Connectivity Map team [131] to
generate connectivity scores between each of the VenomSeq gene expression signatures and
each of the reference signatures in the Connectivity Map database. This procedure, adapted
for VenomSeq, is summarized below.
Let a query qi be the two lists of up- and down-regulated genes corresponding to the
differential expression signature for venom i, and rj ∈ R be a vector of gene-wise Z-scores
in reference signature j. We first generate a Weighted Connectivity Score (WCS) (or Raw
Connectivity Score) between qi and rj:
wqr =

(ESq,rup − ESq,rdown)/2 if sgn(ESq,rup ) 6= sgn(ESq,rdown)
0 otherwise
where sgn denotes the sign function d
dx
|x|, and ESqr· is the signed enrichment score for
either the up- or down-regulated genes in the signature, calculated separately (see below for
details).
Although we validated VenomSeq on only a single human cell line, the reference database
provided by the Connectivity Map provides expression profiles on 9 core cell lines, across
multiple classes of perturbagens. Therefore, we compute normalized versions of WCS called











where µ+c,t and µ−c,t are the means of all positive or negative WCSs (respectively) for the given
cell line and perturbagen type.
The final step in computing connectivity scores between a venom q and a reference r
is to convert NCSq,r into a value named τ , which represents the signed quantile score in the







where N is the number of all expression signatures in the reference database and |NCS| is
the absolute magnitude of an NCS.
Enrichment Score computation For a venom q and reference signature r, the enrichment
score ESqr· is a signed Kolmogorov–Smirnov-like statistic indicating whether the subset of
up- or down-regulated genes in q tend to occur towards the beginning or the end of a list of
all genes ranked by expression level in r. We follow a procedure similar to that described by














− (j − 1)
t
]
where Vqr is the vector of nonnegative integers that gives the indexes of the genes in q within
the list of all genes ordered corresponding to their assumed values in r, t is the number of
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genes in q, and n is the number of genes reported in the reference database (in practice,
t n). We then set ES as follows:
ESqr· =

a if a > b
−b if a < b
Since each query q consists of two lists—one of up-regulated and one of down-regulated
genes—we compute both ESqrup and ES
qr
down, respectively, and use these two values to compute
wqr, as described above. For a more detailed, formalized description of the connectivity
analysis algorithm, refer to Appendix C.1.
Comparing to known diseases using master regulator analysis
We discovered associations between the venom expression profiles and known diseases (coded
as UMLS concept IDs) as the result of two sequential steps: (1) algorithmic determination
of substantially perturbed cell regulatory modules (called regulons), and (2) mapping mas-
ter regulators to diseases using high-confidence associations distributed in the DisGeNET
database. These took as input the same differential expression data used in the connectiv-
ity analysis. IMR-32 regulon data (in the form of an adjacency matrix, where nodes are
genes and edges are measures of mutual information with respect to their coexpression) were
provided by the authors of the ARACNe algorithm.
In order to identify perturbed regulons, we first performed a 2-tailed Student’s t-test
between the genes’ expression in the ‘test’ set (samples perturbed by venoms) and the ‘refer-
ence’ set (control samples). To make the final expression signatures, we then converted the
results of the t-tests to Z-scores, to make them consistent with the models used by down-
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stream algorithms. We generated null scores by performing the same test on the expression
data with permuted sample labels, to account for correlation structures between genes. Once
we had computed Z-scores, we ran the msVIPER algorithm, which derives enrichment statis-
tics for each regulon based on the expression levels of the genes contained in the regulon. The
result of msVIPER is a table of regulons (labeled by their master regulator), with enrichment
scores, p-values, and FDR-corrected adjusted p-values.
We then compared the significantly upregulated regulons to the manually curated sub-
set of TF–disease associations from DisGeNET. To do so, we mapped the statistically signif-
icant master regulator TFs for each venom to TFs reported in DisGeNET, and then mapped
those TFs to their associated diseases. To help with filtering venom–disease associations
with low evidence, we only retained diseases where at least two of the regulons that were sig-
nificantly disregulated by the venom are associated with the same disease. Accordingly, we
considered diseases with the highest number of significantly disregulated master regulators
to comprise the associations with the greatest amount of evidence.
Similarly to how we mapped drugs to drug classes, we mapped diseases to disease cate-
gories. To do so, we identified the set of ICD-9 codes for each disease, based on the diseases’
entries in the UMLS (UMLS CUIs were provided by DisGeNET). We then identified the
disease category as the top-level ICD-9 ‘chapter’ corresponding to that ICD-9 code (e.g.,
NEOPLASMS, MENTAL DISORDERS, DISEASES OF THE RESPIRATORY SYSTEM, etc.). In rare in-
stances where a disease or condition was present in two locations (e.g., ‘hypertension’ is found
in 2 chapters: DISEASES OF THE CIRCULATORY SYSTEM (401), and INJURY AND POISONING




3.4.7. Assessing sequencing technology and cell type compatibility
Since VenomSeq uses a sequencing technology (PLATE-Seq) and a cell line (IMR-32) that
have not been used previously with the connectivity analysis approach, we evaluated their
compatibility using a secondary dataset consisting of IMR-32 cells perturbed with 37 drugs
and sequenced using PLATE-Seq. Since these drugs have known effects—and since many
are present in the L1000 reference dataset—we sought to determine the extent to which
connectivity analysis captures functional similarities between these drug data and the L1000
reference profiles. The 37 drugs are listed in Table 3.5. For the purposes of this discussion,
a “query signature” is an expression signature corresponding to one of the 37 drugs in
the validation dataset, and a “reference profile” is an L1000 expression profile from the
dataset (GSE92742) published by the Connectivity Map team and used in the crude venom
connectivity analysis.
Using these data (consisting of gene count matrices with several technical replicates
per drug), we constructed differential expression signatures and performed the connectivity
analysis algorithm in the same manner as we had for IMR-32 cells exposed to the 25 crude
venoms. We annotated each of the 37 drugs (where possible) with perturbagen classes
(PCLs) defined by the Connectivity Map team, which allowed us to identify L1000 expression
profiles that come from the same drug classes as the drugs in our validation dataset. We
then evaluated connectivity scores among members of the same PCL from two perspectives:
(1) By aggregating all τ scores for reference signatures corresponding to a given compound,
integrating evidence from all cell lines, and (2) by aggregating τ scores within individual




For the first of these two approaches, we collected all values of τ connecting query
signatures in a PCL to reference profiles in the same PCL, and constructed null models
by retrieving τ scores between the same query signature and all reference profiles that are
members of any PCL. We defined the “effect size” of each PCL annotation as the difference
of the mean of the scores within the true PCL and the mean of the scores in the null model.
Additionally, we determined statistical significance using independent two-sample Student’s
t-tests. To correct for multiple testing, we adjusted p-values using the Benjamini-Hochberg
procedure (α = 0.05).
For the second approach—in which we evaluated each of the 9 core L1000 cell lines
separately for each query signature—we retrieved τ scores between query signatures and
each of the 92 PCLs in the reference dataset. Then, for each of the 9 cell lines and each of
the query signatures annotated to a PCL, we constructed ordered lists of all PCLs ranked
by their mean τ score in descending order (highest to lowest connectivity). In each of those
lists, we determined the rank corresponding to the expected (“true”) PCL—which we call
the rank percentiles—and aggregated these ranks separately by (a) the drug corresponding
to the query signature and (b) cell line of the reference profile. These two strategies allow us
to separately assess the effects of drugs and cell lines on the behavior of connectivity scores.
Under the null hypothesis that there is no selective preference for the true PCL in the
connectivity data, the mean rank percentiles would follow a continuous uniform distribution
in the range [0, 1]. Alternatively, if there is a selective preference for the expected PCL in




Integrating and delivering venom
knowledge using semantic data analysis
4.1. Structuring and representing VenomSeq data in
VenomKB
VenomSeq—like each of the other components of this dissertation—was designed to be an
open-access, publicly available resource that others can use to adapt to their own research
needs. To remove ambiguity and encourage reproducibility, we have designed a data schema
for representing the findings of VenomSeq experiments. This schema conforms to the JSON
Schema standard, version draft-061. For reference, the complete schema for VenomSeq data
is listed in Appendix B.
As a result, the entire data contents of VenomKB can be serialized into a simple, intu-
itive JSON format. The raw data generated by PLATE-Seq (i.e., gene counts by sample) are
not stored/distributed on VenomKB, but the schema includes links to these data on NCBI’s
Gene Expression Omnibus. We anticipate that users will prefer to interact with processed
data files, particularly the expression signatures indicating which genes are differentially
expressed on perturbation to each of the 25 venoms.
1available at https://tools.ietf.org/html/draft-wright-json-schema-01
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The logical entity corresponding to a VenomSeq data object is a venom and the effects
that venom exerts on a human cell; therefore, a single VenomSeq data object corresponds to
all PLATE-Seq samples (and analyses derived from those samples) reporting perturbation by
a single venom. In other words, a VenomSeq data object collapses replicates, time points, and
human cell lines (of which we have only used 1, so far), but not venoms. The control samples
(untreated and ‘water only’) are available to explore in the raw data files, and described in
the metadata for the JSON data record. The top-level attributes of a VenomSeq JSON object
are as follows:
experiment-description: String describing the context of the experimentation.
investigators: List of contributing author names and emails.
release-date: When the data were initially made available for public access.
sequencing-platform: String describing which platform was used to produce the data
(e.g., “Illumina HiSeq X”).
cell-type: Structured description of the human cell type(s) used.
venom: Structured description of the venom used.
data: Differential expression profile for the venom.
4.2. The VenomKB Semantic API
Ontologies are incredibly powerful tools that can be adapted to a wide variety of computa-
tional needs, including automation of tasks, standardization of data, and structuring artificial
intelligence applications. In the context of VenomKB and VenomSeq, we are interested in
using the Venom Ontology for the following tasks:
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1. Providing a standardized way to interpret and structure venom data.
2. Enabling reproducibility of VenomSeq experiments, to encourage reuse and adaptation
(e.g., as described in §4.1).
3. Retrieving data with a highly complex underlying structure when given meaningful
queries that correspond to specific research questions.
Of these tasks, we have already described and illustrated uses for the first 2. The 3rd, on
the other hand, is interesting and different for a number of reasons. First, it describes a
use for bioontologies that is of interest to both the knowledge engineering and information
retrieval communities. Additionally, it provides an opportunity to improve accessibility to
the knowledge contained in VenomKB (and the knowledge generated using VenomSeq) for
the broader biomedical research community, by removing the need for users to interact
with the complex underlying data structures that comprise the knowledge base. Most users
would benefit greatly from the implementation of software tools that perform these data
manipulations automatically, and in a way that adapts to the changing data needs of the
user.
Here, we introduce a new concept which we refer to as the Semantic API. Most existing
APIs are capable of simple tasks (e.g., fetching data using a unique identifier) as well as more
complex tasks (e.g., searching a database using queries containing filters, pattern matching,
and secondary data manipulation subroutines), but they almost always are constrained to
operations that have well-defined behavior, which makes the API easier to validate and
integrate into automated workflows, but comes at the cost of limited flexibility and gen-
eralizability. Furthermore, as traditional APIs grow to allow increasingly complex queries
they have a tendency to impose more rigorous demands on the user, requiring knowledge of
intricate data models. This is prohibitive to many classes of users, particularly those with
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limited computational expertise.
The Semantic API is an auxiliary server-side application bundle that interfaces with
VenomKB’s existing REST API. The Semantic API’s structure consists of a graph represen-
tation of the Venom Ontology (stored in a Neo4j graph database [254]) alongside a JavaScript
application that carries out translation between the user and the graph database. We will
take a detailed look at the individual components that make up the Semantic API in §4.2.3,
but first will describe the specific advantages that make it an important step forward for
information retrieval and artificial intelligence.
4.2.1. Related work and advantages over existing tools
The concept of a semantic API draws upon several decades of research conducted in the
fields of biomedical semantics and ontology design. The utility of ontologies and structured
terminologies for representing, integrating, and delivering knowledge for both human and
computer consumption is already well-established [26,28,155]. Unsurprisingly, this has con-
tributed to major advances in related areas like natural language processing (NLP), where
human-provided natural language (from sources such as news articles, web search engine
queries, and free-text medical notes) is parsed and translated into a structured, formal rep-
resentation that can be reused by computers [31, 159]. “Rule-based” NLP is a technique
that uses a predefined grammar and structured knowledge resources (e.g., lexicons, termi-
nologies, or ontologies) to parse user-submitted text2. Rule-based NLP has been especially
effective in domains with distinctive vocabularies and styles for sentence composition, in-
2The other major approach to NLP is probabilistic NLP, which instead interprets text using mathematical
models, typically via machine learning.
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cluding most areas of biomedicine. Some examples of rule-based NLP tools for biomedicine
include MedLEE/BioMedLEE [76,148], which uses context-free grammars and domain lexi-
cons for pattern-matching on biomedical text, and Apache cTAKES [218], which reuses the
lexical analysis tools contained in the National Library of Medicine’s UMLS to parse text.
Previous work has also been conducted on designing programming interfaces that can
communicate with ontologies. The OWL API, for example, is a programmatic interface
for performing high-level access and manipulation capabilities to OWL ontologies, designed
mainly as a resource for implementing semantic web resources [16]. Also developed for the
semantic web, the Jena toolkit [165]—which we used to populate individuals in the Venom
Ontology—is a Java API for manipulating files in the RDF format, which is one of several
file formats compatible with the OWL standard [165]. Arguably the most similar body
of work preceding our semantic API is described by Koutsomitropoulos et al [127], where
they designed their own semantic API with a semantic querying interface to solve similar
problems to ours—namely, that querying semantic resources requires a deep understanding of
data models, querying protocols, and other enigmatic peculiarities of knowledge engineering.
Their proposed tool is an interface that allows users to design an entailment-based query
for Semantic Web resources, and then translates the query to an equivalent SPARQL query
(which is directly compatible with most Semantic Web applications). Unfortunately, we
find that their new semantic query syntax still remains esoteric and out-of-reach for most
potential users. Furthermore, the utility is designed primarily as a proof-of-concept rather
than a tool to support ongoing research in a certain domain (such as our use of a semantic
API for toxinology).
Our Semantic API builds on these projects’ underlying goals in various ways. As far
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as we can tell, our semantic API is one of only a few attempts to create an API that not
only interfaces with ontologies, but uses the ontologies to interpret the implied meaning of
user queries, filling in gaps in the information content of the query using the assertions of
the ontology itself, and the only attempt that truly attempts to accomodate non-expert
users. It also represents a departure from the recent trend (probably related to interest
in the semantic web) of designing ontology-based tools with increasingly general domains
of ontological commitment [23, 71, 95]. Although the Semantic API can be generalized to
virtually any domain of knowledge, its power is largely derived from focusing on a single
specific domain (in our case, toxinology), which substantially augments its inferential capa-
bilities. A final distinction of note is how it is intended to be used—most existing tools that
interface with ontologies are highly infrastructural, and are not intended for direct use by
consumers. The Semantic API is first and foremost a utility meant to be queried directly
(either by writing queries by hand or through a graphical form-based interface), although it
is also completely capable of consuming automatically-generated HTTP queries submitted
by other web services.
4.2.2. A theoretical framework for the semantic API
Before we can describe how this Semantic API can be implemented computationally, we
need to define the theoretical task being performed. An OWL ontology can be abstracted as
two unweighted directed graphs (digraphs) containing the ontology’s class hierarchy and the
individuals that comprise the ontology—which we name C and I—respectively. C consists
of the vertex set VC (ontology classes) and the edge set EC (relationships between classes),
and I consists of the vertex set VI (individuals) and the edge set EI (relationships between
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individuals). We know these two graphs have the following properties:
• Each individual in VI is an instance of a single class in VO (inherited class membership
can be ignored for now).
• If a pair of individuals {vI1 , vI2} ⊆ VI are joined by a relationship eI1 ⊆ EI , an identical
relationship eC1 ⊆ EC must join the classes {vC1 , vC2} ⊆ VC of which those 2 individuals
are members.
• C must be at least weakly connected3, but I can be disconnected. Accordingly, the
larger graph implied by joining all individuals in I to their respective classes in C is
also at least weakly connected.
Additionally, each edge and vertex in I can have an arbitrary number of metadata tags,
known in the ontology engineering community as data properties. Although a complete
ontology specifies many other components (such as domains and ranges, relationship types,
and additional rules and restrictions), we can ignore these for the time being.
The main task of the Semantic API is to find each of the smallest spanning trees4
(s1, . . . , sn) = S(J) of a subgraph J ⊆ I that satisfy the following:
• J contains at least one individual from each of a set of ontology classes G ⊆ VC that are
determined to be ‘relevant’ classes based on the semantic content of a user’s query to
the API, and no individuals from ‘irrelevant’ ontology classes. The way we determine
which classes are relevant is described in §4.2.3.
• The tree satisfies each of an optional set of filters (which we call constraints) provided
in the query.
For example, suppose a simplified ontology is represented by the graphs
3I.e., if you replace all directed edges with undirected edges, the graph will be connected.
4A spanning tree of a graph G is any subgraph T that covers all vertices of G and contains no cycles. A
smallest spanning tree is the spanning tree(s) containing the fewest possible number of edges.
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and that colored nodes indicate class membership. A user submits a query that specifies




If the members of J satisfy all of the metadata constraints in the query, J is considered
a match, and is returned as input to the aggregation subroutines of the semantic API for
further manipulation, as needed.
4.2.3. Semantic API implementation
A simplified schematic of VenomKB’s semantic API is shown in Figure 4.1 (for a more
detailed version, refer instead to Figure 4.2). There are two components to the semantic api:
(1) the query engine, and (2) the graph database. When a user submits a JSON-formatted
POST request to VenomKB’s API containing the base URL semantic/, the request’s body
is passed to a script named Query.js. This script interprets the user query and translates
it into the Cypher graph database query language. This Cypher query is then executed on
the Neo4j graph database instance, and the results are returned to Query.js. The script
then executes any remaining aggregations (such as sorting, counting, formatting, and other
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Figure 4.1.: Simplified schematic of VenomKB’s semantic API. Note that the ‘standard’
(REST) API accepts a semantic query, but much of the computation is performed on a
separate graph database derived from the Venom Ontology. After running the graph query,
the results are translated into a JSON response and returned to the user. For a more detailed
view of the algorithm, see Figure 4.2.
fundamental operations not performed by the graph database server). We will now consider
each of these operations in detail.
The semantic query format
Each call to the Semantic API is called a semantic query. A semantic query is structured as
a JSON object and included in the body of an HTTP POST request sent to the Semantic
API’s URL endpoint (for VenomKB’s Semantic API, this is http://www.venomkb.org/api/























Summarized, this consists of up to 3 fields: select (required), declare (optional),
and aggregate (also optional). In the template, strings in square brackets indicate variable
fields that are filled in by the user, and ellipses (“. . .”) indicate where multiple fields can be
chained together (e.g., the user can declare constraints for 0 or more ontology classes, and
each of those classes can have 1 or more constraints). The details for each of these three
fields are explained in more detail below.
Extracting the result type (“select”)
The semantic API is designed to be far more flexible than most traditional APIs. Many
different queries can be posed to obtain the same conceptual result, so it is important that
the API’s logic can reflect this. Accordingly, the application needs to execute a number of
normalization procedures to interpret the question being represented by a specific query. The
first of these tasks is to identify the ontology class(es) of the desired result. For example, if
the user submits a query to identify the species that produce venom proteins with the word
“phospholipase” in their name, the desired ontology class is Species. This is the one portion
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of the query that is unambiguously provided by the user, so the semantic API simply needs
to validate the query field named select, labeled as such in order to reflect its similarity to
the more familiar SELECT clauses used in all major variants of SQL.
Collecting constraints (“declare”)
The software then reads the declare block to identify filters that reduce the complete graph
representation of the API down to a subgraph consisting of the data relevant to the query.
We call these constraints, because they can be thought of as constraints that are applied to
the subgraph(s) matching a user query. Constraints take the following format:
〈class〉 | 〈attribute〉 | 〈operator〉 | 〈value〉
where 〈class〉 is an ontology class, 〈attribute〉 is an attribute defined for that class in the Ven-
omKB data schema, 〈operator〉 is any valid comparison operator (e.g., =, >=, CONTAINS...),
and 〈value〉 is a string or number.
Finding relevant ontology classes
For a certain query, the relevant ontology classes are simply the set of classes that are
mentioned at least once in either the select or declare blocks of the JSON query. In
other words, they are all classes that either (a.) contain individuals of the type desired in
the response to the query, or (b.) contain individuals that are tested against the constraints
(filters) in the query.
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Finding a shortest path on the ontology class structure
At this point, the semantic query engine begins the process of interpreting the semantic
content of the user’s query. The first task in doing so is to find the smallest subgraph
C ′ that contains relevant ontology classes (i.e., as identified in §4.2.3) within the graph C
containing all ontology classes. The query we will be passing to the graph database server
needs to unambiguously specify a pattern to match against the members of the database in a
format representing a chain of natural language predications, and we therefore need to know
the chain of edges and vertices that links the relevant ontology classes. Finding the smallest
subgraph is not strictly necessary, but it helps to ensure efficiency and improve early error
detection.
Finding the smallest spanning subtree is, unfortunately, a nontrivial task—the most
cutting-edge algorithms run in O(m log n) time [191], and for some graph types it is an NP-
hard problem [112]. Furthermore, combinatorial algorithms need to be used judiciously for
production-quality applications, where a minor drop in algorithmic efficiency is compounded
both by the number of user requests as well as the size of the underlying database being
searched (both of which we hope will expand steadily as VenomKB develops a larger user
base).
Generating a Cypher query
We now have all of the components we need to construct a Cypher query to pass to the
Neo4j database server. Each request we construct consists of at least two mandatory clauses
(delimited by whitespace or a newline character): MATCH and RETURN. The MATCH clause
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consists of a symbolic representation of the shortest path identified in the previous step:
MATCH (c1:Class1)-[:REL 1]-> . . . -[:REL N-1]->(cn:ClassN)
(where the appropriate class and relationship names are used instead of placeholders). When
only one ontology class is relevant (e.g., the query is a simple search on a single datatype),
this reduces to MATCH (c1:Class1). Note that we assign variable names (e.g., the c1 in
(c1:Class1))—these variables are used in subsequent clauses to refer to nodes that match
the pattern specified in MATCH.
If the user has provided constraints, the next clause is WHERE. Since constraints are
optional, if they are not present, the cypher query contains no WHERE clause. Otherwise, the
semantic query engine iterates over the array of constraints, converting them into the format
WHERE c1.〈attribute 1 〉 〈 operator〉 〈value〉 AND c2.〈attribute 2 〉 . . .
and so on, depending on how many constraints are given.
Finally, we build the RETURN clause. This can simply be a variable name that corre-
sponds to the ontology class in the return block of the original query:
RETURN c1
Certain aggregations will also be applied here when the graph database is especially efficient.
These aggregations are sort and unique, each of which has an equivalent reserved keyword
built into the Cypher language (ORDER BY and DISTINCT, respectively).
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Executing the query on the Neo4j graph database
The semantic query engine—which is written in JavaScript and runs on the Node.js runtime
environment, like the rest of VenomKB—communicates with Neo4j using the Bolt driver,
which is maintained and provided by the authors of Neo4j. Once the query engine has
constructed a string containing a properly formatted Cypher query, it initiates the query as
a new transaction with the Bolt driver, and uses the “async/await” pattern to receive the
graph database’s response (allowing concurrent execution of multiple simultaneous queries).
Aggregating results (“aggregate”)
Aggregations are usually defined as functions that accept a list of objects (e.g., rows in a
database, or nodes in a graph) and produce a single summary value describing that list. For
the semantic API, we adopt a slightly more permissive defintion: A semantic API aggregation
is any function that can be used to manipulate the subgraph returned by Neo4j. This includes
single summary values (like in the more strict definition) as well as transformed versions of the
entire list. As mentioned previously, aggregations can be applied either on the results of the
graph database query, or can be embedded into the graph database query itself. This choice
is predetermined for each aggregation function. Aside from the aggregations described above
(see Generating a Cypher query), the rest run on the semantic query engine. For example,
the count aggregation is more efficient (in both time and memory) when performed by
Node.js rather than by the graph database server.
Aggregation functions are modular, and a developer familiar with basic JavaScript and
the code structure of the semantic API can easily add new aggregations (e.g., an aggregation
that searches for the minimum value of a certain attribute can be implemented in just a few
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lines of code). Future work on the semantic API will build on this modularity by providing
simpler ways of including these functions that do not require modification of the query engine
itself.
Semantic API; detailed schematic
Semantic query
{
  “select”: ...,
  “declare”: {…},




  “name”: ...,

















WHERE a.name IS ...








Clean and apply remaining 
aggregations
endstart
1. User provides query
2. Extract query parts
3. Build shortest path query
4. Find 
shortest path
5. Build main query




Figure 4.2.: Detailed schematic of the Semantic API query process. Individual ordered
steps in the algorithm are numbered and labeled in bold.
4.2.4. The benefits of a semantic API
Catering to users with varying levels of technical skill
To enable use of the semantic API by bench researchers and laypersons, we have designed a
graphical query builder incorporated into the VenomKB website. The interface for this tool
is shown in Figure 4.3. Users complete a form, where one segment is devoted to each of
the three sections of a semantic query (select, declare, and aggregate). Since declare
and aggregate can each consist of zero or more statements, the user can add or remove any
number of those statements, as desired. We designed the wording for each section of the
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interface carefully, to clearly represent the semantic meaning of each section and illustrate
to the user how to “tell” the API what they are looking to retrieve.
Reducing time, effort, and errors
Even for experienced users of a given data schema, aggregating items across multiple complex
types with various constraints is a tedious and time-consuming task, usually requiring many
lines of code and a nontrivial amount of debugging. Arguably, using the semantic API (either
by writing a semantic query manually or by defining one using the form-based interface on
the VenomKB website) takes only a fraction of the time. Furthermore, the form of a semantic
query is designed to reflect the intuitive data-needs of the user, and therefore theoretically
requires less effort to translate that need into a format that the software can successfully
interpret. The semantic API also has the potential to reduce user errors in data retrieval—an
issue that is pervasive in database use and causes downstream problems that are sometimes
impossible to detect [228]. This advantage is largely the result of two factors: (1) The user
only interacts with the API a single time, whereas with traditional database appplications
they may have to perform several successive queries to retrieve the desired result, and (2) the
ontology itself acts as a safeguard against errors, preventing incompatible data types from
being “joined” and by unambiguously specifying exactly which relationships exist between
related data elements. Due to the current implementation of the semantic API, this is a
passive process—we extract data from the ontology to populate the graph database, and all
of the previously defined restrictions within the ontology dictate the structure of the graph.
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Facilitating integrative data translation
Projects like the Biomedical Data Translator [46] and the CDISC standards [128] aim—
among other things—to allow disparate systems that conduct transactions on biomedical
data to be able to communicate with one another unambiguously and dynamically [9]. The
Semantic API is capable of addressing this same goal. Since the format of a semantic query
is not tied in any way to the domain of application, semantic queries can be constructed
identically for every Semantic API that follows the format we defined. An application that
is designed to communicate with a Semantic API should be able to communicate with any
Semantic API, and therefore should also be able to integrate data from multiple Semantic
APIs. One major caveat that needs to be addressed is how an instance of a Semantic API
will inform remote systems about the domain content it serves. This could take the format
of something as simple as an XML manifest file, or as complex as a complete distribution of
the OWL ontology on which the Semantic API is running. Another (major) caveat is that
this functionality depends entirely on adoption and implementation of the Semantic API as
a generalizable standard by the larger research community.
4.2.5. Complete example
Consider this meaningful question, which a user may wish to answer using the semantic API:
Which venoms are indicated in treating osteosarcoma, and how many proteins
in those venoms are known to demonstrate this indication?
One way of writing a corresponding query is as follows:
example: {
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WHERE e.name = ’Osteosarcoma’
RETURN DISTINCT s.name, p





































Finally, the semantic API parses these data into a simplified JSON object, and applies the
count aggregation on the object labeled p, yielding:
[
{






Clearly, this response indicates that one species in VenomKB (Crotalus viridis viridis)
contains venom that has been shown to treat osteosarcoma, and 1 protein in its venom is
known to exhibit that activity. By slightly tweaking the select clause in the query, the user
can determine the name of that same protein.
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4.2.6. Task-based evaluation of the semantic API for computational
toxinology
One of the major goals of computational toxinology is to make advanced computational tech-
niques accessible to non-informaticians, but research groups comprised mainly of molecular
biologists and/or field biologists often do not have members with an advanced understand-
ing of how to manipulate complex data models5. Even for users who do have this type
of expertise, many venom-associated questions with relatively simple semantics can require
a great deal of work to answer effectively. Furthermore, issues with venom nomenclature,
conflicting and nonstandardized entries in existing public databases, and a paucity of molec-
ular data make computer-aided large scale data retrieval and analysis virtually impossible in
most contexts concerning venoms. Given the need for reproducibility in modern biomedical
science [158, 253] (particularly when the end-goal is the discovery and development of new
drugs to treat human diseases), it is crucial for the toxinology community to have a “com-
mon ground” for conducting research. The semantic API was designed with the intention of
solving these issues related to the accessibility and normalization of venom data.
To aid advanced users in learning the structure and format of a semantic query—
and how to translate a meaningful research question into a query that retrieves the correct
result(s)—we have provided a gallery of diverse questions and their JSON representation, as
well as the result given by the semantic API. For example, consider the following question:
Do any proteins from cone snail (Conus) venom treat neuralgia?
One way to write this as a semantic query would be
5Conversely, computational labs typically don’t employ members who know how to appropriately handle
reagents and ‘wet lab’ experimental protocols.
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Figure 4.3.: Graphical user interface for building Semantic API queries.
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In other words, the user is looking for species in VenomKB that satisfy two criteria:
(1) Their name contains the string Conus, and (2) they are linked to a SystemicEffect
with the name Neuralgia. The aggregation exists returns the boolean value “true” if any
matches are found6, rather than returning a list of the species. Other examples are provided
in the source repository for VenomKB.
Since the semantic API is meant to solve a new type of need, the best way to evaluate its
success and utility is through specific case studies. Here, we provide narrative walkthroughs
of several such case studies, including examples of (1) retrieving known individual associa-
tions, (2) aggregating multiple fragmented associations to provide a “bigger picture” of the
6At the time of writing, this query does evaluate as “true” when submitted to the semantic API.
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nature of venoms and their therapeutic effects, and (3) providing context and plausibility to
novel associations suggested in the analysis of VenomSeq data.
Insulins in cone snail venom
Conus geographus C. geographus peptide Con-Ins G17
In 2016, Menting et al reported the groundbreaking discovery that a small insulin
peptide purified from the venom of C. geographus contains a human insulin receptor binding
motif, and demonstrated that it strongly mimics the signaling functions of human insulin
within humanized mouse cells [168]. This paper was preceded by the discovery by Safavi-
Hemami et al (including many of the same coauthors) that C. geographus releases the insulin
into the water in order to “stun” prey fish by inducing hyperglycemic shock [216], along with
evidence that similar insulin-like peptides were present in a number of other Conus species.
7PDB ID: 5JYQ [168]
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Its size, stability, and potency make it an excellent candidate for developing better insulin
treatments for patients with diabetes. Being a substantial recent finding in the toxinology


























The semantic API returns 6 C. geographus peptides from VenomKB that are anno-
tated as members of the “Insulin” family: Con-Ins G1b, G1, G1c, G3, G3b, and G2b.
We can then explore these proteins individually, using either the web application or the
REST API (e.g., venomkb.org/api/proteins/P7637538 for Con-Ins G1b). For compari-
son, Figure 4.5 shows the same query constructed using the graphical query builder inter-
face.
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Figure 4.5.: Querying the Semantic API for insulins in C. geographus venom, as described
in the text. Note that the interface closely resembles the JSON version of the query, while
being more accessible to non-expert users.
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This is a good demonstration of the information retrieval capacity of the Semantic
API, but we decided to see whether a follow-up query can be used to make novel discovery,
by asking the question
Do other cone snail species also produce insulin-like peptides?

























In addition to C. geographus, the response to this query gives 8 other Conus species
that produce at least 1 insulin or insulin-like peptide. Of these 9 total species, 8 are discussed
in [216]. However, the 9th species—C. victoriae—does not show up in either of these afore-
mentioned studies, as its venom transcriptome has only recently been characterized [201],
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and is therefore not discussed alongside the other species known to produce insulin-like pep-
tides at the earlier date of publication—essentially a type of selection bias resulting from
media coverage on the Conus insulin phenomenon occurring before the most recent discov-
ery. The Semantic API, however, uses ontology reasoning alone to retrieve data, which is
free from sources of bias like these8.
Scorpio maurus venom and HDAC-like activity
Scorpio maurus Histone Deacetylase 8 crystal structure
Histone deacetylase (HDAC) inhibitors are a class of drugs that have long been used to
treat various psychiatric and neurological disorders, and have recently been investigated for
therapeutic activity against various cancers, inflammatory conditions, and parasitic illnesses.
In the results to our previous benchmarking of VenomSeq (see §3.3.3), we noticed strong
connectivity between S. maurus (Israeli gold scorpion) venom and several known HDAC
inhibitors. Although they are grouped together as a single class of therapeutic drugs, this is
8Ontologies are, of course, subject to other kinds of biases, which are covered extensively in the literature [80,
152].
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misleading—different HDACs9 have highly divergent functions, and since HDAC inhibitors
only bind to certain types of HDACs, it is highly unlikely to find a venom that is similar to
all (or most) types of HDAC inhibitors that are currently known. This suggests that either
alternate classification schemes should be adopted in the CMap dataset, or that we need to
define new metrics for summarizing connectivity at the PCL level that account for sub-class
structure within PCLs.
We chose to investigate these phenomena using the Semantic API, both for the purpose
of exploring possible mechanisms of the HDAC-like activity we observed, and to show that
semantic querying can be used to quickly provide supporting evidence when interesting
putative associations do not pass statistical significance.
4.2.7. Using the semantic API in other research contexts
Although the semantic API was designed specifically to enable discovery from VenomKB and
VenomSeq, the principles on which it operates (as well as the benefits it provides) conceivably
can be extended to virtually any domain of scientific research. The main prerequisite for
adapting the semantic API to a new domain is a correctly formatted and populated OWL
ontology. We developed the Venom Ontology using Prote´ge´, but any appropriate software
that is OWL-compatible and includes validation tools should suffice.
One of the tasks we have planned for continued development of semantic APIs involves
creating a standalone version that can be easily reused for arbitrary applications and is not
tied to the structure or implementation of VenomKB. We also aim to construct a more ef-
9They are generally named HDAC 1 through HDAC 11, and further grouped into classes I through IV,
based on homology to the originally discovered HDACs in yeast [62].
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ficient internal graph representation of the ontology to remove the dependency on Neo4j.
While Neo4j and other popular graph database implementations are an incredible tool that
enabled rapid prototyping of our first version of the semantic API, we only make use of a
limited subset of the features of graph database servers. This suggests that we can vastly
improve performance of the semantic API by reimplementing the important core algorithms
of graph database servers in a slim software package written in an efficient compiled pro-
gramming language (like C++ or Rust). For now, the current implementation is sufficient
for low-throughput applications as a proof-of-concept to demonstrate the importance and
advantages of a semantic API.
4.3. Automating discovery with VenomKB
One of the main purposes of this dissertation is to show exactly how underutilized com-
putational methods can increase productivity in venom research. Traditionally, the main
use for computers was to automate repetitive tasks and computations, and they are still
used ubiquitously for this today. As the quantities of data used in various applications have
grown by many orders of magnitude, and the tasks needed to analyze these data have in-
creased substantially in complexity, computers have grown to be used for the new purpose
of interpreting and summarizing the results of their own computations. This can be seen
in most genomic applications—the individual steps performed in genomic analyses are, fun-
damentally, the same tasks that computers have been used for since the 1960s or earlier
(sorting, searching, indexing data, performing simple hypothesis tests and arithmetic opera-
tions, etc.), but newer techniques are required in order to draw meaningful conclusions from
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these computations (performing ontology annotation, generating null models using Monte
Carlo methods, phenotyping using machine learning, and others).
These patterns can be seen throughout VenomKB. For example, the connectivity anal-
ysis data we generated for 25 venoms used in VenomSeq yielded 11,841,175 τ scores10, and the
primitive operations used to compute these values are simple enough that the algorithm can
be described in detail on approximately 1 page of text (see Appendix C.1). Yet, although
τ is meant to be a normalized score that can be easily interpreted by humans, the sheer
quantity of data makes manual analysis of these results virtually impossible.
The Semantic API provides a means for performing semi-automatic discovery on these
results. Given that the user knows what they want (and how to compose a semantic query),
the Semantic API should be able to interpret the meaning of their request and extract
the appropriate data. In §4.2.6, we show particular examples of how this can be used
for validating existing knowledge and for making new discoveries based on data, like that
produced by VenomSeq as mentioned above. This functionality represents a substantial step
forward in the ability to perform translation from raw molecular data into the effects that
compounds have on human health.
Other tools that are part of VenomKB contribute to automated and semi-automated
discovery, too. As far as we can determine, VenomKB’s REST API is the first venom-centric
web API that allows programmatic access to venom data for batch analyses and comparison,
and therefore allows integration of VenomKB into other biomedical data applications. We
are continuing to add new features to VenomKB, including the ability to submit/modify
data using API calls, as well as advanced searching and filtering functions (aside from those
10The CMap reference dataset we used includes 473,647 expression signatures.
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In the preceding chapters, I have mainly described my efforts in toxinology as a series of
individual research studies (that, granted, build on eachother sequentially). However, I view
this work as a single body of research that can be decomposed into a series of connected mod-
ules. Epistemologically, this dissertation should be considered a description of computational
toxinology from the perspective of a translational bioinformatics specialist. Pragmatically,
the software, algorithms, and data generation/analysis pipelines in the dissertation can be
grouped together as “VenomKB and related tools”. To demonstrate the interconnectedness
of these components, I will now take the opportunity to summarize from a macro level.
5.1. Summary of findings and original contributions
The contributions of this body of research to the fields of informatics, toxinology, and sys-
tems pharmacology can be broadly grouped into 3 categories: (1.) Conceptual advances in
designing a translational infrastructure for drug discovery from venoms, (2.) discovery of
new therapeutic associations between venoms (and their components) and human disease,
and (3.) Newly engineered tools and resources that fill specific needs in the toxinology and
biomedical data science communities.
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Conceptual advances. Translational bioinformatics is still a relatively young field, and is
rich with opportunities for expansion to tasks that are generally neglected with regards to
computational methods. As I mentioned earlier in this text, computational toxinology is a
great example of this—a field with a long history of incredible scientific productivity that is
receiving increasing recognition for its contributions to biomedicine, yet in need of attention
from informatics researchers and computational biologists. Beyond solely demonstrating that
broad application of informatics can be used to facilitate and evaluate therapeutic discoveries
related to venoms, we highlight the present needs to enable continued advances in this line
of research. Specifically, renewed efforts in open-access publications of well-annotated next-
generation sequencing data from venomous species—as well as widely adopted standards in
nomenclature, data representation, and data dissemination—can invigorate computational
toxinology and help ensure a steady flow of new discoveries that benefit human health and
our understanding of the natural world.
New therapeutic associations. In §3.3.3 we found two promising (and plausible) new
associations that merit further experimental validation, and produced a large quantity of
data that can be further analyzed to discover more new associations. The first of these
is a link between A. lobata venom and both PPAR agonist and ATPase inhibitor drugs.
These associations are supported by both the connectivity (CMap) analysis and the master
regulator (msVIPER) analysis, and are further validated by known molecular activities of
certain argiotoxins, which are responsible for much of the bioactivity of Argiope venoms. The
second is a link between S. maurus venom and FGFR inhibitor drugs (also supported by
both connectivity analysis and master regulator analysis), which are anticancer drugs that
are currently of great interest to the pharmaceutical industry. Although current research on
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FGFR inhibitors is incredibly promising, we only know of a few examples of suitable FGFR
inhibitor drug candidates to test in clinical trials, which is exactly why FGFR inhibitor-like
activity in venoms is such an important finding.
New tools and resources. VenomKB, VenomSeq, and the utilities that accompany them
are intended to be substantial resources for toxinologists, pharmacologists, students and
educators, and even laypersons. Every piece of code comprising these studies is released un-
der open-source licenses, and we strongly encourage reuse, modification, and improvements.
VenomKB is meant to be informative by enabling access to previous venom discoveries and
data in a centralized location that works in coordination with (rather than in opposition
to) other biomedical databases related to natural toxins and drug discovery. VenomSeq is
designed to generate much-needed perturbational differential expression data from venoms
in a reproducible and economically efficient way, and we provide this data for 25 venomous
species both for making an initial set of new discoveries and for acting as a proof-of-concept
to potential stakeholders that may want to implement VenomSeq themselves.
The Semantic API is not only a tool for improving accessibility to new venom discov-
eries and validation of existing discoveries, but also a generalizable software paradigm for
computer scientists and knowledge engineers. We designed it to serve a particular need in
computational toxinology (rapidly retrieving and structuring venom knowledge enabled by
ontological inference), but quickly noticed its novelty and possible uses in other domains.
We have shown particular benefits it provides to both expert users of data schemas and users
with limited computational experience, and also used it to validate the specific findings from
our analysis of VenomSeq data. Even more broadly, we propose the Semantic API as a new
application of ontologies integrated with high-throughtput sequencing data, and show that
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they can continue to provide valuable and novel insights with clear practical benefits to
researchers and to biotechnologists.
5.2. Limitations and future work
Like most “big data”-driven biomedical science initiatives, VenomKB, VenomSeq, and the
other tools related to them (Venom Ontology, the Semantic API, etc.) are intended to be
used ‘at-scale’. VenomKB contains only 6236 proteins, 632 species, and 5 genome pages,
which is an ideal size for testing purposes, but these numbers are dwarved by the actual
numbers of venomous species and proteins that exist in nature. Fortunately, next generation
sequencing projects to characterize venom transcriptomes and venomous animal genomes are
being conducted at a constantly increasing rate. Aside from NGS, current data needs within
toxinology include improving the systematics of certain clades of venomous animals1, com-
parative biochemical data of venoms and venom components (e.g., LD50, molecular weight,
dissociation constants, etc.), and the ability to cross-reference existing venom databases cov-
ering more granular areas (ArachnoServer and Conoserver are two of these). Additionally,
VenomKB can benefit from a better representation of the ontology it is built on—for exam-
ple, by adding a tool to the website that renders a certain data element within the ontology
hierarchy, in a similar manner to QuickGO’s “Graph View” of Gene Ontology terms [107].
VenomSeq can generally be improved by expansion in 3 areas: (1.) New venoms, (2.)
new human cell lines, and (3.) using purified venom peptides (rather than crude venoms, as
1Scorpions, in particular, suffer from poorly standardized nomenclature and taxonomy, but other clades of
venomous species do as well.
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we use now). We are currently working with collaborators to expand VenomSeq to purified
peptides with the intention of serving two purposes: to define a sequencing-based assay for
discovering which proteins in a venom bind to (and alter the biochemistry of) human cells,
and for performing the same type of perturbational gene expression analysis that we have
only done with crude venoms to this point. It will be important to compare the data for
crude venoms to the data for their corresponding purified proteins—for example, do venom
proteins tend to contribute synergistically to the expression levels of individual genes, or are
they optimized such that each they tend to alter the expression of unique non-overlapping
sets of genes?
Overall, VenomKB and VenomSeq deserve a great deal of continued development. This
dissertation provides the theoretical and conceptual foundations of what can be turned into
a major initiative in biomedical data science. Ideally, I will be able to develop VenomKB into
a major self-sustaining independent research endeavor that can be a source of new data for
computational toxinologists as well as a contributor of theoretical and translational insights
into therapeutic uses for venoms. Eventually, I would also like to expand to other natural
product classes, to take more complete advantage of the vast diversity of bioactive (and
potentially therapeutic) compounds available in nature.
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Appendix A.
PLATE-Seq quality control data


















































































Figure A.1.: Quality control plots. (a.) Number of detected genes (mapped reads ≥ 2) as
a function of the total number of mapped reads per sample. (b.) Saturation analysis by in





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A.2.: Barplot showing the number of mapped reads per sample.
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Plate 1:
Well Venom Conc. (uG/uL) Time (Hrs)
A1 1 0.008 6 6
B1 2 2.000 0 6
C1 3 0.001 9 6
D1 4 2.000 0 6
E1 5 0.001 6 6
F1 6 0.007 9 6
G1 7 0.003 6 6
H1 8 0.124 7 6
A2 9 0.531 9 6
B2 10 1.085 4 6
C2 11 2.000 0 6
D2 12 2.000 0 6
E2 13 0.754 4 6
F2 14 0.949 1 6
G2 15 0.092 6 6
H2 16 0.000 2 6
A3 17 0.000 2 6
B3 18 0.157 9 6
C3 19 0.024 2 6
D3 20 0.838 2 6
E3 21 0.008 2 6
F3 22 2.000 0 6
G3 23 0.709 7 6
H3 24 2.000 0 6
A4 25 2.000 0 6
B4 Water − 6
C4 Water − 6
D4 Water − 6
E4 Water − 6
F4 Untreated − 6
G4 Untreated − 6
H4 Untreated − 6
A5 1 0.008 6 24
B5 2 2.000 0 24
C5 3 0.001 9 24
D5 4 2.000 0 24
E5 5 0.001 6 24
F5 6 0.007 9 24
G5 7 0.003 6 24
H5 8 0.124 7 24
A6 9 0.531 9 24
B6 10 1.085 4 24
C6 11 2.000 0 24
D6 12 2.000 0 24
E6 13 0.754 4 24
F6 14 0.949 1 24
G6 15 0.092 6 24
H6 16 0.000 2 24
A7 17 0.000 2 24
B7 18 0.157 9 24
C7 19 0.024 2 24
D7 20 0.838 2 24
E7 21 0.008 2 24
F7 22 2.000 0 24
G7 23 0.709 7 24
H7 24 2.000 0 24
A8 25 2.000 0 24
B8 Water − 24
C8 Water − 24
D8 Water − 24
E8 Water − 24
F8 Untreated − 24
G8 Untreated − 24
H8 Untreated − 24
A9 1 0.008 6 36
B9 2 2.000 0 36
C9 3 0.001 9 36
D9 4 2.000 0 36
E9 5 0.001 6 36
F9 6 0.007 9 36
G9 7 0.003 6 36
H9 8 0.124 7 36
A10 9 0.531 9 36
B10 10 1.085 4 36
C10 11 2.000 0 36
D10 12 2.000 0 36
E10 13 0.754 4 36
F10 14 0.949 1 36
G10 15 0.092 6 36
H10 16 0.000 2 36
A11 17 0.000 2 36
B11 18 0.157 9 36
C11 19 0.024 2 36
D11 20 0.838 2 36
E11 21 0.008 2 36
F11 22 2.000 0 36
G11 23 0.709 7 36
H11 24 2.000 0 36
A12 25 2.000 0 36
B12 Water − 36
C12 Water − 36
D12 Water − 36
E12 Water − 36
F12 Untreated − 36
G12 Untreated − 36
H12 Untreated − 36
Plate 2:
Well Venom Conc. (uG/uL) Time (Hrs)
A1 1 0.008 6 6
B1 2 2.000 0 6
C1 3 0.001 9 6
D1 4 2.000 0 6
E1 5 0.001 6 6
F1 6 0.007 9 6
G1 7 0.003 6 6
H1 8 0.124 7 6
A2 9 0.531 9 6
B2 10 1.085 4 6
C2 11 2.000 0 6
D2 12 2.000 0 6
E2 13 0.754 4 6
F2 14 0.949 1 6
G2 15 0.092 6 6
H2 16 0.000 2 6
A3 17 0.000 2 6
B3 18 0.157 9 6
C3 19 0.024 2 6
D3 20 0.838 2 6
E3 21 0.008 2 6
F3 22 2.000 0 6
G3 23 0.709 7 6
H3 24 2.000 0 6
A4 25 2.000 0 6
B4 Water − 6
C4 Water − 6
D4 Water − 6
E4 Water − 6
F4 Untreated − 6
G4 Untreated − 6
H4 Untreated − 6
A5 1 0.008 6 24
B5 2 2.000 0 24
C5 3 0.001 9 24
D5 4 2.000 0 24
E5 5 0.001 6 24
F5 6 0.007 9 24
G5 7 0.003 6 24
H5 8 0.124 7 24
A6 9 0.531 9 24
B6 10 1.085 4 24
C6 11 2.000 0 24
D6 12 2.000 0 24
E6 13 0.754 4 24
F6 14 0.949 1 24
G6 15 0.092 6 24
H6 16 0.000 2 24
A7 17 0.000 2 24
B7 18 0.157 9 24
C7 19 0.024 2 24
D7 20 0.838 2 24
E7 21 0.008 2 24
F7 22 2.000 0 24
G7 23 0.709 7 24
H7 24 2.000 0 24
A8 25 2.000 0 24
B8 Water − 24
C8 Water − 24
D8 Water − 24
E8 Water − 24
F8 Untreated − 24
G8 Untreated − 24
H8 Untreated − 24
A9 1 0.008 6 36
B9 2 2.000 0 36
C9 3 0.001 9 36
D9 4 2.000 0 36
E9 5 0.001 6 36
F9 6 0.007 9 36
G9 7 0.003 6 36
H9 8 0.124 7 36
A10 9 0.531 9 36
B10 10 1.085 4 36
C10 11 2.000 0 36
D10 12 2.000 0 36
E10 13 0.754 4 36
F10 14 0.949 1 36
G10 15 0.092 6 36
H10 16 0.000 2 36
A11 17 0.000 2 36
B11 18 0.157 9 36
C11 19 0.024 2 36
D11 20 0.838 2 36
E11 21 0.008 2 36
F11 22 2.000 0 36
G11 23 0.709 7 36
H11 24 2.000 0 36
A12 25 2.000 0 36
B12 Water − 36
C12 Water − 36
D12 Water − 36
E12 Water − 36
F12 Untreated − 36
G12 Untreated − 36
H12 Untreated − 36


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure A.3.: Barplot showing the number of detected genes per sample.
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Plate 2
Figure A.4.: Detected genes and spike-ins. (a.) Association between the number of mapped
reads and detected genes for each of the 96 analyzed samples. (b.) Heatmap showing the





"$schema": "http://json -schema.org/draft -06/schema #",
"$id": "http:// venomkb.org/schemas/venomseq -schema.json",
"title": "VenomSeq data",




















"description": "Name of sequencing platform used to generate









"items": { "type": { "$ref": "#/ definitions/cell -type" } }
},
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"description": "Dataset used for comparison (e.g.,
Connectivity Map data)",
"properties": {
"url": { "type": "string" },
"name": { "type": "string" },






"name": { "type": "string" },
"species": {
"type": "string",
"description": "Cell type species of origin (usually human
for VenomSeq)"
},
"morphology": { "type": "string" },
"venomseq -data": { "type": { "$ref": "#/ definitions/cell -






"dosage": { "type": "number" },
"dosage -unit": { "type": "string" },
"genes -up": {
"type": "array",
"items": { "type": { "$ref": "#/ definitions/cell -type/




"items": { "type": { "$ref": "#/ definitions/cell -type/












"entrez -gene -id": { "type": "number" },
"base -mean": { "type": "number" },
"log2-fold -change": { "type": "number" },
"lfc -se": { "type": "number" },
"test -stat": { "type": "number" },
"pvalue": { "type": "number" },
"padj": { "type": "number" },










"species": { "type": "string" },
"common -name": { "type": "string" },
"venomkb -id": {
"type": "string",
"description": "VenomKB identifier for the species from




"description": "E.g., lyophilized, fresh, frozen, etc.,















Algorithm C.1.1 (Connectivity score algorithm). Given a query {q = (qup, qdown) | q ⊂ G}
and a reference database of gene-wise Z-scores R ∈ RN×M—where G is the set of all genes
in the human genome, N is the number of expression signatures in R, and M is the number
of genes (or probe sets) reported in R—computes connectivity scores that correspond to the
signed enrichment of the genes in q versus the scores in R. This algorithm is derived from
the methods used by the Connectivity Map team, described in [234].
1. [Find Vqr.] Let tup = |qup|. Define ri := rowi R (i = 1, . . . , N)—the row of R
corresponding to expression profile i. For each profile, construct a vector Vqupri ,







1 {ri[k] ≤ qup[j]}
⌋
















− (j − 1)
t
]




aup if aup > bup
−bup if aup < bup
4. [Repeat for “down” gene sets.] Do steps 1. through 3. again, substituting “down” for
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“up” in q, t, a, b, and ES. We now have both up and down enrichment scores between
q and each of the signatures in R.
5. [Compute WCSs.] For each i, find the weighted connectivity score between q and
ri. We introduce sparsity by setting the connectivity score to 0 when the “up” and
“down” enrichment scores do not have opposing signs.
wqri =
{
(ESupqri − ESdownqri )/2 if sgn(ESupqri) 6= sgn(ESdownqri )
0 otherwise
6. [Normalize WCSs.] To reduce bias, we normalize connectivity scores both by cell
type and by perturbagen class (e.g., small molecule, genetic loss-of-function, genetic
overexpression, etc.). Let sgn(x) be the sign function ddx |x|. µ+ct is the mean of all
WCSs with the same cell type c and perturbagen type t as wqri that are positive










7. [Find τ .] τ is the signed connectivity, where the magnitude of a score represents the






[|NCSjri | < |NCSjri |]
C.2. VIPER and aREA-3T1
Algorithm C.2.1 (msVIPER). Performs virtual inference of protein-activity by enriched
regulon analysis as described by Alvarez et. al. in [4].
1. [Initialize.] Let GES be a matrix of gene expression, where rows represent genes (or
probe sets) and columns represent samples. The matrix values can be either relative
1These two algorithms were written and originally described by members of the Califano Lab at Columbia
University. I have included them here for completeness, but all credit goes to the original authors.
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expression (e.g., fluorescence) or absolute expression (e.g., gene counts). Let REGUL
be an adjacency matrix corresponding to a regulatory network for the cell type rep-
resented by GES, generated using the ARACNe algorithm [15]. The values of REGUL
roughly correspond to measures of coregulation (based on mutual information) be-
tween pairs of genes.
2. [Create signatures.] For the perturbational state of interest p, perform Student’s t-test
on each row of GES, comparing columns corresponding to samples in p to columns rep-
resenting “control” samples p0 (i.e., unperturbed). Let TSTAT be the list of computed
t-statistics and PVAL be the list of p-values.
3. [Normalize signatures.] Normalize the signature values by converting to estimated
Z-scores. Let QNORM() be a function that converts a vector of numbers into their







4. [Generate null model.] Perform step 3. 1000 times on a version of GES with columns
(samples) randomly shuffled (producing a matrix with dimensions |SIG| × 1000, with
correlation structures between genes preserved). Store the result in matrix NULL. (If
fewer than 5 samples are present, generate the null model by permuting rows [genes]
instead.)
5. [Run aREA.] Perform the aREA-3T algorithm on SIG:
RES← aREA3T(SIG, REGUL)
6. [Run aREA on null model.] Perform the aREA-3T algorithm on NULL:
TMP← aREA3T(NULL, REGUL)
7. [Estimate statistical significance.] RES and TMP are vectors of regulon enrichment
scores for the true data and the null model, respectively. Let RES[i] be the enrich-
ment score of regi in the observed data, and TMP[i,:] be the vector of enrichment
scores of regi under the null model. The p-value for each regulon regi is given by
Pr ( |TMP[i,:]| ≥ |RES[i]| )× 2. Compute each p-value and store the result in a vec-
tor PVAL. Compute a vector of FDR-corrected p-values using the Benjamini-Hochberg
procedure [20] (in the R programming language, this can be performed using the
p.adjust() function), and store the result in a vector FDR.
8. [End.] Return RES, PVAL, and FDR to the user (each should be of the same length, and
each index i corresponds to regi).
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Algorithm C.2.2 (aREA-3T ). Performs analytic Rank-based Enrichment Analysis us-
ing a 3-tailed approach. Given a regulon object and an expression signature (see Algo-
rithm C.2.1), tests whether the genes within each regulon shift towards the front or the
back of the rank-sorted expression signature. The 3-tailed test separately computes 1-tailed
and 2-tailed enrichment statistics and integrates the two values using the Mode of Regulation
statistic (see [4] for further details).
1. [Initialize.] Let SIG be a gene expression signature of Z-scores and REGUL be a regulon,
as described above.
2. [Make vectors of ranks.] Construct a vector of ranks—named RANK2—such that
{SIG[RANK2[i]] ≥ SIG[RANK2[i− 1]] ∀i ∈ [1, |SIG|]}. Similarly, construct another vec-
tor of ranks (RANK1) using the magnitudes (absolute values) of the Z-scores. These
will be used to compute ES2 and ES1 below, respectively.
3. [Find 1-tailed enrichment.] For each regulon regi ∈ REGUL, compute an enrichment
statistic ES1 as the mean of the quantile scores of members of regi within RANK1.
4. [Find 2-tailed enrichment.] Perform step 3. using RANK2 instead of RANK1.
5. [Determine Mode of Regulation.] The Mode of Regulation is used to weight the
contributions of ES1 and ES2 in the final enrichment score ES. Define three Gaus-
sian random variables: G1 (repressed targets), G2 (activated targets), and G3 (non-
monotonically regulated targets), and estimate their parameters using whichever method
is preferred2.
6. [Integrate for 3-tailed enrichment.] The enrichment score for each regulon is the sum
of ES1 and ES2 weighted by the magnitude of MoR:
ES← |MoR|ES2 + (1− |MoR|)ES1
C.3. The Semantic API
Algorithm C.3.1 (Semantic query). Interprets a “semantic query” request submitted via
the Semantic API.
2The authors of aREA-3T use the mixtools package for the R programming language.
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1. [Parse user query.] Create an empty list CLASSES. Iterate over elements of select,
declare, and aggregate in the query, and push any encountered ontology classes to
the end of CLASSES. Delete duplicate entries from CLASSES. Set k ← |CLASSES|. If
the query contains a declare key, create an empty list CONSTRAINTS and fill it by
iterating over elementsof declare, parsing according to the template
〈class〉 | 〈attribute〉 | 〈operator〉 | 〈value〉
and appending the JSON object to the end of CONSTRAINTS. Copy the value for the
query’s select key to an object variable named SELECT.
2. [Find subgraph.] Let C = (V,E) be the graph representing class relations in the OWL
ontology of interest, and let V ′ =
{
{v′1, v′2, . . . , v′k}, V ′ ⊂ V
}
be the set of vertices
corresponding to the members of CLASSES. Find the subgraph with the fewest possible
edges3 C ′ = (V ′, E ′), which corresponds to the generalized distance d(v′1, . . . , v
′
k).
When k is small, this can be approximated efficiently by finding the shortest paths
between all pairs of nodes in V ′ and then taking the union of those paths.
3. [Construct MATCH clause.] Build a string MATCH by walking the nodes and edges of
C ′ until all nodes and edges have been visited. Append (〈ai〉:〈CLASSES[i]〉) at each
node, and -[:〈relationj〉]-> at each edge, where ai is an alphanumeric variable name
referring to classi. Nodes and edges may be visited more than once, but ai and
CLASSES[i] must be reused consistently.
4. [Construct WHERE clause.] If CONSTRAINTS is defined, iterate over its elements, con-
vert each element to a Cypher-formatted string (e.g., s.name contains ’Conus’),
matching the variable name at the beginning of the string to the corresponding vari-
able name in the MATCH clause for the ontology class of interest. Join each of these
strings with the delimiter ’ AND ’, and append the result to the end of the string
’MATCH ’. If CONSTRAINTS is not defined, do nothing.
5. [Construct RETURN clause.] Convert the value of SELECT to a string formatted as a
Cypher RETURN clause, replacing ontology class names classi with their respective
variable names ai.
6. [Preprocess data aggregations.] If the query contains a key aggregate, iterate over
its keys and process them as defined for each aggregation function. For example,
distinct: { class: ’ai’ } should be handled by inserting DISTINCT into the
RETURN clause, between RETURN and ai. Aggregations that are meant to be applied to
the result of the Cypher query should be saved for later.
3Sometimes called the Steiner tree.
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7. [Assemble Cypher query.] Create a new string QUERY by appending the values of
MATCH, WHERE, and RETURN.
8. [Execute query.] Initiate a new transaction with the graph database server using the
contents of QUERY. Retrieve the server’s response to the query and store it in RESULT.
Trim unnecessary metadata included in the server’s response.
9. [Perform remaining aggregations.] If any aggregation functions (sorting, counting,
etc.) remain, handle them as specified, and modify the contents of RESULT accordingly.




All code used in the experiments described within this dissertation is open source and pub-
licly accessible. Most of the software I wrote is available from my GitHub profile, located
at https://github.com/JDRomano2. This includes the web application and API code for
VenomKB, the code used to produce and evaluate the Venom Ontology, and all code and
data related to the analysis of VenomSeq results. All production-quality releases of per-
tinent code are mirrored on the Tatonetti Lab GitHub profile, which can be found at
https://github.com/tatonetti-lab. Additionally, I have included Digital Object Identi-
fiers (DOIs) in the dissertation text pointing to “frozen” versions of the different software
packages as they existed at the time of publication (usually hosted on figshare). Some of
the features related to the semantic API are not yet ready for deployment on the VenomKB
website, but all progress is tracked on the VenomKB source repository and can be run locally.
I am happy to provide additional data, documentation, or help as needed, and all questions
pertaining to the code itself should be directed to me.
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